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Migraine impact and clinical presentation
Migraine is a paroxysmal neurovascular disorder with a prevalence of 15% that 
affects a large proportion of the general population.1 It is a highly debilitating disease, 
which has been ranked by the WHO as the 3rd disabling disease in women and the 
7th disabler when both sexes are considered together.2 The 2 most prevalent subtypes 
of migraine are migraine without aura (MO) and migraine with aura (MA). Patients 
with MO have migraine attacks that can last up to 72 hours, suffering from headache 
accompanied by autonomic nervous system dysfunctions such as photophobia, 
phonophobia and nausea. The attacks in MA patients are similar to those in MO 
patients, but preceded by an aura phase. During this phase, which can have a duration 
of 5-60 min, patients mostly experience visual disturbances, although paresthesia, 
speech disturbance and motor symptom can also occur.3  
Migraine pathophysiology and CGRP
The pathophysiology of migraine is poorly understood, although there is consensus 
on the trigeminovascular system as the key structure being involved. Migraine is 
considered to be a result of the activation of the trigeminovascular system with the 
primary dysfunction located in brainstem centers regulating vascular tone and pain 
sensation.4 During a migraine attack the vasodilatory neuropeptide calcitonin gene-
related peptide (CGRP) is released from trigeminal sensory nerves.5, 6 The resulting 
vasodilatation of meningeal arteries and activation of the nociceptive system are 
thought to be the basis of the headache during migraine.7 The key role of CGRP is 
emphasized by the finding that plasma concentrations of CGRP are elevated during 
migraine headache and normalize after treatment with triptans (specific acute anti-
migraine drugs) in parallel with alleviation of headache.8 In view of the key role of 
CGRP in the pathophysiology of migraine, and evidence that blocking CGRP aborts 
migraines, CGRP and its receptors have now become a novel drug target for anti-
migraine therapy.9 
Migraine and female sex
Migraine is a predominantly female disease, as it affects women much more than men 
with a female-to-male ratio of 3:1.10, 11 Especially hormonal milestones accompanied 
by fluctuations in estrogen levels such as menarche, pregnancy and menopause seem 
to have vast effects on migraine prevalence and frequency. The onset of migraine 
in women usually coincides with menarche and a close relation between migraine 
occurrence and the menstrual cycle remains during the reproductive years.12 
Approximately 50% of women with migraine are affected by menstrually-related 
migraine (MRM),13 i.e. MO that occurs on day 1±2 of the menstrual cycle in at least 
2 of 3 consecutive menstrual cycles with additional attacks with or without aura that 
can occur at other times of the month.14 Migraine frequency drops during pregnancy,15, 
16 particularly during the second and third trimester, when serum levels of estradiol 
and progesterone are much higher than peak levels during the menstrual cycle. 
Postpartum, migraine reoccurs, but less in lactating women. During perimenopause, 
changes in migraine prevalence have been reported.17 Major fluctuations in estrogen 
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levels take place during perimenopause, ultimately leading to dropping levels.18 The 
prevalence of migraine headaches during this period seems to be higher in patients 
who previously had a history of MRM and premenstrual syndrome.19, 20 
Vascular disease and migraine
Besides the considerable migraine disease burden, migraineurs have an increased 
ischemic stroke risk. This risk is highest in young female MA patients using oral 
contraceptives.21 Imaging studies have confirmed the association between MA and 
ischemic stroke, by showing an increased risk of silent infarct-like lesions in MA 
patients.22 Deep white matter lesions are also increased in women with MO and MA. 
The risk for both types of lesions increases with rising attack frequency.22 Migraine 
has recently been identified as a major cardiovascular risk factor in women (IR = 7.9; 
6.2-10.0).23 A recent meta-analysis of observational studies indicated an increased 
risk of myocardial infarction (pooled adjusted effect estimate 1.33, 95% confidence 
interval 1.08–1.64; P = 0.007) and of angina (pooled adjusted effect estimate 1.29, 
95% confidence interval 1.17–1.43; P < 0.0001) in migraineurs compared to non-
migraineurs. Migraine seems to be an even larger risk factor than well-known risk 
factors such as diabetes, obesity or smoking.23 Interestingly, systemic vascular 
dysfunction in migraine patients, expected based on the increased cardiovascular 
disease risk, has not been confirmed.24 
Migraine and monogenic diseases
The rare monogenic microvascular disorders comorbid with migraine, RVCL 
(autosomal dominant Retinal Vasculopathy with Cerebral Leukodystrophy, 
caused by a mutation in the TREX1 gene, encoding for a DNA exonuclease) and 
CADASIL (Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts 
and Leukoencephalopathy, caused by mutations in the NOTCH3 gene), provide a 
unique opportunity to study not only the genetic mechanisms involved in migraine 
but also the vascular mechanisms. In RVCL patients primarily the microvessels in 
the brain and retina are affected and patients develop retinopathy and in the endstage 
of the disease, cerebral mass lesions.25 MO, with 59% of the patients affected, is 
a prominent feature of RVCL.26 Endothelial dysfunction in RVCL patients has 
been recently identified.27 Approximately 30% of CADASIL patients have MA 
and migraine is often the presenting symptom.28 White matter hyperintensities and 
lacunar infarcts are the most prominent features of CADASIL. The NOTCH3 gene 
encodes a cell surface protein that in human adult tissue is only expressed in vascular 
smooth muscle cells.29, 30 Functional tests have revealed impaired smooth muscle cell 
relaxation in skin resistance vessels of CADASIL patients.27 CADASIL and RVCL 
mouse models have been developed to further investigate both diseases and their 
association with migraine.31, 32
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Aims
Aims of this thesis
In Part I the focus is on experimental models of migraine, that are applied in 
pharmacological as well as in pathophysiological studies. Calcitonin gene-related 
peptide is the key neuropeptide in migraine pathophysiology. CGRP is being 
extensively researched, especially as a novel anti-migraine drug target. In Chapter 
3 we review existing experimental models that can be applied to study the effects of 
the novel CGRP receptor antagonists and the recently developed antibodies directed 
against CGRP and its receptor. In Chapter 4 we comment on an existing experimental 
model to demonstrate its limitations with regard to distinguishing between structures 
important to migraine, like the intracranial part of the middle meningeal artery. In 
Chapter 5 we describe our experimental trigeminal nerve-mediated vasodilatation 
model. We developed this model to study trigeminovascular pathophysiological and 
pharmacological mechanisms of migraine. In Chapter 6 we investigate the effects 
of the anti-migraine drug sumatriptan with this model, to validate it as a biomarker 
for studies on future anti-migraine drugs.
Besides its direct burden, migraine has recently also been identified as a major 
independent risk factor for cardiovascular disease. Yet, cross-sectional studies 
investigating the vascular dysfunction in migraine patients have reported conflicting 
results. This may relate to the fact that the experimental models used to identify 
vascular dysfunction were diverse and often limited. Therefore, in Chapter 7 we 
compared different measures of vascular function to assess their reproducibility and 
their usefulness to identify endothelial dysfunction. In Chapter 8 we applied one of 
these measures, the post-occlusive reactive hyperemia (PORH), to characterize the 
microvascular  function in a knock-in mouse (V235fs KI mice) model of migraine. 
In Part II we evaluate the role of female sex hormones in migraine. The prevalence 
of migraine is much higher in women than in men. Hormonal milestones in women 
are accompanied by changes in frequency and prevalence of migraine. In Chapter 
9 we review the effect of the perimenopausal period on migraine. In Chapter 10 we 
have performed a detailed pathophysiological study to investigate the influence of 
the menstrual cycle on trigeminovascular activation in patients with menstrually-
related migraine, making use of the trigeminovascular model described in Chapter 5. 
In Chapter 11 we performed a similar study on the human forearm, allowing a 
comparison of the forehead findings with peripheral findings. 
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Part I
CHAPTER 3 
Discovery techniques for calcitonin gene-related peptide 
receptor antagonists for potential antimigraine therapies
S. Labruijere, K. Ibrahimi, K.Y. Chan & A. MaassenVanDenBrink
Abstract 
Introduction: Calcitonin gene-related peptide (CGRP) exerts a key function in 
migraine pathophysiology through the trigeminovascular system. Influencing this 
system via CGRP receptor antagonists seems to be an important new option in 
treating migraine attacks. To characterize new compounds, models are used to study 
the vascular effects as well as their effects on the central nervous system. 
Areas covered: The authors review the clinical trials and many different in vitro 
and in vivo experimental models that have been used to investigate effects and side 
effects in animals, healthy subjects and patients. These experimental models are 
essential, not only in characterizing new CGRP receptor antagonists, but also to get 
more insight into the pathophysiological mechanisms behind migraines. 
Expert opinion: Although triptans were a major breakthrough in migraine 
treatment, they are not effective for every patient and contraindicated in patients 
with cardiovascular disease. There is still a demand for other acute antimigraine 
acting drugs with CGRP receptor antagonists being the most promising candidates. 
CGRP plays a role in protection against ischemia, but CGRP receptor antagonists 
do not seem to affect this protection to a harmful extent, when used incidentally as 
acute antimigraine treatment. In order for drug specificity to be increased, the site 
of action needs to be identified; this consequently may lead to a decrease in dosing 
with fewer side effects.
1. Introduction
Migraine is a disabling neurovascular disorder, characterized by a unilateral throbbing 
headache that lasts from 4 to 72 hours. The headache is often accompanied by nausea, 
vomiting, phonophobia and photophobia and worsens by physical exercise.1 There 
are different types of migraine where migraine with aura (MA) and migraine without 
aura (MO) are the most common forms.2 A migraine attack can have different phases, 
the prodromal or premonitory phase, the aura phase, the headache phase and the 
postdromal phase. During the premonitory phase, patients have often symptoms like 
yawning, nausea and craving for food. The migraine aura is thought to be caused by 
a cortical spreading depression (CSD). During the postdromal phase, which can last 
hours to days after the resolution of the headache, patients are often tired.3 Migraine 
has a worldwide prevalence of 10% and a prevalence of 15 – 20% in the Western 
Countries.4 This shows that migraine is a major health problem, which also involves a 
high financial burden to society. Migraine pathophysiology is not clearly understood, 
but the trigeminovascular system is thought to play an important role in it.5
Apart from the more general analgesics there are different medicines available to treat 
migraine. These drugs can be divided into two types: i) drugs aimed at abolishing 
migraine attacks and ii) drugs aimed at preventing migraine attacks. The latter group 
is prescribed to patients that have frequent attacks and in which the acute drugs do 
not have sufficient effect, in order to reduce the severity or the number of attacks.6 
The first drugs used to treat acute migraine attacks were the ergot alkaloids, 
which were discovered in the beginning of the 20th century. Ergot alkaloids are 
20
Chapter 3
vasoconstrictors that act by binding of 5-hydroxytryptamine (5-HT) receptors, 
α-adrenoceptors and dopamineD2 receptors. Due to their multiple receptor binding 
properties these drugs have many side effects.7 In the 1990s of the former century, 
the triptans were introduced. These drugs have shown to be as effective as the ergot 
alkaloids in treating migraine attacks, but with less sideeffects due to their specificity 
for 5-HT1B/1D receptors.
8, 9 Triptans are not effective in all migraineurs and contra-
indicated in patients with cardiovascular disease, so it is important that more drugs 
are developed to abolish migraine attacks.10 In the early nineties, Edvinsson and 
Goadsby discovered an increase in calcitonin gene related peptide (CGRP) levels in 
plasma of the jugular vein during a migraine attack and the CGRP levels normalized 
after treatment with triptans.11, 12 CGRP is a potent vasodilator and is widely present 
in the brain (especially the trigeminal system) and the cardiovascular system together 
with its receptor, which is composed of three parts: receptor activity modifying 
protein 1 (RAMP1), calcitonin-like receptor (CLR) and receptor component protein 
(RCP).13, 14 
A migraine attack is thought to start in the brainstem due to certain triggers, which 
have not been exactly identified yet, leading to the release of CGRP at trigeminal 
nerve endings innervating meningeal arteries.15 CGRP binds to its receptor that is 
present on the smooth muscle cell membrane, activating adenylate cyclase, causing 
an increase in intracellular cyclic AMP (cAMP). This leads to activation of different 
signalling pathways and vasodilatation, where activation of nitric oxide synthase 
(NOS), leading to an increase in nitric oxide (NO),16 may also be involved. The 
vasodilatation is thought to affect sensory neurons which, in turn, activate the 
trigeminal system, passing on sensory information to higher brain regions, but also 
leading to other neurological symptoms as phono- and photophobia.17, 18 
The first potent and selective CGRP receptor antagonist was olcegepant and showed 
to be effective in the acute treatment of migraine attacks similar to the triptans, but 
without its cardiovascular side effect profile.19 Because of its low oral bioavailability, 
other CGRP receptor antagonists with improved oral bioavailability were developed.20, 
21 Telcagepant was the first improved, orally available CGRP receptor antagonist 
that was tested in multiple clinical trials, as well as other ones developed later on. 
These clinical trials are discussed below. It is crucial that various effects and side 
effects of newly developed CGRP receptor antagonists are characterized to be sure. 
Furthermore, as migraine is a syndrome involving multiple physiological systems, 
it is very important to obtain more knowledge about the underlying mechanisms 
causing migraine. This may eventually lead to more specific treatment for specified 
migraine patient groups. Since migraine involves multiple organ systems, both 
vascular and neuronal, there are many different research models, which are used 
to study different aspects of migraine and antimigraine medication. The aim of this 
review is to describe the experimental in vivo and in vitro models that can be used for 
the discovery and characterization of new CGRP receptor antagonists.
21
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2. Clinical trials with CGRP receptor antagonists 
CGRP receptor antagonists have proven to be effective in the acute treatment of 
migraine in multiple clinical trials (Table 1). Olcegepant (BIBN4096BS) was the first 
CGRP receptor antagonist to be tested in clinical trials. In phase I trials olcegepant 
showed good safety and tolerability19, 22 and adverse events (AE’s) reported were only 
transient and mild paresthesias. In a Phase II trial in 126 migraine patients, olcegepant 
proved to be an effective drug for the acute treatment of migraine and headache 
relief after 2 hours was achieved in 66% of the migraineurs.23 Due to the chemical 
structure of olcegepant it can only be administered intravenously and is consequently 
unfeasible in a clinical setting. It was clear that a CGRP receptor antagonist with an 
improved pharmacokinetic profile was required. Telcagepant (MK-0974) was the 
first orally bioavailable CGRP receptor antagonist that was discovered. In a Phase II 
trial, where several doses of telcagepant were compared to rizatriptan, telcagepant 
proved to be effective in the acute treatment of moderate or severe migraine attacks. 
Headache relief after 2 hours was achieved in 68% of the migraineurs when treated 
with the highest dose that was used in this trial (600 mg), compared to 69% when 
treated with rizatriptan.24 In Phase III trials telcagepant repeatedly acted effectively 
as acute treatment of migraine when compared to placebo.25, 26 However, when 
raised levels of liver transaminases were detected in a few participants in a Phase 
II trial (NCT00797667) where telcagepant was assessed as a prophylactic treatment 
for migraine, the development of telcagepant was suspended.27 The development 
of another CGRP receptor antagonist (MK-3207) with higher bioavailability than 
telcagepant and also effective in the acute treatment of migraine, was discontinued 
as well after reports of raised levels of liver transaminases.21, 28 The CGRP receptor 
antagonist BI 44370 TA has proven to be successful in treatment of acute migraine in 
a Phase II trial. Headache relief after 2 hours was reached in 27% of the participants 
for BI 44370 TA (400 mg), compared to in 9% of the participants for placebo and 
there were very few reports of AE’s, with an incidence of ≤ 3 %.29 Finally, in a 
recent Phase I trial, the CGRP receptor antagonist BMS-927711 showed to be safe 
and tolerable in eight healthy subjects at single doses up to 1500 mg and multiple 
doses up to 600 mg. No serious AE’s were reported.30 Though clinical trials provide 
an excellent opportunity to study the pharmacokinetics and pharmacodynamics 
of a drug, they provide little information of the underlying mechanisms of action. 
Consequently, in vitro and in vivo research models are needed to allow us insight into 
these mechanisms. 
3. Experimental Models
Clinical trials in healthy subjects and patients cannot be performed without prior 
characterization studies of the potential drug in experimental models. There is no 
experimental model in which a complete migraine attack can be studied. All available 
models focus on a specific component of the disease. Different in vitro and in vivo 
models are used to investigate effects and side effects of prospective antimigraine 
drugs (Table 2 and Figure 1). 
22
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3.1 In vitro models
Because migraine is a heterogeneous disease and pain is difficult to measure in 
animals, different in vitro models have been developed to study separate components 
of the disease. Since migraine is a neurovascular disease, various models have been 
developed that focus on the vasculature. CGRP is a very potent vasodilator31 so newly 
developed CGRP receptor antagonists can be studied for their potency in different 
types of isolated blood vessels. Apart from its effects on the vasculature, CGRP also 
plays an important role in different brain regions.14 CGRP has shown to be present in 
perivascular nerves, but also in the trigeminal system, amygdalae, striatum, colliculi, 
hypothalamus, cerebellum and brainstem.13 In vitro models focussing on brain tissue 
can be used to study effects of CGRP receptor antagonists on its neurotransmitter 
function. In general, in vitro models have a number of advantages: i) multiple 
tissue samples can be studied of the same tissue, making it possible to perform a 
detailed pharmacological analysis and ii) there is no influence of varying blood 
pressure, circulating hormones or central and autonomous nervous system, reducing 
the number of confounding factors when performing pharmacological analyses. 
However, in vitro models are not sufficient to completely predict a therapeutic effect 
or to predict the pharmacokinetics, including brain penetration, of a compound, 
and should thus be used complementary to in vivo models, which will be described 
further on in this review. 
3.1.1 Isometric tension measurements in blood vessels from experimental 
animals and humans 
Organ baths for isometric tension measurements are experimental models in which 
vasoconstrictor or vasodilator properties of compounds can be studied in isolated 
blood vessels. There are different sizes of organ baths, made for blood vessels with 
different diameter size. Vessel segments with a diameter of 0.05 – 3 mm and a length 
of 2 – 5 mm can be mounted in wire myographs between two wires. One of the wires 
is connected to a force transducer and computer and the vessels are stretched to a 
23
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CGRP receptor 
antagonist
Administration 
route
Last  trial phase 
completed (headache 
relief after 2h)
Antimigraine 
effective dose
Adverse events 
reported (>5%)
Status
Olcegepant 23 i.v Phase II (66%) 2.5 mg Mild paresthesias Discontinued 
due to low oral 
availability
Telcagepant 25 Oral Phase III (24-27%) 140-400 mg Dry mouth, nausea, 
somnolence, dizzi-
ness and fatigue
Discontinued 
due to increased 
liver enzymes
MK-3207 28 Oral Phase II (36%) 200 mg Dry mouth, nausea, 
vomiting, dizzi-
ness, fatigue and 
headache
Discontinued 
due to increased 
liver enzymes
BI 44370 TA 29 Oral Phase II (27%) 400 mg none In development
BMS-927711 30 Oral Phase I  (unknown) unknown Headache, consti-
pation, dizziness 
and nausea
In development
24
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Table 2. Overview of experimental models.
Experimental model In vivo/ 
In vitro
Description Advantages Disadvantages 
Isometric tension mea-
surement 31
In vitro Study of vasoconstrictor or vaso-
dilator properties of compounds on 
isolated blood vessel segments in 
organ baths
Multiple 
segments can be 
studied at once
No difference can be 
made between luminal and 
abluminal side
Pressure myography 35 In vitro Study of vasoconstrictor or vaso-
dilator properties of compounds 
on isolated blood vessel segments 
in organ bath in which compounds 
can be administrated luminally or 
abluminally
Effects can 
be studied on 
luminal and 
abluminal side 
of the blood 
vessel
Mounting of segments is 
time consuming so only 
a few segments can be 
studied at once
Brain slices 21 In vitro Binding of CGRP receptor antago-
nists in the brain can be studied
Binding prop-
erties can be 
studied in detail 
in the brain
No information on brain 
access, penetration or 
functional response
Vascular animal models 37 In vivo Effects of both exogenous and 
endogenous CGRP can be studied in 
living animals
Hemodynamic 
effects can be 
studied
No information on brain 
activity
Intravital microscopy via 
closed cranial window  
40-42
In vivo Study of  dural blood vessel  proper-
ties via a thinned skull (closed cranial 
window)
The effect on 
dural vessel can 
be studied in a 
living animal
No information on brain 
activity
Imaging models 47, 50 In vivo Real time imaging of blood vessels 
and brain via MRI, Bold-MRI and 
PET 
Effects in 
living animals or 
humans
expensive and time con-
suming
Laser Doppler perfusion 
imaging 56
In vivo Measurement of skin perfusion with 
laser Doppler scanner
small resistance 
vessels are 
studied, non 
invasive
No measurements of dural 
blood vessels
Human migraine models 
60, 63, 67, 72
In vivo Infusion of migraine-inducing com-
pounds in either migraine patients or 
healthy volunteers
Effect of 
CGRP receptor 
antagonists can 
be studied in 
human
Not all subjects get 
headache. Headache is not 
identical to  migraine
Fos expression 77 In vivo Expression of the Fos protein is 
related to neuronal activation  and 
can be used to study activation of the 
trigeminovascular system
Central effects 
of CGRP recep-
tor antagonists 
can be studied.
Fos is not expressed in all 
neurons and stimulations 
necessary to induce Fos 
expression are sometimes 
higher than physiological
Electrophysiological 
recordings 91
In vivo Measurement of action potential 
activity in brain of living animal via 
electrodes
Living animal, 
physiological
Small area can be mea-
sured, no information on 
vascular system
Transgenic mice models 
127
In vivo Mice in which a gene of another 
species is inserted and expressed
The physiolog-
ical role of the 
CGRP-ergic 
system can be 
studied
Difficult to examine 
migraine symptoms in 
animals
force that is comparable to a normal blood pressure. Different organ bath studies 
have been performed on the characterization of the CGRP receptor antagonist 
olcegepant and telcagepant. As may be expected from their mechanism of action that 
differs from that of the triptans that are vasoconstrictors, CGRP receptor antagonists 
have been found to be devoid of vasoconstrictor effects per se.22, 31 However, it is 
important to assess their potency to antagonize vasodilator responses to CGRP in 
isolated blood vessels. In both human and bovine cerebral arteries it was shown that 
olcegepant blocked the effect of exogenously administrated CGRP.32, 33 Furthermore, 
it was shown in human isolated coronary as well as in cranial arteries that telcagepant, 
similar to olcegepant, antagonized vasodilator responses to CGRP, and moreover 
did not induce any contraction or relaxation of the blood vessels (Figure 2).31, 34 
A disadvantage of this model is that the compounds under investigation reach the 
blood vessels from both the luminal and abluminal side, which is not physiological, 
because neuropeptides like CGRP are released form nerve afferents on the abluminal 
side of the artery. In contrast, drugs are transported through the blood and need to 
cross the blood vessel wall to reach the smooth muscle cells, where for example, 
CGRP receptors are located.34 This is especially important in the brain, were the 
blood brain-barrier is present. Therefore another model was developed, which is 
described below.
3.1.2 Pressure myography in blood vessels from experimental animals and 
humans
In the pressure myograph model a segment of a blood vessel is placed over a small 
glass pipette tip at both sides and securely tied up by small wires. A flow is established 
through the vessel, leading to a certain pressure, which can be measured. The blood 
vessel is mounted in an organ bath, with the abluminal side of the vessel completely 
separated from the luminal side. This model can be used for example to investigate 
ability of a substance to cross the endothelial layer of a blood vessel (e.g. the blood 
brain barrier),35 but also to study receptors that are present on smooth muscle cells 
and activated by release of proteins through nerve endings, in a more physiological 
way.35 It was shown with this model that luminally applied olcegepant could not 
block the relaxing effect of abluminally applied CGRP in middle cerebral arteries. 
This indicates that olcegepant possibly cannot cross the blood brain barrier.36 A 
disadvantage of this model is that only a few pieces of vessel can be studied at 
a time resulting in a very time consuming method. Furthermore, because a stable 
intraluminal pressure is needed, the construction of concentration response curves is 
difficult from the luminal side of the blood vessel. 
3.1.3 Brain slices of experimental animals
Brain slices can be used to study binding of antagonists to a receptor. A study in 
rhesus monkey brain slices on a new CGRP receptor antagonist, MK-3207, showed 
a very high density of binding in the meninges, cerebellum and brainstem and a very 
low binding in the cortex, providing information about the potential central sites 
of action of the CGRP receptor antagonist.21 Obviously, results obtained from such 
methods should be complemented by investigations on the brain penetration of the 
CGRP receptor antagonists.
3.2 In vivo models 
Major limitations of the in vitro models that are used to study migraine are that 
they are not physiological and thus cannot be used without complementary in vivo 
studies to predict therapeutic effects and pharmacokinetics of investigational drugs. 
In the next part, in vivo models for migraine that can be used to characterize effects 
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of CGRP receptor antagonists on vasculature as well as the central nervous system 
are discussed. 
3.2.1 Vascular models in experimental animals 
A main part of research performed for the development of the triptans was based 
on purely vascular models in experimental animals (for review, see Villalón and 
Gupta10). For research on CGRP receptor antagonists, a neuronal component should 
be implicated as well, since otherwise only effects on exogenously administered 
CGRP can be studied. Administration of capsaicin induces endogenous CGRP 
release, which in turn leads to vasodilatation.  This model has been applied in 
anaesthetized vagosympathectomized dogs.37 An alternative approach to induce 
endogenous CGRP release is electrical spinal stimulation, for example in pithed 
rats.38 These models may well be used to study the hemodynamic effects of CGRP 
receptor antagonists.
3.2.2 Closed cranial window model in experimental animals
The dilation of blood vessels in the meninges is caused by activation of the 
trigeminovascular system.39 The closed cranial window model is a preclinical in 
vivo model, which is based on intravital microscopy for a direct measurement of 
dural blood vessel diameter through a closed cranial window in anaesthetized rats40 
or mice.41 In this model the skull is not opened, thus avoiding alteration of vessel 
reactivity due to brain swelling or change in pressure. Dilation of the dural artery can 
be induced by intravenous injection of CGRP or capsaicin40 as well as by electrical 
stimulation on the surface of the skull.42 Due to the different stimulations to induce 
dural vasodilatation, effects of antimigraine drugs can be studied on three levels; 
postsynaptic at the blood vessels due to exogenous CGRP injection, presynaptic 
at the transient receptor potential cation channel subfamily V member 1 (TRPV1) 
channel due to capsaicin injection and in trigeminovascular neurons due to electrical 
stimulation. Exogenous CGRP exerts its effect by binding to the CGRP receptor 
located on the vascular smooth muscle cells, capsaicin induces endogenous CGRP 
release by binding on the TRPV1 channel of TRPV1 channel containing neurons 
and electrical stimulation induces endogenous CGRP release by depolarization of 
perivascular trigeminal nerves.
In the past years, different potential antimigraine drugs like the neuronal NOS 
inhibitor, s-methyl-l-thiocitrulline,43 the antiepileptic drug, topiramate44 and different 
P/Q-,N- and L-type calcium channel blockers45 have shown to block electrical 
stimulation-induced neurogenic vasodilatation, but not exogenous CGRP-induced 
vasodilatation. This suggests that all these compounds inhibit CGRP release from 
the perivascular nerve via presynaptic blockade of trigeminovascular neurons. In 
contrast, Chan et al. showed that the glutamate receptor antagonist LY466195, 
which shows antimigraine effects, did not affect CGRP release or its vasodilator 
effects, suggesting a central mechanism not involving CGRPergic pathways.46 The 
cranial window model can be used to study the effect of potential CGRP receptor 
antagonists on dural vasodilatation in vivo. As may be expected from their mechanism 
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of action, CGRP receptor antagonists inhibit vasodilator responses to both exogenous 
and endogenous CGRP.41 Furthermore, this model can be used to study differences 
between exogenous and endogenous CGRP on dural vasodilatation, providing 
information about (patho)physiological factors affecting either the release of CGRP, 
or the response mediated by its receptors. 
3.2.3 Imaging models in human
In recent years, imaging of the brain and its related vasculature has become 
important in migraine drug research. Positron emission tomography (PET), a 3D 
imaging technique that can be used to image functional processes of the body, has 
successfully been used to study the effects of antimigraine drugs. With PET imaging, 
rizatriptan was shown to cause a decrease of cerebral blood flow (CBF) and blood 
volume of around 13%.47 PET imaging was also used to show that sumatriptan 
can normalize the migraine-related increase in brain serotonin synthesis.48 More 
recently, central CGRP receptor occupancy was investigated with PET imaging in 
healthy subjects. The investigators showed low receptor occupancy (4 - 10%) after 
dosing with the lowest clinically effective dose of telcagepant and moderate receptor 
occupancy (43 - 58%) after dosing with a supra-therapeutic dose of telcagepant. 
They therefore concluded that central antagonism of CGRP receptors may not be 
required for a CGRP receptor antagonist to be effective in migraine treatment.49 Due 
to the low temporal and spatial resolution of PET imaging, this technique is limited 
to investigating large areas of the brain. Consequently, magnetic resonance imaging 
(MRI) and especially, blood oxygenation level-dependent functional MRI (BOLD-
fMRI) has become more accepted as the technique to assess altered brain activation 
and functional connectivity between brain regions.50 BOLD-fMRI is favored 
because it is a noninvasive technique with high spatial and temporal resolution.51 The 
effect of CGRP infusion and subsequent application of a subcutaneous therapeutic 
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dose of sumatriptan on the visual cortex BOLD signal response was investigated 
and no changes in the visual neuronal activity after either CGRP infusion or 
subcutaneous sumatriptan were detected.52 Using magnetic resonance angiography, 
an MRI technique to image blood vessels, Asghar et al. showed dilatation of the 
middle meningeal artery after infusion of CGRP and the reversal of this dilatation 
by subcutaneous sumatriptan in healthy volunteers.53 The application of imaging 
techniques in the study of migraine headache, spontaneous or provoked by infusion of 
drugs, can provide information on the yet poorly understood underlying mechanism 
of migraine. In the research of CGRP receptor antagonist, imaging techniques can 
offer insight into the mode and location of action of the drugs. 
3.2.4 Dermal blood flow in response to stimulation with capsaicin as well as 
electrical stimulation in animal models and humans
Capsaicin, the active ingredient of chili peppers, stimulates the TRPV1 channel 
and causes release of CGRP from perivascular nerve terminals.54 Topically applied 
capsaicin on the human forearm skin is known to increase dermal blood flow (DBF), 
which can be measured with laser Doppler perfusion imaging.55 This increase in 
DBF was inhibited by the CGRP receptor antagonist telcagepant.56 Endogenous 
CGRP release can also be accomplished by electrical stimulation.11, 57 In humans, 
current-induced vasodilatation can be inhibited by local anesthesia and reduced by 
desensitization of C-nociceptive fibers.58 Though not confirmed with the application 
of a CGRP receptor antagonist, current induced vasodilatation is thought to be 
mediated mostly by CGRP and substance P. Current-induced vasodilatation may 
be used to study the release of endogenous CGRP, without the involvement of the 
TRPV1 channel. A combination of the capsaicin application response and the current-
induced vasodilatation provides a suitable model to study CGRP receptor antagonists, 
especially to elucidate the role of the TRPV1 receptor in migraine headaches.59 An 
advantage of this model is that due to its direct translatability between species, this 
model can be applied in both humans and animal models. 
3.2.5 Human migraine models
Human migraine models play an important role in the research for new antimigraine 
drugs. There are several models in either healthy volunteers or migraine patients.  In 
the latter group, migraine-like attacks can be triggered through infusion of drugs. 
3.2.5.1 CGRP infusion
Infusion of CGRP in migraine patients, but not in healthy volunteers can induce 
delayed (1-12 hours after infusion) headache fulfilling the International Headache 
Society (IHS) criteria for 67% of MO patients and in 57% of MA patients.60-62 The 
mechanism behind migraine after CGRP infusion is still not clear. Recently a study by 
Asghar et al. revealed that CGRP infusion leads to dilation of the middle meningeal 
artery but not to dilation the middle cerebral artery.53 It would be interesting to 
investigate the effects of CGRP receptor antagonists in the CGRP infusion model on 
the delayed migraine-like headache.
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3.2.5.2 Glyceryl trinitrate infusion
Glyceryl trinitrate (GTN) infusion in migraine patients also triggers headache attacks, 
fulfilling the IHS criteria for MO, 4-5 hours after infusion in 50% of patients with 
MA and in 80% of patients with MO. In healthy volunteers GTN infusion does not 
cause a delayed migraine attack, although headache during and immediately after 
infusion does occur.63, 64 As with the CGRP infusion model, the exact mechanism 
behind the GTN migraine model is not known. GTN infusion leads to the production 
of NO, a potent vasodilator, in the body. NO-inhibitors are currently under research 
as possible new therapy target for migraine.65 Although more studies are needed to 
draw categorical conclusions, the GTN migraine model may not be suitable to study 
the effects of CGRP receptor antagonists, since Tvedskov et al. showed that GTN-
induced migraine was not prevented by olcegepant.66 A possible explanation could 
be that CGRP exerts its effect earlier than NO in the events leading to migraine after 
GTN infusion. 
3.2.5.3 Pituitary adenylate cyclase activating polypeptide infusion
The pituitary adenylate cyclase activating polypeptide (PACAP) migraine model is a 
model that also makes use of a strong vasodilator. PACAP infusion induces migraine 
in 58% of patients with MO.67 Infusion of vasoactive intestinal peptide (VIP) does 
not cause migraine in migraine patients.68 VIP and PACAP share receptors, except 
the PACAP type 1 receptor (PAC1), which suggests the involvement of PAC1 in the 
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Figure 2. Relaxant effect of αCGRP on human proximal (top left) and distal (top right) coronary arteries 
and human meningeal arteries (bottom). Concentration–response curves to αCGRP were constructed in the 
absence or presence of 300 nM telcagepant (proximal), 30 nM to 1 μM telcagepant (distal), and 1 μM telcagepant 
(meningeal). Values given represent mean ± S.E.M. (n = 4–8). Adapted from: Chan et al, JPET 2010, 334, 746-
752 and Edvinsson et al. Cephalalgia 2010;30:1233-1240.
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migraine attacks seen after PACAP infusion.69 PACAP and CGRP are hypothesized 
to share the cAMP signaling pathway and it would be interesting to investigate 
whether CGRP receptor antagonists can abort PACAP-induced migraine.70, 71
3.2.5.4 Prostaglandin infusion
Finally, infusion of prostaglandin E2 can also induce migraine.
72 After prostaglandin 
infusion, 75% of patients with MO experience migraine-like attacks.73 The migraine-
like attacks occur during and immediately after infusion, which is different from 
the other pharmacologically induced migraine models. The immediate onset of 
the attacks points towards a role for prostaglandins in the late phase of migraine 
development. This is an interesting model to investigate the effect of CGRP receptor 
antagonists in this phase of migraine.
3.2.6 Fos expression in experimental animals
Immunoreactivity of the Fos protein, which is a nuclear protein that regulates 
transcription of other target genes, has been shown to be a marker of neuronal 
activity.74, 75 To identify related nociceptive pathways in migraine, activation of 
Fos expression in the trigeminovascular system has been used.76 The expression 
of the Fos protein occurs in vivo after a certain stimulus, although obviously the 
measurement of the protein is performed in vitro. Fos expression can be activated 
by applying mechanical, electrical or chemical stimuli in either extracranial or 
intracranial tissues innervated by the trigeminal nerves. This includes electrical 
stimulation of the trigeminal ganglion and superior sagittal sinus (SSS) as well as 
chemical stimulation of the meninges (dura mater) with capsaicin or other irritant 
substances.75 
3.2.6.1 Stimulation of the trigeminal ganglion and meninges
Trigeminal ganglion activation is a well-established method for the activation of the 
trigeminovascular system. Electrical stimulation of the trigeminal ganglion induces 
expression of c-Fos mRNA and Fos protein in trigeminal nucleus caudalis (TNC) of 
pigs77 and rats.78 However, trigeminal ganglion stimulation may induce widespread Fos 
expression by discharging many other afferents than those innervating the meninges, 
which is a limitation of this method.75 A more direct activation of the meninges is 
chemical stimulation using capsaicin or other irritant substances.75 Primary sensory 
fibers supplying the meninges are activated by injection of capsaicin or other irritant 
substances through a small catheter into the cisterna magna through the atlanto-
occipital membrane. Fos protein immunoreactivity is detected in both sides of the 
TNC 2 h after injection and capsaicin increases Fos protein immunoreactivity in a 
dose-dependent manner.79 The limitation of chemical stimulation of the meninges 
is that no comparison can be made between the two sides of the TNC.75 To provide 
more information about the site of action in the TNC, stimulation of the SSS to 
induce Fos expression seems to be the most suitable model. 
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3.2.6.2 Stimulation of the superior sagittal sinus
Mechanical and electrical stimulation of the SSS has been used to induce Fos 
immunoreactivity in the TNC of rat80, cat81 and non-human primate.82 Activation of 
brainstem structures after SSS stimulation, which is observed in different studies, 
reflects to the neurovascular activation of pain-sensitive structures during a migraine 
attack.75 Moreover, neurons in the TNC that are activated through SSS stimulation are 
primary located in the deeper part of the nucleus caudalis, lamina V which correspond 
to Aδ-fiber input81, 83 and SSS stimulation induces the release of neuropeptides like 
CGRP and VIP in a pattern similar to that observed during migraine attacks.12, 84 
3.2.6.3 Systemic infusion of stimuli
Systemic infusion of noxious stimuli can also be used to induce Fos protein expression. 
GTN (an NO donor) infusion induced Fos expression in the trigeminocervical complex 
(TCC, TNC and C1/2 spinal cords levels),85 which suggests a role of NO donors in 
activating the trigeminovascular system. This is supported by the results that the NOS 
inhibitor N-Nitro-L-Arginine Methyl Ester (L-NAME) decreases capsaicin- as well 
as electrically-induced Fos expression,83, 86 Infusion of CGRP has also been shown to 
induce Fos expression in TNC.87 The CGRP receptor antagonist, olcegepant inhibits 
systemically administered capsaicin-induced Fos expression in the spinal trigeminal 
nucleus, but not the increased phosphorylated extracellular signal-regulated kinase 
in the trigeminal ganglion when capsaicin is injected unilaterally in the face.88 This 
might suggest that olcegepant exerts its effect mainly in the central nervous system 
rather than periphery including the trigeminal ganglion, which is activated when 
capsaicin is injected in the face.88 On the other hand, olcegepant was administered 
intravenously so it is questionable if the concentration that reached the central 
nervous system is high enough to exert any effects, because of its incapability of 
crossing the blood brain barrier (paragraph 3.2.2). More studies with CGRP receptor 
antagonists comparing central and peripheral effects need to be done to investigate 
this proposition.
Fos protein expression models are only good models when the stimulus drives the 
expression of Fos protein.75 However, to induce a Fos expression to quantifiable 
levels, a strong, consistent stimulation is required that is often not physiological.89 
Moreover, since Fos is not expressed in all neurons,74 lack of Fos expression does not 
mean that there is no neuronal activity.90 Despite these limitations, the Fos expression 
model with its different stimulations is a good model to investigate the neuronal 
activity of the trigeminovascular system on different levels.75, 90 The different 
stimulations have allowed the identification of a subpopulation of neurons that is 
activated in response to noxious stimuli and thus identifying related nociceptive 
response.90 The Fos expression model already greatly increased our understanding 
of the trigeminovascular system75, 76 and the role of CGRP signaling in this system. In 
addition, the therapeutic mechanisms of possible CGRP receptor antagonists in the 
trigeminovascular system can be investigated via determination of neuronal activity. 
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3.2.7 In vivo electrophysiological recording in experimental animals
Electrophysiological recording is a method to measure action potential activity or 
local field potentials, which represent the net activity of a population of cells, in 
neurons by placing electrodes into the brain area of interest in a living animal.76 In 
migraine research, electrophysiological recordings are performed in different parts 
of the trigeminovascular system, like the trigeminal ganglion91 and the TCC.92, 93 
Moreover, since functional imaging studies in spontaneous migraine attacks as well 
as human models using trigeminal nociceptive stimulation have shown a consistent 
activation of the thalamus94-96 and the majority of the secondary neurons in the TCC 
project to the thalamus,97 the ventral posteromedial thalamic nucleus (VPM) is also 
an area of interest.76 Indeed, electrophysiological studies in experimental models 
demonstrate that trigeminovascular nociceptive stimulation activates neurons in the 
VPM.12, 98 Action potentials in the TCC and VPM, measured by electrophysiological 
recordings, can be triggered by electrical stimulation of SSS (see Fos protein), 
electrical stimulation of dura mater (see cranial window) and micro-iontophoresis of 
L-glutamate in either TCC
93 or VPM.99 
This model can be used to investigate the effect on neuronal activity in the second 
order neurons of TCC and the third order neurons of VPM for a possible site of action 
of antimigraine drugs.76 Moreover, using micro-iontophoresis of Lglutamate, effects 
on postsynaptic action of neuronal elements including dendrites and cell bodies distal 
to the synaptic cleft can be studied more specifically.99 The great advantage of this 
model is the real-time resolution of the response to a stimulus or pharmacological 
intervention. Although the neuronal activity can only be studied in a few neurons at 
the same time,76 potential targets of triptans92, 98 as well as prophylactic antimigraine 
drugs have been discovered with this model.99, 100 
CGRP release has been shown in many structures of the trigeminovascular system, 
including second-order neurons in the TCC.39 Therefore, CGRP receptor antagonists 
might also affect the TCC and the VPM. Intravenous administration of olcegepant 
has been shown to reduce spinal trigeminal activity induced by electrical stimulation 
of the dura mater91 and thalamic cell firing in VPM101 as well as TCC102 by SSS 
stimulation. Moreover, the CGRP receptor antagonist, CGRP8-37, is able to inhibit 
cell firing induced by micro-iontophoresis of Lglutamate and SSS stimulation in the 
VPM.101, 102 These results suggest that VPM might be a possible therapeutic target 
for CGRP receptor antagonists.102 Because of the positive results obtained with the 
CGRP receptor antagonists olcegpant and CGRP8-37, electrical recording of TCC and 
VPM seems an excellent experimental model to identify the effect of CGRP receptor 
antagonists in the second-order neurons of the TCC and the third order neurons of 
the VPM as a possible site of therapeutic action. 
3.2.7.1 Cortical spreading depression
CSD is regarded to be a main pathogenic step in migraine with, and possibly 
also without, aura.  Although the potential role of CGRP in CSD has not yet been 
examined in detail, a recent study suggests that CGRP is involved in CSD and that 
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CGRP receptor antagonism reduces CSD. This suggests, in contrast to the low CGRP 
receptor expression in cortex21 and the limited CNS penetration of telcagepant49 
mentioned earlier in this review, that central CGRP receptors may be a relevant 
target for CGRP receptor antagonism.
3.2.8 Transgenic mice 
Another model in which the physiological role of the CGRP-ergic system can be 
studied are transgenic mice. In these animals a gene of another species is inserted 
and expressed. A recently developed transgenic mouse model is the nestin/hRAMP1 
mouse model. These animals over-express the RAMP1 part of the human CGRP 
receptor in the central and peripheral nervous system and show an aversive behaviour 
against light, which increases enormously after injection of intracerebroventricular 
CGRP.103 Interestingly, CGRP concentrations in cerebrospinal fluid are increased 
in these mice, suggesting a positive feedback mechanism that is not yet fully 
understood.103 It was shown that this light aversive behaviour in these animals could 
be blocked by olcegepant. Furthermore some CGRP knockout mice show decreased 
pain responses and increased blood pressure.104, 105 These transgenic animals can thus 
be used to study effects of newly developed CGRP receptor antagonists. 
4. Future developments
4.1 CGRP receptor blockade for the prophylactic treatment of migraine
While blockade of CGRP receptors has been demonstrated to be effective and well 
tolerated in the acute treatment of migraine, this concept has also been proposed 
as a mechanism of action for prophylactic antimigraine drugs, which are used by 
patients who suffer from highly frequent attacks, or where acutely acting drugs 
are contraindicated. Indeed, there is a need for effective preventive antimigraine 
treatments. Of the current prophylactics, none is specific for migraine (e.g., valproate 
was developed as an anti-epileptic drug and betablockers were developed to treat 
high blood pressure), explaining the high number of side effects due to their low 
specificity.106 In addition, prophylactic drugs are generally effective in only 50% of 
patients. 
Chronic CGRP receptor blockade can be reached via different strategies. Firstly, 
CGRP receptor antagonists can be administered on a (twice) daily basis. As 
described above in paragraph 3, this approach has been followed for telcagepant, 
which induced raised levels of liver transaminases and subsequent termination of the 
development of telcagepant. Alternatively, chronic CGRP receptor blockade may 
be reached by the administration of antibodies directed against the CGRP receptor. 
Using this latter approach, the CGRP receptor is blocked for up to 7 days after one 
single administration.107 While a permanent blockade of the CGRP receptors could 
indeed be effective against migraine, it should be born in mind that, under such 
conditions, the physiological role of CGRP is constantly repressed. CGRP is one of 
the main contributors to the maintenance of normal vascular tone under ischemic 
conditions and protects the brain as well as peripheral organs, including the heart, 
against excessive vasoconstriction.108-112 These important protective functions of 
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CGRP would most likely be blocked when CGRP receptor antagonists or antibodies 
directed against the CGRP receptor are used as a prophylaxis, which could have 
potentially harmful consequences. On the other hand, in mice and rat no evidence was 
found that CGRP receptor antagonists have a negative effect on ischemic injury113 
and in rat and pig no effect of CGRP receptor antagonists olcegepant and CGRP8-37 
was seen on infarct size in ischemia/reperfusion studies.114, 115 Because these results 
are still contradictive, it is of crucial importance that extensive preclinical, as well 
as clinical studies are performed to elucidate whether it is safe to constantly repress 
the function of CGRP.
An alternative approach to blockade of the CGRP receptor is the use of an antibody 
directed against the CGRP protein itself.116 Currently, the antibody LY2951742 is 
under investigation in a clinical trial. The potential objections mentioned above for 
repression of the CGRP receptor function obviously also apply for eliminating the 
function of the CGRP protein itself. 
4.2 CGRP receptor antagonists against migraine as well as hot flushes during 
menopause?
Menopause is known to disturb the secretion of CGRP, resulting in lower levels of 
plasma CGRP in postmenopausal women compared to fertile women.117 Vasomotor 
changes, such as hot flushes, on the other hand, are accompanied by a temporary 
rise in plasma CGRP levels in menopausal women. Indeed, infusion of CGRP can 
cause facial flushing.118 Thus, CGRP may be an important factor in the occurrence of 
hot flushes.119 As about one quarter of women visiting menopause clinics also report 
migraine,120 a combined treatment of both the vasomotor symptoms and the headaches 
would seem useful. The vasomotor changes in menopausal women are until now 
treated with hormone replacement therapy (HRT).121 However, at the onset of HRT 
migraine attacks may become more frequent.122 In addition, HRT is associated with 
cardiovascular side effects.123 An alternative treatment for the vasomotor changes 
during menopause seems to be required. The perimenopausal migraine headaches 
are treated not differently from any other migraine headaches.124 CGRP receptor 
antagonists could be effective against both the perimenopausal migraine, as well 
as the vasomotor symptoms. However, considering the transient character and 
short duration of the hot flushes, CGRP receptor antagonists should probably be 
administered as prophylaxis. Obviously, the same potential drawbacks as described 
above for the use of CGRP receptor antagonists as prophylactic treatment against 
migraine apply, and the safety should be well investigated.
5. Conclusion
CGRP receptor antagonists seem to be promising new compounds for the acute 
treatment of migraine attacks, but no compound has passed clinical trials yet. The 
advent of novel compounds is awaited with great interest. Before a compound is 
tested in clinical trials, different preclinical experimental models may be used to 
characterize its pharmacological properties. As migraine is a neurovascular disease 
and no integrative model exists encompassing all components of this disease, the 
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models used to study new CGRP receptor antagonists include both vascular models 
as well as models of the central nervous system. All these models study specific 
properties of a compound, and their results should be integrated to get a complete 
picture of the effects and side-effects. Furthermore, these models can also be applied 
for more basic studies to obtain a better understanding of the pathophysiology of 
migraine.
6. Expert Opinion
The most widely used acute antimigraine drugs available are the triptans. Although 
they provided a major breakthrough in the acute treatment of migraine attacks 
when they were discovered, they are not effective in all patients and because of 
their vascular side-effect potential contraindicated in patients with cardiovascular 
disease. Thus, a major proportion of migraine patients cannot use, or has no profit of 
the use of triptans. Therefore it is highly relevant to find novel types of antimigraine 
drugs with fewer side effects. The discovery of the important role of CGRP in 
the pathophysiology of migraine prompted the search for a new type of acute 
antimigraine drugs, the CGRP receptor antagonists. The outcome of the first studies 
with the CGRP receptor antagonists, olcegepant and telcagepant, was positive. Both 
drugs showed little side effects and their effectivity against migraine was comparable 
to that of the triptans. CGRP receptor antagonists do not cause any constriction of 
coronary arteries 31, which may be an advantage compared to the triptans in view of 
cardiovascular safety. Furthermore, the patients that respond well to CGRP receptor 
antagonists are not necessarily the same patients that respond well to the triptans.125 
Therefore, CGRP receptor antagonists may fulfil a complementary role in the acute 
treatment of migraine and may hopefully also be of benefit to non-responders to 
triptan therapy.
It is still a question where CGRP receptor antagonists exert their therapeutic effects 
in migraine. Some studies, for example the above-mentioned study showing only 
moderate brain receptor binding for telcagepant,49 suggest that a central action 
may not be essential for the effects of CGRP receptor antagonists. Other studies, 
however, suggest that vascular changes in migraine are absent or an irrelevant 
epiphenomenon.126 While it is still unclear where the therapeutic site of action of 
the CGRP receptor antagonists is located, possibly the efficacy or lack of efficacy of 
antibodies directed against the CGRP receptor, that are unlikely to penetrate into the 
brain in view of their high molecular weight, may shed more light on this discussion. 
It is important in this light to realize that the trigeminal ganglion is located outside 
the blood brain barrier, and could also serve as a target for ligands without central 
penetration.
As described above, it remains to be demonstrated whether continuous blockade 
of CGRP receptors does not increase the risk for myocardial or cerebral ischemia. 
Further, since overexpression of the CGRP receptor in mice leads to increased CGRP 
levels in cerebrospinal fluid,103 it is important to investigate whether blockade of 
CGRP receptors would lead to an opposite effect, i.e., decrease the levels of CGRP.
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Since CGRP receptor antagonists act via a different mechanism of action than the 
triptans, it is important that their effects are assessed in adequate models. Currently 
available experimental migraine models only study a small part of all potentially 
relevant processes that are going on during a migraine attack. Integrated neurovascular 
animal as well as human models that measure both vascular and neuronal components 
simultaneously would increase the knowledge on the mechanism of action of 
prospective CGRP receptor antagonists. Further, more emphasis should be put on the 
translation of the human infusion model to animal models, where effects of infusion 
of migraine triggers may be studied in detail.  It would be desirable to perform 
more studies in awake animals, where behaviour can be studied and results are not 
confounded by the use of anesthetics. The use of transgenic animals in these models 
may be of additive value. 
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After reading the interesting Article by Faisal Mohammad Amin and colleagues,1 
we were confused about the conclusion made by the authors, namely that “future 
migraine research should focus on the peripheral and central pain pathways rather 
than simple arterial dilatation”.  This conclusion was based on their observation 
that during a migraine attack, “no statistically significant dilatation was seen of 
the extracranial arteries on the pain side” and “only a slight dilatation” of cerebral 
arteries was detected. 
Although the authors correctly comment that they could not exclude possible 
dilatation of dural branches of the middle meningeal artery (MMA) given that these 
small branches could not be analyzed due to technical limitations, they still felt 
justified to draw the above-mentioned conclusion.  We perceive this limitation as an 
important issue and fear that their interpretation is premature. Amin and colleagues 
disregard the fact that an intracranial branch of an artery, such as the intracranial dural 
branches of the MMA, can differ from its extracranial branches.2, 3 In particular, they 
did not measure intracranial MMA circumference in any of their human magnetic 
resonance angiography studies, but instead based their findings on assessments of 
only the extracranial  MMA. By 1961, Hassler3 showed structural changes in the 
basilar artery wall between the open and closed skull after craniotomy. In the open 
skull preparation the basilar artery had profoundly changed its vessel wall properties; 
hence we argue that the structure (and consequently also function) of the extracranial 
MMA might differ substantially from the intracranial MMA.
We are further surprised by a previous report by the same group, in which they 
concluded that “migraine without aura is associated with dilatation of extra- and 
intracerebral arteries and that the headache location is associated with the location 
of vasodilatation”.4 Admittedly, the migraine attacks observed in this study4 were 
induced by systemic infusion of calcitonin gene-related peptide (CGRP). Their finding 
that spontaneous migraine attacks are not associated with dilation of extracranial 
arteries suggests that provocation with CGRP infusion is a flawed migraine model.
Alternatively, this discrepancy might be related to some concerns regarding the 
study population and the procedures applied in the study by Amin and colleagues.1 
The migraine attacks reported were of moderate severity and time between attack 
and attack-free scans was 5-274 days, as opposed to only a few hours in their CGRP 
infusion study.4 The arterial circumference changes measured between attack and 
attack-free scans were slight and had large SD. These limitations could have resulted 
in an underpowered study measuring minor changes from variable baseline values 
owing to the long period between scans.
We acknowledge the sheer complexity of doing magnatic resonance angiography 
scans during spontaneous migraine attacks and value the study by Amin and 
colleagues.1 However, we contest their, in our view, premature conclusion. We 
sincerely approve of findings that help our understanding of migraine and migraine 
pain, but these should be based on solid arguments and data. 
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Abstract
Background: During migraine, trigeminal sensory nerve terminals release calcitonin 
gene-related peptide (CGRP), inducing nociception and vasodilatation. Applied on 
the skin, capsaicin activates the transient receptor potential vanilloid type 1 (TRPV1) 
channel and releases CGRP from sensory nerve terminals, thus increasing dermal 
blood flow (DBF). Using capsaicin application and electrical stimulation of the 
forehead skin, a trigeminal nerve-innervated dermatome, we aimed to develop a 
model to measure trigeminal nervemediated vasodilatation in humans. Methods: 
Using laser Doppler imaging, forehead DBF responses to application of capsaicin 
(0.06 mg/ml and 6.0 mg/ml) and saline, with and without iontophoresis, were studied 
in healthy subjects. The within-subject coefficient of variation (WCV) of repeated 
DBF measurements was calculated to assess reproducibility. Results: Maximal DBF 
responses to 6.0 mg/ml capsaicin with and without iontophoresis did not differ (Emax 
459±32 and 424±32 arbitrary units (a.u.),  WCV 6±4%). In contrast, DBF responses to 
0.06 mg/ml capsaicin were significantly larger with than without iontophoresis (Emax 
307±60 versus 187±21 a.u., WCV 21±13%).  Saline with iontophoresis significantly 
increased DBF (Emax: 245±26 a.u, WCV 11±8%), while saline application without 
iontophoresis did not affect DBF. Conclusion: Topical application of capsaicin and 
electrical stimulation induce reproducible forehead DBF increases and therefore are 
suitable to study trigeminal nervemediated vasodilatation in humans.
Introduction
Migraine is a neurovascular disorder1 involving: (i) activation of the 
trigeminovascular system with the primary dysfunction located in brainstem centres 
regulating vascular tone and pain sensation;1 (ii) release of vasoactive neuropeptides 
from trigeminal sensory nerves including calcitonin gene-related peptide (CGRP);2, 
3 and (iii) vasodilatation of intracranial arteries and of the extracranial branches of 
the external carotid artery.4, 5 Indeed, it has been reported that plasma concentrations 
of CGRP are elevated during migraine headache and they diminish to normal levels 
after treatment with triptans in parallel with alleviation of headache.6 In view of the 
key role of CGRP in the pathophysiology of migraine, CGRP and its receptors have 
now become a novel drug target for antimigraine therapy.7
CGRP is predominantly located in sensory neurons and perivascular (including 
trigeminal sensory) nerves.2, 3, 8-10 Upon release in the cranial circulation, CGRP dilates 
cranial blood vessels and is involved in nociception.8 Release of endogenous CGRP 
from trigeminal nerves can experimentally be induced by electrical stimulation6, 
11, 12 or by chemical stimulation with capsaicin,13-15 the latter through activation 
of the transient receptor potential vanilloid type 1 (TRPV1) cation channel.16, 
17 Administration of capsaicin in the carotid artery has been reported to induce 
vasodilatation of the extracranial circulation of pigs18 and dogs.19 These capsaicin-
induced vasodilator responses can be blocked by CGRP receptor antagonist.18, 20 
Similarly, both electrically and capsaicin-induced intracranial dural vasodilatation 
in rats21 and mice22 are mediated by trigeminal CGRP release. Likewise, topically 
applied capsaicin on the human forearm skin increases dermal blood flow (DBF), 
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and this response can be prevented by  CGRP receptor antagonists23 as well as by 
monoclonal antibodies preventing the binding of CGRP with its receptor.24, 25 This 
“peripheral” human capsaicin model has been succesfull as a biomarker in early 
clinical drug development by providing proof of target engagement in phase I clinical 
trials and guiding dose selection for phase II clinical trials. Although the capsaicin-
induced increase in DBF of the human forearm was shown to be reproducuble and 
user friendly, its major limitation remains the uncertainty about the translation of 
peripheral versus cranial vascular responses induced by capsaicin.  
Until now straightforward and reproducible human methods for the analysis 
of trigeminal nerve-mediated vasodilatation with minimal demands of the test 
subject have been lacking. Since the dermatome of the forehead is innervated 
by the trigeminal nerve, the forehead seems well suited to investigate trigeminal 
mechanisms. Gazerani et al. have developed a capsaicin model for trigeminal 
sensitization and have applied the model to investigate for example gender-specific 
differences and the effect of Botulinum Toxin type A.26-29 However, this is an 
invasive model where human subjects receive intradermal capsaicin injections to 
the forehead, resulting in unilateral, throbbing, headache  and symptoms of general 
trigeminal sensitization. Similarly, May et al. applied subcutaneous capsaicin 
injections in an experimental pain model to examine the neurovascular mechanisms 
in cluster headache.30 Participants of this study reported “terrible pain” after the 
subcutaneous capsaicin injections. We primarily aimed with our study to investigate 
whether measurement of local blood flow in  the forehead region, using laser Doppler 
imaging, in response to either electrical stimulation,  or capsaicin application could 
be used as a novel model to assess local trigeminal nerve-mediated vasodilation 
in humans. Whereas application of capsaicin induces CGRP release via activation 
of TRPV1 channels23 electrical stimulation induces neuropeptide release without 
direct activation of these channels.31 In recent years interest in transdermal drug 
delivery techniques that enhance permeation of drugs into the skin has increased.32 
One such technique is iontophoresis, where a solution of a compound or drug is 
put in an electrode reservoir bearing the same charge as the compound or drug 
of interest. When an electric current is applied to the reservoir, ions set in motion 
toward the electrode of opposite charge and more easily penetrate into the skin.32 In 
this study, as a secondary aim, we wanted to investigate whether iontophoresis of 
capsaicin might improve its delivery on the human forehead, resulting in a higher 
response and/or a shorter response latency. 
Materials and methods
Subjects
Twenty-four healthy human volunteers (14 women and 10 men) were studied 
(Table 1). The study protocol was reviewed and approved by the Independent 
Ethics Committee of Erasmus MC, Rotterdam, The Netherlands and all participants 
gave written informed consent after explanation of the purpose of the study. The 
study was conducted in accordance with local laws, the ethical principles of the 
Declaration of Helsinki, as well as the principles of Good Clinical Practice.
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Experimental setup
Experiments were performed in a quiet, temperature-controlled room. Participants 
were not allowed to use any drugs for 48 hours preceding the experiment and they 
fasted for at least three hours before the start of the experiment. To investigate 
short term reproducibility, two research visits with three to four days in between 
were scheduled for the participants to study potential neuropeptide depletion and 
receptor desensitization in this period. Some of the subjects participated in multiple 
experiments; in these cases the time between two subsequent experiments was at 
least 14 days to exclude any potential interference of previous experiments.  The 
forehead DBF responses induced by topical application of capsaicin, vehicle and 
Male Female All
Population, n 10 14 24
Age, years 32 (11) 33 (10) 33 (10)
BMI, kg/m2  23.5 (2.4) 24.0 (2.6) 23.8 (2.5)
BP, mmHg
     Systolic 
     Diastolic 
115 (7)
69 (6)
110 (8)
68 (9)
112 (8)
68 (7)
HR , bpm 68 (6) 64 (10) 66 (9)
Table 1. Demographics of the study population. BMI, body mass index. BP, blood pressure. HR, heart rate. 
Mean (SD).
physiological saline with and without iontophoresis were measured with a laser 
Doppler perfusion imaging device (LDPI; Periscan PIM 3 system, Perimed AB, 
Järfälla, Sweden). Subjects received topical applications of capsaicin (0.06 mg/ml 
and 6.0 mg/ml), vehicle (a mixture of ethanol 100%, Tween 20 and distilled water; 
3:3:4) or physiological saline (0.9% NaCl, 0.5 ml in each case) on the forehead 
in electrodes with reservoirs specifically designed for this purpose (Perimed AB, 
Järfälla, Sweden). For electrical stimulation of the forehead skin, iontophoresis of 
physiological saline was applied. 
Capsaicin was obtained from Sigma-Aldrich (Zwijndrecht, the Netherlands). We 
decided to use a methodology and dose similar to that previously reported by Van 
der Schueren et al.33 In addition, since we intend to use our model also for studies 
aimed at observing trigeminal hyperreactivity, we furthermore decided to analyze 
the effect produced by a two log unit lower concentration in an attempt to be able to 
detect low responses around the activation threshold. 
Trigeminal nerve-mediated vasodilatation model 
For the trigeminal nerve-mediated vasodilatation model, we used two electrodes with 
0.06 and 6.0 mg/ml capsaicin solution and a cumulative successive rate of currents 
applied to an electrode containing physiological saline (0.2, 0.4, 0.6, 0.8 and 1.0 
mA, each lasting one min, with an interval of six min between successive current 
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intensities). To assess reproducibility these experiments were performed twice at an 
interval of three to 10 days. The trigeminal nerve-mediated vasodilatation model was 
evaluated in 12 subjects.
In-depth characterization of the trigeminal nerve-mediated vasodilatation model
Capsaicin iontophoresis was performed on the forehead by application of a small 
current (0.4 mA, lasting one min) to two electrode chambers, filled with either 0.06 
mg/ml or 6.0 mg/ml capsaicin in seven subjects. In these seven subjects, a third 
electrode was placed on the forehead for iontophoresis of vehicle (0.4 mA, lasting 
one min). 
To evaluate potential effects of electrode location, iontophoresis was performed on 
two electrodes placed on either the left or right side of the forehead during the same 
experiment. To investigate iontophoresis-independent effects of vehicle, vehicle 
was topically applied on the forehead without iontophoresis in four subjects. 
Figure 1. (a) Illustration of electrode placement. From left to right: electrical stimulation, application without 
iontophoresis 0.06 mg/ml capsaicin and application without iontophoresis of 6.0 mg/ml capsaicin. (b) Color-coded 
perfusion images of forehead dermal bloodflow measured at baseline and 10, 20 and 30 minutes. In the white 
circles from left to right: electrical stimulation, application without iontophoresis of 0.06 mg/ml capsaicin and 
application without iontophoresis of 6.0 mg/ml capsaicin. Perfusion is indicated in color code that ranges from 
black (no perfusion) to red (high perfusion).
Data presentation and statistical evaluation
The DBF values are presented in arbitrary units (a.u.) as means ± S.E.M.  Student’s t 
test (paired or unpaired where appropriate) was used to compare maximal responses 
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(Emax) to application and iontophoresis of different solutions for groups with n≥7.  
Wilcoxon matched pairs test or Mann-Whitney test was applied where appropriate 
for groups with n<7 to compare means. Emax was defined as the maximum DBF 
response in a.u. after subtraction of baseline DBF. Within-subject coefficient of 
variation (WCV) and intraclass correlation coefficient (ICC) were calculated as 
measures of reproducibility and agreement. We also performed correlation analysis 
using the Pearson correlation coefficient and Bland-Altman analysis. The between 
subject coefficient of variation (BCV) was also calculated. Sample size calculations, 
given a type I error probability (α) of 0.05 and a power of 80%, were performed 
without assumptions on an eventual increase in statistical power because of a 
paired nature of measurements (unpaired model).  Calculations were based on the 
application without iontophoresis of the 6.0 mg/ml capsaicin solution to detect a 
DBF response difference of 10%, 20%, and 30%. A p value <0.05 was considered 
to indicate statistical significance.
Without iontophoresis
DBF Emax in a.u.
With iontophoresis
DBF Emax in a.u.
Saline 10 ± 5 *  (n=4) 245 ± 26 *   (n=12)
Vehicle 153 ± 45 *   (n=4) 356 ± 53 *   (n=11)
Capsaicin 0.06 mg/
ml 187 ± 21 
*   (n=12) 306 ± 60 *   (n=12)
Capsaicin 6.0 mg/
ml 459 ± 32    (n=12) 424 ± 43    (n=7) 
Results
Forehead application of the capsaicin solutions (0.06 mg/ml and 6.0 mg/ml) with 
and without iontophoresis and forehead electrical stimulation were well tolerated 
and side effects other than local redness were not encountered. None of the subjects 
reported pain.
Trigeminal nerve-mediated vasodilatation model
Application without iontophoresis of the 0.06 mg/ml and the 6.0 mg/ml capsaicin 
solutions resulted in fast increases in DBF (Figure 1) with an Emax of respectively 
187±21 and 459±32 a.u. (Table 2). The DBF responses at 30 min, averaged for 
both visits, were 123±10 a.u. for the low and 370±28 a.u. for the high capsaicin 
concentration (Figure 2(a)). The time to reach Emax was 22±3 and 11±1 min for 0.06 
and 6.0 mg/ml capsaicin, respectively. The DBF response to electrical stimulation 
differed from baseline for each applied current ranging from 0.2 to 1.0 mA (Figure 
2(b)). The between-visit DBF responses for either of the two capsaicin solutions or 
electrical stimulation did not differ (Figure 2(a) and (b)). 
Table 2. Maximal forehead dermal blood flow responses to physiological saline, vehicle, 0.06 mg/ml capsaicin 
and 6.0 mg/ml capsaicin with and without iontophoresis.
Iontophoresis with 0.4 mA during 1 min. Grey shaded columns depict parameters of our trigeminal nerve-
mediated vasodilatation model. *: Significant difference in Emax between application only and application with 
iontophoresis.  
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2(a) 2(b)
Figure 2. (a) Time course of forehead dermal blood flow responses to 0.06 mg/ml (○) and 6.0 mg/ml (◊) application 
of capsaicin without iontophoresis during visit 1 (open) and during visit 2 (filled). n=12. *: Difference from baseline, 
t-test: p<0.05. (b) Response of forehead dermal blood flow to increasing currents of electrical stimulation of a 
physiological saline solution during visit 1 (open) and visit 2 (filled). n=7.*: Significantly different from baseline. 
The application of 6.0 mg/ml capsaicin without iontophoresis and electrical 
stimulation with 1.0 mA at the end of the cumulative successive rate of currents 
were the best reproducible experimental approaches of the trigeminal nerve-
mediated vasodilatation model, whereas the reproducibility of the DBF response to 
Experiment ICC WCV (%) (95% CI)
Electrical stimulation 
(Emax) 
0.2 mA
0.4 mA
0.6 mA
0.8 mA
1.0 mA 
0.68
0.74
0.84
0.80
0.91
28 (10, 122)
33 (0, 48)
24 (0,34)
15 (0,22)
11 (0, 16)
Application capsaicin 
(Emax) 
0.06 mg/ml                                         
6.0 mg/ml
0.35
0.96
40 (20, 53)
6 (3, 8)
Table 3. Reproducibility. ICC, Intraclass correlation coefficient indicating strength of agreement; WCV, Wit-
hin-subject coefficient of variation.
0.06 mg/ml capsaicin application without iontophoresis and electrical stimulation 
with currents lower than 1.0 mA was fair to good (Table 3 and Figure 3).    
The BCV was 38% for 0.06 mg/ml capsaicin, 24% for the 6.0 mg/ml capsaicin and 
35% for electrical stimulation with 1.0 mA. We performed sample size calculations 
based on the application of 6.0 mg/ml capsaicin without iontophoresis. The required 
group sizes to detect differences in DBF response resulted in groups of n=91, 23 and 
11 subjects to detect a 10%, 20% or  30% shift, respectively.
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Figure 3. Scatter plots (left-hand side) show correlation between Visit 1 and Visit 2 calculated for DBF responses 
to 0.06 mg/ml capsaicin application without iontophoresis (upper panel), 6.0 mg/ml capsaicin application without 
iontophoresis (middle panel) and electrical stimulation (lower panel). 0.06 mg/ml capsaicin: r = 0.35, p = 0.26; 6.0 
mg/ml  capsaicin: r = 0.96, p <0.0001; electrical stimulation: r = 0.93, p <0.005. Bland-Altman plots (right-hand 
side) show bias (dotted lines) and limits of agreement (solid lines). n=7-12.
In-depth characterization of the trigeminal nerve-mediated vasodilatation model
Compared to application only, iontophoresis (0.4 mA) of 0.06 mg/ml capsaicin 
resulted in a marked increase in forehead DBF ( Table 2). In contrast, compared to 
application only, iontophoresis of the high dose of capsaicin did not cause a further 
increase in DBF (Table 2). In comparison to application without iontophoresis, 
the response latency was significantly shorter for application with iontophoresis 
of 0.06 mg/ml capsaicin (time to Emax of 13±2 min), but not for application with 
iontophoresis of 6.0 mg/ml capsaicin (time to Emax of 10±2 min). 
Interestingly, application of vehicle, but not saline, without iontophoresis also 
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caused a modest increase in DBF comparable to the DBF response to application 
without iontophoresis of 0.06 mg/ml capsaicin, whereas iontophoresis of vehicle 
and saline caused a further marked increase in DBF (Table 2). Electrode placement 
site had no influence on the DBF response (Emax at 0.4 mA right side of the forehead: 
430 ± 58. Emax at 0.4 mA left side of the forehead: 456 ± 91). 
Discussion
We here present a novel human model for measuring trigeminal nerve-mediated 
vasodilatation in the forehead skin. With our results we show reproducible DBF 
responses to topical capsaicin application and electrical stimulation. We have 
demonstrated that iontophoresis of capsaicin does not result in higher DBF 
responses or shorter response latency in comparison to application of capsaicin 
without iontophoresis. In addition to the chemical stimulation with capsaicin, 
electrical stimulation allows us to stimulate the trigeminal afferents without direct 
activation of  the TRPV1 channel. Advantages of the model we developed are its 
noninvasiveness, its relative simplicity and its suitability to be used in humans. 
Furthermore, the topical application of a high and low concentration of capsaicin 
allows one to study not only high responses, but probably also to distinguish 
between subjects with a lower or higher threshold response to TRPV1 channel 
activation. Altogether, the developed model has the potential to be applied for 
studying trigeminal-nerve-mediated disorders as well as for the evaluation of (new) 
drugs for these conditions. 
Analysis of our data revealed that the DBF responses to the highest intensity of 
electrical stimulation (1 mA) and the application without iontophoresis of the 
high concentration of capsaicin (6.0 mg/ml) were well reproducible, with an ICC 
that indicated an almost perfect strength of agreement for the maximal measured 
effects. These are also the two experimental approaches of our trigeminal nerve-
mediated vasodilatation model with the lowest WCV and the highest (maximally) 
observed values. The high maximal values, combined with the lower variability, 
suggest that in these experiments responses were approaching a physiological 
maximum response. In contrast, the application without iontophoresis of 0.06 mg/
ml capsaicin had a low ICC and a high WCV. Electrical stimulation with current 
intensities lower than 1.0 mA also resulted in lower ICC values and higher WCV 
values. With the 0.06 mg/ml capsaicin the maximal DBF response was low, 
indicating an incomplete response. While acknowledging the higher variation of 
the low capsaicin concentration and electrical stimulation with currents lower than 
1.0 mA, we included these parameters into the model as potential methods to detect 
individual response threshold differences. For example, capsaicin induces gender-
specific sensory and vasomotor responses,26 indicating that individual threshold 
response differences may exist.
In our experiments we observed no significant difference in DBF responses between 
male and female subjects (results not shown). Obviously, the number of subjects in 
our experiment (three males and nine females) is too small to discern potentially 
small sex differences. Furthermore, we did not select female participants based on 
the phase of their menstrual cycle, pre- or postmenopausal status or use of hormonal 
contraceptives. Sex differences should be explored in future experiments as previous 
studies have shown that estradiol blood levels may influence vasodilatory responses 
of capillary blood flow in women.26, 34
The DBF response to vehicle application with and without iontophoresis and saline 
iontophoresis requires discussion. The vehicle consists of a mixture of ethanol 
100%, Tween 20 and distilled water (3:3:4). Since distilled water can be considered 
harmless and Tween 20 has been shown to have a neutralizing effect on toxicity 
when mixed with skin irritants,35 the DBF response to application of vehicle without 
iontophoresis is most likely induced by ethanol. Indeed, ethanol is known to induce 
TRPV1 channel activation.36-38 Thus, it seems likely that a part of the blood flow 
responses to capsaicin in our study were caused by ethanol in its vehicle. This is 
especially relevant in the case of 0.06 mg/ml capsaicin, where the response was not 
significantly different from that to vehicle. Notwithstanding, we decided to include 
0.06 mg/ml capsaicin solution in our model to have a mode of stimulation (ethanol 
plus capsaicin) of the TRPV1 channel with a low intensity, which, as described 
above, may be useful in detecting trigeminal hyperreactivity as observed in disease 
states.36 In this light, we have decided to express our responses relative to the 
baseline responses at the start of the experiment and not relative to the response to 
the vehicle, since this, as described above, also includes activation of the TRPV1 
channel. 
The application of vehicle with iontophoresis resulted in considerable increases in 
DBF. This could be explained by additional current-induced effects of iontophoresis 
that have been reported previously31 on top of the DBF response to ethanol. Our 
exploration of the effects of iontophoresis on capsaicin revealed that DBF responses 
were higher and the response latency shorter only when applying 0.06 mg/ml 
capsaicin with iontophoresis to the forehead skin. Given that the DBF responses 
to 0.06 mg/ml capsaicin were not significantly different to the DBF responses to 
vehicle, the higher response and shorter latency could be attributed to the current 
induced vasodilatation. Thus, we conclude that the addition of iontophoresis to the 
application of the capsaicin had no advantages in our model. 
With iontophoresis of physiological saline the current-induced DBF effects were 
used as an electrical stimulation parameter in our model, complementary to the 
effects of chemical TRPV1-mediated trigeminal activation by capsaicin. Since the 
current-induced vasodilatation can be inhibited by local anaesthesia and is reduced 
by desensitization of C-nociceptive fibres, as demonstrated by Durand et al., we 
assume that these effects are largely mediated by CGRP and substance P.31 Contrary 
to the effects of capsaicin, CGRP release without direct activation  of the TRPV1 
channel  may be studied with electrical stimulation. Thus, similar as described 
above for the two different concentrations of capsaicin, the application of several 
current intensities allows to discern both differences in threshold for stimulation, as 
well as in maximal response. 
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Admittedly, the involvement of CGRP in the responses to capsaicin, vehicle, as 
well as electrical stimulation could not unequivocally be proven in the current study 
since this would require the administration of a CGRP receptor antagonist, as was 
performed previously in the capsaicin-induced vasodilatation model in the human 
forearm.23, 33 Unfortunately, we do not have a CGRP receptor antagonist available 
that we can administer to human subjects. Similarly, an orally available TRPV1 
antagonist would be required to unequivocally assess the involvement of this 
channel in DBF responses to capsaicin and electrical stimulation.
Comparison with capsaicin-induced dermal vasodilatation in the human forearm
It is interesting to compare the properties of our model with those of the previously 
described model measuring capsaicin-induced dermal vasodilatation in the human 
forearm.33 In the forearm model, maximal vasodilator responses to capsaicin (1000 
µg, dose per mm2 of skin corresponding to our 6.0 mg/ml solution) are observed 
after 30-40 min.  In contrast, in our model maximal responses to application 
without iontophoresis of this concentration were observed after an average of 11 
min. Applying iontophoresis to the 6.0 mg/ml capsaicin solution did not result in a 
shorter response latency in our model, since Emax of 6.0 mg/ml with iontophoresis 
was reached after 10 min. 
Intriguingly, in the forearm model, the vehicle of capsaicin did not induce a 
discernible increase in vasodilatation, while in our model, as described above, 
vehicle-induced effects were considerable. These differences between forearm and 
forehead skin responses to capsaicin are probably related to the well-established 
variation in skin response to topical irritants that exists throughout the body.39 
Furthermore, evidence exists that especially the face is more sensitive to capsaicin 
compared to other dermatomes of the body.40 
In conclusion, using capsaicin topical application and electrical stimulation of 
the forehead skin, we have developed a noninvasive, reproducible model that can 
evaluate trigeminal-nerve mediated vasodilation. Future investigations should learn 
whether the model is suitable to differentiate between subjects with and without 
trigeminal nerve-mediated conditions including migraine and whether it is useful 
for the evaluation of novel potential anti-migraine drugs. 
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CHAPTER 6 
A trigeminovascular biomarker for antimigraine drugs; 
randomized trial with sumatriptan
K. Ibrahimi, A.H.J. Danser, G.M. Terwindt, A.H. van den Meiracker 
& A. MaassenVanDenBrink 
Abstract 
Current antimigraine drugs like sumatriptan are believed, besides their direct 
vasoconstrictive effect, to inhibit calcitonin gene-related peptide (CGRP) release 
from trigeminal nerve endings during a migraine attack. Objective: To establish 
a biomarker for the CGRP-interfering effect of antimigraine drugs. Methods: We 
quantified the effect of sumatriptan on the trigeminal nerve-mediated rise of dermal 
blood flow (DBF) of the forehead, induced by capsaicin application (0.6 mg/ml) 
and electrical stimulation (0.2-1.0 mA), in a randomized, double-blind, placebo-
controlled cross-over study in healthy male (n=11, age±SD: 29±8 yrs) and female 
(n=11, 32±7 yrs) subjects. Results: DBF responses to capsaicin were significantly 
attenuated by sumatriptan (∆DBF, mean±SEM: 82±18 A.U., p=0.0002), but not 
by placebo (∆DBF: 21±12 A.U., p=0.1026). Conclusion: We demonstrated that 
sumatriptan inhibits increases in dermal blood flow, induced by the release of CGRP. 
Thus, our model may be used as a biomarker to establish the trigeminovascular effects 
of (future) antimigraine drugs, such as CGRP receptor antagonists or antibodies 
directed against CGRP or its receptor.
Introduction
Understanding the mechanism of action of drugs helps to unravel underlying 
disease pathophysiology. Although the antimigraine drug sumatriptan, one of 7 
triptans currently available, was introduced about two decades ago, its precise action 
remains elusive. Besides direct vasoconstriction, mediated by 5-HT1B receptors,
1 
triptans may also presynaptically inhibit release of the key neuropeptide in migraine, 
calcitonin gene-related peptide (CGRP),1 most likely via 5HT
1D(/1F) 
receptors.1 
Despite its success, 14-30% of patients do not respond to subcutaneous sumatriptan.2 
To understand the mechanism behind therapeutic nonresponse in migraine, a non-
invasive biomarker, e.g., based on sumatriptan’s effect on trigeminal CGRP release, 
is needed, especially now that antagonists and antibodies directed against CGRP 
or its receptor are developed.3 Early trials indicate that they are not effective in all 
patients, reinforcing the importance of investigating their trigeminovascular effects.3 
To identify such a biomarker, we performed a randomized, double-blind, placebo-
controlled cross-over study in healthy volunteers to investigate the blocking effect 
of sumatriptan, the most established acute antimigraine therapy,1 on the CGRP-
mediated rise of capsaicin-induced dermal blood flow (DBF). We hypothesized that 
sumatriptan inhibits the capsaicin-induced DBF increases. To exclude physiological 
antagonism by direct vasoconstriction to sumatriptan, we used electrical stimulation 
(ES) of trigeminal afferents, increasing DBF partly via CGRP, but also via other 
mechanisms such as substance P and prostaglandin synthesis.4
Methods
Standard Protocol Approvals, Registrations, and Patient Consents
The study protocol was reviewed and approved by the Ethics Committee of Erasmus 
MC, Rotterdam, and registered at the Netherlands Trial Register (ID:NTR4171). 
All participants gave written informed consent and the study was conducted in 
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accordance with local laws, the ethical principles of the Declaration of Helsinki and 
the principles of Good Clinical Practice.
Design and procedures
Healthy non-smoking male and female subjects, aged 18-50 years (BMI 18-30 kg/
m2), without history of cardiovascular disease or use of medication, were eligible. 
Female subjects were using oral contraceptives and continued their use without 
the “stop week” to avoid the confounding influence of varying steroid levels.5 The 
validated LUMINA questionnaire6 was used to exclude migraineurs. 
Subjects were investigated between September and November 2013 in a quiet, 
temperature-controlled room. The subjects rested supine and did not speak. For 
all subjects, two visits were scheduled with a one-week washout in between and 
during the same time of the day.  Participants refrained from using vasoactive drugs 
(including NSAIDs) for >48 hours, and from consuming alcohol, caffeine-containing 
beverages and chocolate for at >3 hours prior to the start of experiments. A light meal 
3 hours before the start of the experiments was allowed. 
Blood pressure and DBF responses to capsaicin (0.6 mg/ml) and ES (0.2 mA-1.0 
mA) were measured before and 30 min after (different locations on the forehead 
used for each measurement) either placebo or sumatriptan during the two research 
visits. Capsaicin- and ES-induced dermal forehead vasodilatation, measured with a 
laser Doppler perfusion imager, is described in detail in our model validation paper.4 
Subjects were injected subcutaneously with sumatriptan (6 mg; a gift of 
GlaxoSmithKline, Zeist, The Netherlands) or placebo (saline) at the lateral side of 
the upper thigh. Randomization, allocation and blinding was coordinated by the 
Erasmus MC pharmacy. ‘Insulin syringes’ with placebo or sumatriptan were prepared 
and labelled on the experiment day in a room inaccessible to the researchers. With a 
questionnaire at the end of each experiment, side effects were registered. 
Statistical analysis
Sample size was based on detection of a 25% decrease in capsaicin-induced DBF 
after sumatriptan,4 at 5% significance (two-tailed) with 80% power. Baseline and 
maximal DBF (Emax) response, expressed in Arbitrary Units (A.U.), to capsaicin 
and ES, was calculated before and after sumatriptan or placebo. Differences in 
DBF responses to capsaicin (our primary endpoint) and ES during sumatriptan and 
placebo were calculated for each subject. Responses to sumatriptan and placebo were 
compared within subjects using Student’s paired t-test.  Current response curve of 
the ES sequence (0.2 mA-1.0 mA) were analyzed with repeated measures ANOVA. 
P<0.05 was considered to indicate significance.
Results
Twenty-two healthy volunteers (11 males) participated (Figure 1 and Table 1). Since 
results were similar between sexes, data were pooled.
Systolic and diastolic blood pressure significantly increased after sumatriptan, while 
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diastolic blood pressure slightly increased after placebo (Table 2). 
Baseline DBF decreased after sumatriptan (∆DBF: 11±4 A.U., p=0.0126), but not 
after placebo. The DBF response to capsaicin decreased after sumatriptan  (∆DBF: 
82±18 A.U., p=0.0002) but not after placebo (∆DBF: 21±12 A.U., p=0.1026. 
Figure 2(A)).  ∆DBF sumatriptan was different from ∆DBF placebo (p=0.0036). 
A sub-analysis showed that in 5/22 volunteers the DBF response to capsaicin did 
not decrease after sumatriptan. The DBF response to ES was not affected by either 
sumatriptan or placebo (Figure 2(B)). 
Pain at the injection site was the most reported side effect after sumatriptan (15/22) 
compared to placebo (6/22), followed by a general heavy pressing feeling (14/22 
after sumatriptan versus 1/22 after placebo). 8/22 volunteers reported stiffening of 
Male Female All
Population, n 11 11 22
Age, years 29 (8) 32 (7) 30 (8)
BMI, kg/m2 23.0 (1.6) 23.8 (3.4) 23.4 (2.6)
BP, mmHG
       Systolic
       Diastolic
114 (13)
66 (9)
110 (8)
66 (6)
112 (11)
66 (7)
HR, bpm 58 (10) 55 (7) 57 (8)
Table 1. Demographics of the study population. BMI, body mass index. BP, blood pressure measured 
recumbent. HR, heart rate. Mean ± (SD).
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Figure 1. Recruitment fl ow diagram
the neck muscles after sumatriptan, this was not reported after placebo. Anxiety was 
reported by 4/22 volunteers after sumatriptan and by none after placebo.
Discussion
Our major finding is the inhibition of capsaicin-induced vasodilatory DBF responses 
after sumatriptan but not after ES, confirming our hypothesis that sumatriptan 
inhibits the release of CGRP, the key neuropeptide in migraine. Blood pressure 
changes1 and side effects were as expected. While side effects may have reduced 
the blinding efficiency in some subjects during recording, a potential limitation of 
our study, it is important to highlight that data analysis was performed completely 
blinded. Although our study was performed in subjects without migraine, the 
proportion (5/22, i.e., 23%) that did not display inhibition of capsaicin-induced DBF 
increases after sumatriptan, is in the same range as the number of non-responders 
to subcutaneous sumatriptan.2 Future studies should elucidate whether clinical non-
Pre s.c. inject. Post s.c. inject. Change p
Placebo, BP, mmHg
       Systolic
       Diastolic 
HR, bpm
111 (9)
66 (7)
56 (8)
110 (9)
68 (6)
55 (9)
-1
2
-1
0.7707
0.0369
0.3646
Sumatriptan, BP, mmHg
       Systolic
       Diastolic 
HR, bpm
112 (10)
65 (7)
58 (9)
118 (7)
76 (6)
56 (11)
6
11*
- 2
0.0009
< 0.0001
0.1349
Table 2. Blood pressure during experiments. BP, blood pressure measured recumbent after 15 min acclimatization. 
HR, heart rate. Mean ± (SD). * Significant increase in diastolic BP after sumatriptan compared to increase in diastolic 
BP after placebo.
Figure 2. Forehead dermal blood flow responses to capsaicin and ES. (A): maximal DBF response to capsaicin 
before (grey bars, Pre) and after (black bars, Post) placebo and sumatriptan. (B):  maximal DBF responses to 
ES with an increasing stimulation current before placebo (grey triangle), after placebo (black circle), before 
sumatriptan (grey diamond) and after sumatriptan (black square). Data are presented as mean ± SEM. * Significant 
decrease in DBF response to capsaicin after sumatriptan.
(A) (B)
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responders to subcutaneous sumatriptan do correlate to the non-responders in our 
model, although the design and execution of such a trial is complicated due to the 7 
different triptans now available.7
The decrease in baseline DBF after sumatriptan indicates direct vasoconstriction, in 
agreement with several preclinical8 and clinical (magnetic resonance angiography, 
MRA) studies.9, 10 Nevertheless, not all MRA studies are consistent. A study with 
provoked migraine in patients demonstrated sumatriptan-induced constriction of the 
middle meningeal but not the middle cerebral artery, while sumatriptan constricted 
both arteries in healthy volunteers.9 In spontaneous migraine attacks, sumatriptan 
constricted extracranial arteries and the cavernous portion of the internal carotid 
artery.10 The constriction of the cranial vasculature in these studies did not uniformly 
coincide with the resolution of pain, suggesting involvement of additional mechanisms 
in the efficacy of triptans. Indeed,  several studies suggest that part of the action of 
triptans is mediated via inhibition of neuropeptide release. For example, elevated 
serum levels of CGRP were normalized after sumatriptan.11 As DBF responses to 
capsaicin are almost entirely inhibited by CGRP receptor blockade,12 the inhibition 
of capsaicin-induced DBF responses by sumatriptan in our experiments clearly 
shows that triptans may inhibit CGRP release. The 26% decrease in DBF response 
after sumatriptan in our study may seem modest, but is similar to the 33% decrease 
in jugular CGRP in migraineurs using subcutaneous sumatriptan as reported earlier.11
 
Hypothetically, the decrease of capsaicin-induced DBF could have been due to 
physiological antagonism (direct vasoconstrictor effect of sumatriptan), as described 
above. However, the responses to ES should then have been affected by sumatriptan 
as well, which was not the case (Figure 1B). Thus, we conclude that the inhibition 
of capsaicin-induced DBF after sumatriptan is due to its effects on neuropeptide 
release, most likely of CGRP.
In conclusion, trigeminovascular effects of future antimigraine drugs, such as 
antagonists or antibodies directed against CGRP or its receptor, can be investigated 
with our human model. 
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Work in progress
CHAPTER 7 
Local thermal hyperaemia and fl ow-mediated dilatation as 
measures of endothelial function are unrelated
K. Ibrahimi, Y. de Graaf, R. Draijer, A.H.J. Danser, 
A. MaassenVanDenBrink & A.H. van den Meiracker
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Abstract
Background: Flow-mediated dilatation (FMD) of the brachial artery to determine 
endothelial function is a well-accepted, but investigator-demanding method. Local 
thermal hyperaemia (LTH) of the skin measured with a laser Doppler flow imager is 
less demanding and may be a suitable alternative to determine endothelial function. 
We investigated the reproducibility and NO-dependency of LTH and its correlation 
with FMD. Methods: FMD and LTH were measured in healthy non-smoking (n=14) 
and smoking (n=7) men on two occasions, one week apart. Local dermal application 
of L-NMMA by means of iontophoresis was used to measure the nitric oxide (NO)-
dependency of LTH. Results: The coefficient of variation of the LTH peak and 
plateau response was 16% and 21% and of the FMD response 12%. The LTH peak 
response tended to be lower, while the LTH-plateau response was significantly lower 
in smokers than non-smokers, whereas The FMD response in smokers and non-
smokers was similar. Both in non-smokers and smokers the LTH-peak and plateau 
response was inhibited by L-NMMA, but the inhibition was much less pronounced 
in smokers. Conclusions: 1) The reproducibility of LTH is not better than that of 
FMD. 2) Both the LTH peak and plateau response are in part mediated by increased 
NO release. 3) This NO-dependency of the LTH response apparently is diminished 
in smokers. 4) Information about endothelial function obtained by FMD and LTH 
measurements may not be interchangeable. 
Introduction
The microcirculation is embedded in all organs and serves to provide nutrients and 
oxygen and to remove metabolic end products e.g. CO2. In addition, it is essential 
for fluid exchange and delivery of hormones.  Flow-mediated vasodilation (FMD) 
is a common, clinically applied tool to assess endothelial vascular function. FMD is 
usually assessed at the brachial artery and represents the ability of this artery to dilate 
in response to an increase in blood flow induced by an ischemic period of 5 minutes. 
Evidence indicates that release of nitric oxide (NO) is largely responsible for flow-
induced vasodilatation in human peripheral conduit arteries.1 This accords well with 
studies showing that low FMD values associate with cardiovascular risk factors 
that are known to impair NO bioavailability.2 Conversely, cholesterol-lowering and 
anti-hypertensive treatment improve FMD,3 but also nutritional interventions like 
consumption of cocoa, tea, and beetroot juice appear to be effective in improving 
FMD.4-6
The relationship between vascular function in the relatively large conduit brachial 
artery and vascular function in the microcirculation has been studied occasionally, 
yielding divergent results.7-9 The association between the muscarinic receptor-
stimulated increase in microvascular muscle perfusion in the forearm and FMD is 
weak, despite the fact that NO-dependent vasodilation underlies both measurements.7, 
8 The correlation between FMD and peripheral artery tonometry (EndoPat) values is 
moderate.9 In contrast, FMD and increases in skin perfusion caused by iontophoretic 
application of acetylcholine appear to be closely related.10 Local thermal hyperaemia 
(LTH) causes a temperature-dependent sustained increase in skin blood flow that 
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is largely NO-dependent and therefore may be considered as the microvascular 
counterpart of FMD.11 Combined with the Periscan PIM 3 system, which measures 
skin blood flow by a laser Doppler technique, the reproducibility of this technique 
has been reported to be excellent.11 Compared to FMD measurements, measurement 
of the thermally-induced increase in dermal blood flow with the Periscan PIM 
3 system is easier to perform and less operator-dependent. It may therefore be a 
welcome alternative of FMD. Dermal post-occlusive reactive hyperaemia (PORH) is 
also a measure that can be used to assess microvascular function, and like FMD, it is 
measured after a period of ischemia.12 In the present study we compared FMD with 
LTH and PORH in healthy non-smoking and smoking men. We included a group of 
smokers in order to obtain a relatively wide range of FMD values. In addition we 
investigated to what extent the increase in skin blood flow in response to local heating 
is NO-dependent by locally applying the NO synthase inhibitor NG-monomethyl-
l-arginine (L-NMMA), using iontophoresis.13-17 We expected a close correlation 
between LTH and FMD responses since both techniques are presumed to be highly 
NO-dependent. We also hypothesized that the PORH response would correlate with 
FMD as well as with LTH. PORH may correlate with FMD as ischemia-induced 
increases in blood flow underlie both measurements. The expected correlation 
between PORH and LTH would be based on the involvement of endothelium-derived 
hyperpolarizing factor (EDHF) pathway activation during both PORH and LTH.18, 19 
Methods
Standard Protocol Approvals, Registrations, and Patient Consents 
The study protocol was reviewed and approved by the Independent Ethics Committee 
of the Erasmus MC, Rotterdam, The Netherlands. All participants gave written 
informed consent after explanation of the study, which was conducted in accordance 
with local laws, the ethical principles of the Declaration of Helsinki, as well as the 
principles of Good Clinical Practice.
Design and procedures
For our study we included healthy male non-smokers and smokers. Women were 
excluded to avoid confounding due to the influence of hormonal changes related to 
the menstrual cycle on vascular function. All participants were recruited via flyers 
distributed in the Erasmus MC, the recruitment agency Link2Trials (Hilversum, 
The Netherlands) or via advertisements in local (Rotterdam, The Netherlands) 
newspapers. Men in general good health, aged between 25-65, with a body mass 
index (BMI) between 18-30 kg/m2 and with a systolic blood pressure <160 mmHg 
were included. Non-smokers that had been non-smoking for at least 5 years and 
smokers that had been smoking for at least 5 years were eligible to be included. A 
history of cardiovascular disease, use of vasoactive drugs and drug and/or alcohol 
abuse were exclusion criteria. Subjects were not allowed to drink wine or eat 
chocolate 24 hours prior to the study and caffeine-containing food and beverages 
were not allowed 6 hours prior to the study. To investigate reproducibility, 2 research 
visits with 7 days in-between were scheduled for all test subjects. For each individual 
subject measurements were performed at the same time of the day, in a temperature 
controlled room, while subjects had fasted for 3 hours. All measurements were 
performed with the subjects in the supine position.
LTH Measurement
We determined the skin LTH response at the volar site of the right forearm using 
the PeriScan PIM 3 system (Perimed AB Sweden) and SHP3 heating probes (Moor 
Instruments Ltd) to induce local heating. A drug delivery electrode containing a 
0.5 ml reservoir and a control electrode (Perimed AB Sweden) were placed on the 
forearm at least 15 cm apart. The drug delivery electrode was filled with a 2% solution 
of  L-NMMA (Clinalfa, Laufelfingen, Switzerland) in sterile water (Fresenius Kabi, 
Schelle, Belgium). With the positive lead of the iontophoresis device (Periont 382b, 
Perimed, Sweden) connected to the electrode containing L-NMMA, subsequently a 
current (100 μA for 15 minutes) was applied to this electrode. After iontophoresis, 
the electrodes were removed and the two heat probes were attached to the skin using 
two-sided adhesive tape and filled with water. One heat probe was placed exactly 
over the area of the L-NMMA iontophoresis electrode and one on a non-treated area. 
Before the start of the heating protocol, the heater was set to 33°C for 5 minutes 
to standardize the skin temperature. Subsequently, baseline skin blood flow was 
recorded for 5 minutes at 33°C followed by a recording at 40°C for 35 minutes. 
FMD measurement
The FMD was measured with the SONIX TOUCH ultra-sound system (Ultrasonix, 
Richmond, Canada) with the L14-5/38 transducer (Ultrasonix, Richmond, Canada). 
A blood pressure cuff was placed around the left forearm immediately below the 
antecubital crease. The echo probe was positioned on the dorsal site of the upper 
arm approximately 5 cm from elbow in a way that a clear longitudinal section of the 
brachial artery remained visible. The baseline blood vessel diameter was recorded 
for 1 minute. Subsequently, the cuff was rapidly inflated to 260-280 mmHg. This 
cuff pressure was maintained for 5 minutes. After 5 minutes occlusion, the cuff 
pressure was released and the diameter of the brachial artery was recorded for 4 
minutes. The FMD data were processed with Cardiovascular Suite™ version 2.0, 
Quipu, Pisa, Italy. 
PORH measurement
Simultaneously with the FMD measurements we also measured the PORH response 
that occurred after the release of the pressure cuff used for the FMD measurements. 
PORH was measured at the volar site of the left forearm just under the pressure 
cuff, using a laser speckle imager (FLPI, Moor Instruments Ltd, Axminster, United 
Kingdom).
Statistical analysis
LTH was expressed as change in a.u. from baseline. LTH peak was defined as the 
maximal dermal blood flow (DBF) response within the first 10 minutes of heating 
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to 40°C. The LTH plateau phase was defined as the average DBF response in a.u. 
during the last 5 minutes of the 35 minutes-lasting 40°C heating period. FMD was 
expressed as the maximal percentage increase in vessel diameter during the reactive 
hyperaemia relative to the diameter before occlusion. PORH, quantified in a.u., was 
expressed as the DBF percentage change from baseline. Values are expressed as mean 
± SEM unless indicated otherwise. Correlations between FMD, LTH and PORH 
were determined by Pearson’s coefficient of correlation (r). FMD, LTH and PORH 
response differences between smoking and non-smoking subjects were compared 
with Student’s unpaired t-test, while differences within groups were examined 
by Student’s paired t-test. Coefficient of variation (CV) and intraclass correlation 
coefficients (ICC) were calculated as measures of reproducibility and agreement. 
Two tailed P-values < 0.05 were considered to indicate a statistically significant 
difference. 
Results
Subjects
A total of 14 non-smoking and 7 smoking volunteers were included. The smoking 
subjects had been smoking for an average of 23 ± 3 years. Their current smoking 
amounted to 14 ±1 cigarettes per day. Demographic characteristics such as age, 
BMI, waist-to-hip ratio, blood pressure and heart rate were similar in non-smokers 
and smokers. Baseline values of LTH, FMD and PORH did not differ between non-
smokers and smokers (Table 1).
Non-Smokers Smokers
Population, n 14 7
Age, years 38(13) 40(9)
BMI, kg/m2 
WHR 
24(2)
0.89(0.09)
23(3)
0.88(0.05)
BP, mmHg
     Systolic 
     Diastolic 
MAP 
113(4)
66(5)
83(4)
115(4)
69(4)
87(4)
HR, bpm 52(6) 57(5)
LTH BL (a.u.) 27(9) 37(18)
FMD BL (pre-occlusion diameter, mm) 4.30(0.43) 4.26(0.40)
PORH BL (a.u.) 70(37) 85(29)
Table 1. Demographics of the study population and baseline values of measurements. BMI, body mass index. 
WHR, waist to hip ratio. BP, blood pressure. MAP, mean arterial pressure. HR, heart rate. BL, baseline. Mean (± SD).
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LTH measurement
Both the LTH peak and the LTH plateau response were well reproducible, with 
the lowest CV (16%) and highest ICC (0.80) for the peak LTH response (Table 
2 and Figure 1A-1D). The LTH peak DBF response was inhibited by L-NMMA 
administration in non-smokers and in smokers (% inhibition non-smokers vs. 
smokers: 43 ±3% . vs. 23 ± 4%, P<0.0001). Likewise the LTH plateau DBF response 
was inhibited in non-smokers by 73 ±2 % and in smokers by 60 ± 3% (P<0.0001, 
Figure 1E and 1F). Compared to non-smokers the LTH plateau phase, but not the 
LTH peak response, in smokers was significantly lower with respective values of 158 
± 12 and 109 ± 22 a.u., P=0.045 (Figure 1E and 1F).  
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Figure 1. LTH reproducibility and LTH response non-smokers vs. smokers. Reproducibility assessed in non-
smokers (n=14). Correlation between visit 1 (V1) and visit 2 (V2) LTH peak (A) and plateau (B) DBF responses 
(Peak: r = 0.79, p = 0.0006; plateau: r = 0.68, p = 0.007).  Bland-Altman plots (C and D) show bias (solid line) and 
95% limits of agreement (dashed lines) for peak (C)  and plateau (D) LTH DBF responses.  The effect of smoking 
and LNMMA administration on peak (E) and plateau (F) LTH response. * Significant decrease in LTH response 
after LNMMA administration. # Significantly lower LTH response smokers (n=7) compared to non-smokers. 
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FMD measurement
Like LTH, FMD was well reproducible with a CV of 12% and an ICC of 0.87 (Table 
2). The FMD of non-smokers (4.8 ± 0.6%) did not differ from the FMD of smokers 
(6.1  ± 1.3%, P=0.283, Figure 2). 
 Reproducibility Correlation (r)
CV(%) ICC FMD PORH Peak PORH AUC
LTH Peak 16 0.80* 0.22 0.27 0.03
LTH Plateau 21 0.63* 0.12   0.56* 0.38
FMD 12 0.87* - 0.36    0.64*
PORH Peak 11 0.90* - - -
PORH AUC 10 0.89* - - -
Table 2. Reproducibility and Correlation. Reproducibility of the different measurements in non-smokers (n=14). 
Correlation between different measurements in nonsmokers (n=14) and smokers (n=7). * Statistically significant 
intraclass correlation coefficient (ICC) or correlation coefficient. 
Figure 2. FMD reproducibility and FMD of non-smokers vs. smokers. FMD (% increase in vessel diameter 
during hyperaemia relative to the diameter before occlusion) reproducibility assessed in non-smokers (n=14). 
Correlation (A) between visit 1 (V1) and visit 2 (V2) FMD r = 0.88, p <0.0001. Bland-Altman plot (B) shows bias 
(solid line) and 95% limits of agreement (dashed lines) between FMD V1 and V2. FMD responses (C) of non-
smokers (n=14) and smokers (n=7).
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PORH measurement
PORH was also well reproducible with the lowest CV for PORH AUC (CV= 10%) 
and the highest level of agreement for PORH peak (ICC 0.90, Table 2 and Figure 
3A-3D). The results of the PORH contained 1 outlier that we could not exclude 
based on the other study measures, as they were normal. The outlier response did not 
have a significant effect on the PORH outcome measures. The PORH peak response 
or PORH AUC between non-smokers and smokers did not differ. 
Correlations between LTH, FMD and PORH measurements
The correlations between different measures of vascular function for all 21 volunteers 
are displayed in Table 2. For the analysis of correlation between measures we 
pooled the data from non-smokers and smokers, because there was only significant 
difference in LTH response between both groups. By pooling the data we also 
increased our range of values, benefitting the correlation analysis. The LTH plateau 
phase correlated with the PORH peak response (r = 0.56, P=0.008), whereas FMD 
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Figure 3. PORH reproducibility and PORH of non-smokers vs. smokers. Reproducibility assessed in non-
smokers (n=14). Correlation between visit 1 (V1) and visit 2 (V2) PORH peak (A) and AUC (B) DBF responses 
(Peak: r = 0.93, p < 0.0001; AUC: r = 0.89, p <  0.0001).  Bland-Altman plots (C and D) show bias (solid line) and 
95% limits of agreement (dashed lines) for peak (C)  and AUC (D) AUC DBF responses.  The effect of smoking 
on peak (E) and AUC (F) of PORH DBF responses.
and PORH AUC were closely correlated (r = 0.64, P = 0.002), but all other measures 
of vascular function were unrelated. 
Discussion
The main findings of our study are that 1) all measurements of vascular function 
are well reproducible with the best reproducibility of PORH, 2) the LTH and FMD 
measurements are unrelated,  3) LTH and FMD measurements are both correlated with 
PORH measurements and 4) of the three measurements only the LTH measurement 
shows a distinction in microvascular function between smokers and non-smokers, 
with a lower response in smokers. 
76
Chapter 7
It has been well accepted that endothelial dysfunction, reflected by diminished 
NO-dependent vasodilation, is an early marker of vascular damage, preceding 
the process of atherosclerosis and cardiovascular disease.1, 20 Hence several non-
invasive techniques with the potential to measure endothelial dysfunction have been 
developed. Of these techniques FMD has been most frequently applied and its value 
for predicting vascular disease is well established.20 A disadvantage of FMD is its 
operator-dependency, requiring an experienced technician to obtain reliable results 
21. LTH may be an alternative measurement of NO-dependent endothelial function 
at the level of the microcirculation.10, 22 LTH is characterised by 2 phases; the initial 
peak blood flow during the first 10 minutes followed by a plateau phase after 
approximately 30 minutes. The peak DBF response appears to be largely mediated 
by the skin sensory nerves and the plateau phase by NO.23, 24 Iontophoresis with 
L-NMMA in our study indicates that over 40% of the LTH peak response and over 
70% of the LTH-plateau phase is NO-dependent. Because LTH measurements are 
relatively easy to perform and the relative magnitude of the response is much larger 
than for FMD, on forehand we had expected a better reproducibility of LTH. This 
appeared not be the case. With a CV of 16% for the LTH peak and a CV of 21% 
for the LTH plateau phase the reproducibility of LTH was somewhat lower than the 
reproducibility of FMD (CV 12%). It must be emphasized that in the current study 
FMD was measured by a highly qualified investigator (YdG).  
Contrary to our hypothesis neither the LTH peak nor the LTH plateau responses 
correlated with the FMD response. Given that both responses are largely NO-
dependent, this absent association, although in agreement with previous work 
applying a similar group size,25 is surprising. Is should be remarked that the dynamic 
range of LTH and FMD is quite different; while with LTH the DBF response can 
increase by 900% from baseline DBF, with FMD only diameter changes of up to 
12% can be achieved. Furthermore, the LTH measurement is restricted to the skin 
superficial microcirculation, while FMD is measured in a conductance artery. 
In line with our hypothesis, because post-ischemic hyperaemia underlies both 
measurements, FMD and PORH responses were correlated.  Confirming our 
hypothesis, the LTH plateau phase and PORH peak response were also correlated. 
Indeed, during both peak PORH and PORH time course as well as during LTH peak 
response and LTH plateau phase the EDHF pathway is activated.4, 7 Although the 
PORH response depends on multiple mechanisms, it has been demonstrated that 
this response is diminished in patients with coronary artery disease, indicating an 
association between coronary macrovascular and skin microvascular disease.12 
Importantly, LTH responses in our study were lower in smokers than in non-smokers. 
This was mainly due to a diminished NO-dependent vasodilation in smokers as 
the difference in response between smokers and non-smokers almost completely 
abolished by local application of L-NMMA (Fig. 1). The FMD and PORH 
measurements did not detect a difference in vascular function between smokers and 
non-smokers. Our findings therefore suggest that LTH is more sensitive than FMD or 
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PORH measurements to detect changes in (NO-dependent) vascular function. With 
LTH measurements impaired skin microvascular function has also been previously 
demonstrated in smokers.22, 26 In accordance with our study, Fujii et al., using local 
skin heating, showed a decreased cutaneous vascular conductance (both peak 
response and area under the curve) in response to intradermal microdialysis of L-N-
Arginine-Methyl-Ester (L-NAME) in non-smokers, but not in smokers, implying 
decreased NO-bioavailability in smokers.27 Conversely, Dreyfuss et al. showed 
that L-NAME iontophoresis-mediated inhibition of skin thermal hyperaemia was 
greater in smokers than in non-smokers, suggesting increased bioavailability of NO 
in smokers.22 The reason for these discrepant findings is not clear. The smokers in 
our study, although healthy, were considerably older than those included in the study 
of Dreyfuss et al.6 However, in the study of Fujii et al. only young smokers were 
included.21 
In the present study no difference in FMD between smokers and non-smokers 
was observed. Studies investigating the effect of smoking on FMD have provided 
inconsistent results.28-30 These variable findings are not easy to explain but, in part, 
may be related to the age and general health of the smokers included. With advancing 
age endothelial and vascular function deteriorate; as a consequence the negative 
effect of smoking op FMD may no longer be detectable. 
In conclusion, the dermal LTH response is in part NO dependent and a well 
reproducible measure that can be applied to assess the microvascular endothelial 
function. The absent correlation between LTH and FMD measurements may imply 
that these measurements provide complementary information about endothelium-
dependent vascular function. 
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Abstract
Retinal vasculopathy with cerebral leukodystrophy (RVCL) is an autosomal dominant 
microvascular vasculopathy caused by heterozygous C-terminal frameshift mutations 
in the TREX1 gene that encodes the major mammalian 3’ to 5’ DNA exonuclease. It 
is currently unknown how mutations lead to RVCL pathology, which is characterised 
by retinal telangiectasias, microaneurysms, cerebral white matter lesions, ischemic 
strokes and migraine attacks. We generated the first transgenic knock-in (KI) mouse 
model for RVCL by introducing the human pathogenic V235fs TREX1 frameshift 
mutation in the endogenous mouse Trex1 gene using a targeting approach. Molecular 
analyses confirmed the correct introduction of the TREX1 mutation and expression 
at the RNA and protein level. Moreover, Western blotting confirmed that the 
V235fs mutation resulted in a truncated protein of the expected size. In view of 
the vascular dysfunction in RVCL patients, we set out to characterize the vascular 
function of homozygous V235fs KI mice at various ages (13-100 weeks). To this 
end, we executed in vivo microvascular characterization by post-occlusive reactive 
hyperaemia (PORH) measurements of the hindleg with laser Doppler flowmetry. In 
addition, a detailed pharmacological characterization of the macrovascular function 
of V235fs KI mice in vitro, using Mulvany myographs was performed. The PORH 
responses were significantly attenuated in V235fs KI animals across all age groups 
[F(1,65)=5.7, p=0.02]. In in vitro studies, acetylcholine induced lower relaxations 
in the aortae of 100-week-old V235fs mice (Emax:37±8%, n=7) than in the wild-type 
mice (Emax:65±6%, n=7, p=0.01). In accordance with preliminary observations in 
patients, our analysis suggests vascular abnormalities in this RVCL mouse model 
that may be assigned to decreased endothelial function. Our data suggest that this 
RVCL mouse model can be used to further our understanding of Trex1 pathology, 
and more specifically, can help us to unravel the pathophysiology of RVCL, and 
perhaps migraine.
Introduction
Retinal vasculopathy with cerebral leukodystrophy (RVCL) is a systemic 
microvascular vasculopathy with middle-age onset and predominantly retinal and 
neurovascular features leading to visual loss, cognitive disturbances, depression, 
ischemic strokes and migraine attacks, generally without aura.1-3 Other symptoms 
can include renal and liver dysfunction, gastro-intestinal bleedings and Raynaud’s 
phenomenon.2 The vascular retinopathy is characterized by telangiectasias, 
microaneurysms and retinal capillary obliteration starting in the macula.4 MRI 
imaging and histopathological analysis of cerebral tissue show cerebral mass lesions 
mainly in the white matter, thrombosis of microvessels, as well as inflammatory 
gliosis.5 The presence of Raynaud’s phenomenon in a proportion of RVCL patients 
points towards vascular dysfunction, but functional studies are limited. Preliminary 
data suggest that endothelial dysfunction and vascular stiffness may underlie RVCL 
in patients.6    
RVCL is caused by heterozygous C-terminal frameshift mutations in the TREX1 
gene.3 TREX1 encodes the protein Trex1, which is the major mammalian 3’ to 5’ 
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DNA exonuclease, thought to be ubiquitously expressed.3, 7 Frameshift mutations 
causing RVCL all lead to truncation of the Trex1 protein. This truncated protein 
lacks the endoplasmatic reticulum (ER)-binding domain, but the exonuclease 
function of the protein is still intact.3, 8 In contrast, TREX1 missense mutations in 
the N-terminus of the protein lead to diminished exonuclease function and have 
been found, among others, in patients with the Aicardi-Goutierres Syndrome (AGS)9 
and Systemic Lupus Erythematosus (SLE).10-12 It remains an enigma how mutant 
Trex1 leads to disease. One possibility is that Trex1 has a preventive role in immune 
responses. The Trex1 protein is specific for single-stranded DNA and a key regulator 
of the interferon-stimulatory DNA (ISD) response13 and is therefore believed to play 
an important role in the body’s response to viral pathogens.14 Another possibility is 
that Trex1 may play a role in the cellular response to DNA damage. Trex1 is part of a 
SET-protein complex, a multimeric 270-420 kDa endoplasmic reticulum associated 
complex, that is involved in DNA degradation and the response to oxidative stress 
by translocating to the nucleus.15 
Trex1 knock-out (KO) mice develop severe inflammatory myocarditis leading to a 
drastically reduced lifespan.16 This Trex1 deficiency model may be more suitable as a 
model for AGS, as mutations cause a loss-of-function of exonuclease activity, while 
in RVCL a stable functioning Trex1, but mislocated protein is believed to be present. 
Therefore, we generated the first knock-in mouse model for RVCL by introducing 
the human pathogenic V235fs frameshift mutation in the endogenous Trex1 gene. 
Details on the generation and molecular characterization of this KI model will be 
published elsewhere; here we will only describe the essentials of the mouse model. 
To investigate whether there is vascular dysfunction in V235fs KI mice that may 
eventually lead to vascular pathology, as seen in RVCL patients, we performed a 
vascular characterization of homozygous V235fs KI mice compared with wild-type 
(WT) mice. Given the fact that RVCL is predominantly a microvascular disease, we 
assessed the in vivo skin microvascular function of V235fs KI mice with post occlusive 
reactive hyperaemia (PORH) measurements. In addition detailed pharmacological 
characterization of macrovascular function was determined in vitro.  
Material & methods
Generation and molecular characterisation of transgenic TREX1 V235fs mice
To generate TREX1 V235Fs mice, the Trex1 gene was modified using a gene-
targeting approach, in such a manner that the single-exon Trex1 gene contained 
the human V235fs frameshift mutation that had been introduced in the targeting 
construct by site-directed mutagenesis (Figure 1).17 In the targeting construct, a 
PGK-driven neomycin selection cassette, flanked by LoxP sites, had been introduced 
downstream of Trex1 and upstream of neighbouring Scotin, between the two polyA 
sequences of the two genes to avoid disruption of RNA expression. Chimeras were 
obtained by injecting correctly targeted E14 ES cells into C57BL/6J blastocysts. 
In mice that were used for the experiments, the selection cassette was deleted by 
crossing the original transgenic TREX1 V235Fs mice with transgenic mice of the 
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EIIA-Cre delete strain,18 which express Cre recombinase driven by the EIIA early 
promoter. Offspring that contained V235Fs, but no longer the selection cassette, was 
subsequently interbred to provide litters containing homozygous mutant and WT 
genotypes that were used for the experiments. Mice were genotyped by PCRs specifi c 
for the mutation using standard molecular methods. Semi-quantitative Western blot 
analysis of cortical protein extracts revealed 26 KDa mutant (as predicted from 
the truncation) and 32 KDa WT Trex1 protein bands. In this experiment, actin was 
used as a loading control. Animals were kept under standard housing conditions in 
accordance with the National Institutes of Health Guidelines for the Care and Use of 
Experimental Animals. All experiments were approved by the Animal Experiment 
Ethics Committee of both the Leiden University Medical Centre and the Erasmus 
University. For all experiments, the investigator was blinded to the genotype.
(A)
(B)
Figure 1. Generation of V235fs TREX1 Knock-in Mice. (A) Relevant part of the genomic structure of the WT 
Trex1 allele, targeting vector and predicted structure after homologous recombination (V235fs KI NEO allele), and 
after Cre-mediated deletion of the Neo-cassette (depicted as gray box) (V235fs KI allele). LoxP sites are indicated 
by triangles. Black boxes indicate respective exons, with the V235fs mutation in exon 1. Black horizontal lines 
indicate probes for Southern and Northern. Primers used for genotyping and confi rmation of the V235fs mutation 
are depicted schematically by a pair of arrows. Restriction sites: EI, EcoRI; EV, EcoRV; K, KpnI; A, ApaI; X, XbaI. 
(B) Western blot of cortical protein extracts isolated from WT and homozygous V235fs KI mice probed with Trex1 
or actin antibody. Higher levels of Trex1 protein are present in homozygous V235fs KI mice compared with WT.
Animals
Twenty-four hours before dermal blood fl ow (DBF) measurements, the hair of 
the left hind leg of homozygous V235fs KI mice (background C57BL/6j, male 
and female, age 13, 26, 52 and 100 weeks, n=7-17) and WT mice (male and 
female) of corresponding ages, was removed with a hair removal cream (Veet®, 
ReckittBenckiser Inc., Berkshire, UK). On the day of measurement, mice were 
anesthetized using 4% isofl urane/O2 ventilation, and kept on a heating pad regulated 
by a rectal thermometer to keep the body temperature stable between 36.4°C and 
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37.0°C. After PORH measurements, mice were sacrificed by decapitation and aortas 
were collected for in vitro measurements. 
Post-occlusive reactive hyperaemia measurements
In vivo microvascular characterization was obtained by PORH measurements of 
the hindleg using laser Doppler flowmetry. With PORH the increase of the hindleg 
perfusion after a transient occlusion of the blood flow (reactive hyperaemia) is 
measured. In brief, after 5 min of equilibration, 10 min of baseline perfusion was 
recorded. Subsequently, the hindleg circulation was occluded for 2 min with a 
tourniquet. After release of the tourniquet, blood flow was monitored till return of 
blood flow to baseline values (max. 10 min). 
Mulvany myograph organ baths 
For the in vitro macrovascular pharmacological characterization, segments of the 
mouse aorta (inner diameter 0.5-1 mm) were mounted in a Mulvany myograph with 
separated 6-mL organ baths containing carbonated (5% CO2 and 95% O2) Krebs-
Henseleit buffer (composition in mM: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, 
H2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 7.4) at 37°C. Tension was normalized 
to 90% of the estimated diameter at 100 mmHg of transmural pressure. A reference 
contractile response of vessel segments was determined with 100 mM KCl. For the 
acetylcholine (ACh) and sodium nitroprusside (SNP) concentration response curves 
(CRCs), aorta segments were pre-contracted with the thromboxane A2 analogue 
U46619 (10-100 nM). Relaxant effects of ACh (endothelium-dependent) and SNP 
(endothelium- independent) and contractile effects of 5-hydroxytryptamine (5-HT) 
were examined with cumulative application of increasing concentrations of the 
drugs. 
Statistical analysis
For the analysis of PORH, the results were expressed as relative values compared 
to baseline. Results were expressed as the area under the response curve (AUC), 
maximal hyperaemia response (Max) and time-to-maximal hyperaemia (TTM). 
One-way ANOVA followed by Bonferroni post hoc tests were used to compare 
V235fs KI mice with WT. For the in vitro experiments, the vasorelaxant responses 
to ACh and SNP were expressed as the percentage of maximum contraction induced 
by U46619. The contractile responses to 5-HT were expressed as percentage of the 
response to 100 mM KCl. CRCs were analysed using 1-way ANOVA followed by 
Bonferroni post hoc tests. Data are expressed as mean ± standard error of the mean 
(SEM). P-values <0.05 were considered to indicate statistical significance. 
Results
Animals
There was no difference in weight between male WT and V235fs KI (33 ± 1 g vs. 31 
± 2 g) or between female WT and V235fs KI (26 ± 1 g vs. 24 ± 1 g) mice. Male and 
female microvascular function and macrovascular pharmacological properties were 
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similar (however, our study was not powered to detect gender differences), therefore 
data obtained from both sexes were pooled.
Microvascular reactivity in V235fs TREX1 KI mice: in vivo PORH measurements
The analysis of the PORH curves revealed that the area under the PORH curve was 
significantly lower in V235fs KI mice across all age groups (Figure 2A, [F(1, 65)=5.7, 
p=0.02]). The max PORH responses were similar between WT and homozygous 
V235fs KI mice (Figure 2B). Parameters such as baseline DBF and TTM were not 
different between V235fs KI mice and WT (Table 1).
13 wk 
WT
13 wk 
TG
26 wk 
WT
26 wk 
TG
52 wk 
WT
52 wk 
TG
100 wk 
WT
100 wk 
TG
BL (AU) 39±5 58±7 63±13 40±7 85±31 57±10 70±14 52±4
TTM (Sec) 83±38 111±57 114±17 150±23 77±13 47±9 64±10 45±10
Table 1. Skin baseline DBF and time max hyperemia for V235fs Trex1 Knock-in and WT mice. Data expressed 
as mean±SEM. TG = homozygous V235fs KI mice, BL = Baseline DBF and TTM = time to max.
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Figure 2. PORH of V235fs TREX1 Knock-in (red bars) and WT Mice (black bars). (A) The area under the reactive 
hyperemia curve for 13- to 100- week-old mice (n=4-13). * Statistically significant difference between WT and 
V235fs KI mice across all age groups. (B) Maximal reactive hyperemia response for 13-100 week old mice (n=4-13).
Macrovascular reactivity in V235fs TREX1 KI mice: Mulvany myograph studies 
Contraction to 100 mM KCl was not significantly different between WT and V235fs 
KI mice at (13 weeks: 7±1 vs. 8±0 mN, 26 weeks: 9±1 vs. 9±1 mN, 52 weeks: 
10±1 vs. 10±1 mN, 100 weeks: 8±1 vs. 8±1 mN).Maximal relaxation induced by 
ACh was attenuated in 100-week-old V235fs KI mice compared to 100-week-old 
WT mice (Emax: 65±6% vs. 37±8%, respectively, p=0.011), however the ACh CRCs 
between the 13- to 52-week-old V235fs KI mice and the 13-52 week old WT mice 
did not differ from the 13- to 52-week-old WT mice (Figure 3A-3D). SNP-induced 
relaxations were not significantly different between V235fs KI and WT mice (Figure 
3E-3H). The maximal contraction induced by 5-HT (Figure 3I-3L) tended to be lower 
in the 52- and 100-week-old V235fs KI mice (respectively Emax: 26±8% and Emax: 
50±13%) than in the 52- and 100-week-old WT mice (respectively Emax: 48±9%, 
p=0.06 and Emax: 73±11%, p=0.19).
88
Chapter 8
ACh 13 WK
56789
0
25
50
75
100
A
-Log [ACh] (M)
R
el
ax
at
io
n 
(%
 U
46
61
9)
ACh 26 WK
56789
0
25
50
75
100
B
-Log [ACh] (M)
R
el
ax
at
io
n 
(%
 U
46
61
9)
ACh 52 WK
56789
0
25
50
75
100
C
-Log [ACh] (M)
R
el
ax
at
io
n 
(%
 U
46
61
9)
ACh 100 WK
56789
0
25
50
75
100
*
D
-Log [ACh] (M)
R
el
ax
at
io
n 
(%
 U
46
61
9)
SNP 13 WK
456789
0
25
50
75
100
E
-Log [SNP] (M)
R
el
ax
at
io
n 
(%
 U
46
61
9)
SNP 26 WK
456789
0
25
50
75
100
F
-Log [SNP] (M)
R
el
ax
at
io
n 
(%
 U
46
61
9)
SNP 52 WK
456789
0
25
50
75
100
G
-Log [SNP] (M)
R
el
ax
at
io
n 
(%
 U
46
61
9)
SNP 100 WK
456789
0
25
50
75
100
H
-Log [SNP] (M)
R
el
ax
at
io
n 
(%
 U
46
61
9)
5-HT 13 WK
56789
0
25
50
75
100
I
-Log [5-HT] (M)
C
on
tr
ac
tio
n
(%
 o
f 1
00
 m
M
 K
C
l)
5-HT 26 WK
56789
0
25
50
75
100
J
-Log [5-HT] (M)
C
on
tr
ac
tio
n
(%
 o
f 1
00
 m
M
 K
C
l)
5-HT 52 WK
56789
0
25
50
75
100
K
-Log [5-HT] (M)
C
on
tr
ac
tio
n
(%
 o
f 1
00
 m
M
 K
C
l)
5-HT 100 WK
56789
0
25
50
75
100
L
-Log [5-HT] (M)
C
on
tr
ac
tio
n
(%
 o
f 1
00
 m
M
 K
C
l)
Figure 3. In vitro macrovascular characterization of V235fs TREX1 Knock-in (red squares) and WT (black 
circles) mice. In vitro macrovascular characterization of isolated aorta obtained from homozygous V235fs KI and 
WT mice. Panels depict concentration response curves to acetylcholine (ACh, A-D, n=7-16), sodium nitroprusside 
(SNP, E-H, n=7-17) and serotonin (5-HT, I-L, n=5-15). *Statistically significant attenuated relaxant responses to 
ACh in 100 week-old V235fs KI mice compared to WT mice.
Discussion
We performed an in vivo microvascular and in vitro macrovascular pharmacological 
characterization of the first knock-in mouse model for RVCL in which the human 
pathogenic V235fs TREX1 mutation was introduced by a gene targeting approach. 
With our study we identified microvascular dysfunction in 13- to 100-week-old 
V235fs KI mice. Detailed pharmacological macrovascular (aorta) characterization 
showed endothelial dysfunction only in mice aged 100 weeks.
The functional PORH test measures the cutaneous microvascular function.  The 
PORH response is caused by interplay of different vasodilatory factors. During the 
time course of the PORH response, important for the PORH parameter AUC, the 
endothelium-derived hyperpolarizing factor (EDHF) pathway is activated and causes 
the resulting vasodilation.19 During the hyperaemia peak the release of neuropeptides 
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from perivascular nerves plays a major role.20 Our results show that in V235fs KI mice 
the PORH peak is not different from WT, while the AUC is lower in V235fs KI mice 
across all ages that we studied (13- to 100-week-old mice) compared with WT. The 
lower PORH AUC points toward endothelial dysfunction in the microvasculature of 
the V235fs KI mice. Although studies assessing vascular function in RVCL patients 
are scarce, the preliminary results of the study by Vermeersch et al., where the FMD 
response was lower in the RVCL patients compared to healthy controls, are in line 
with our results.6 
The macrovascular in vitro characterization shows that the aortic endothelial function, 
evaluated by the vasorelaxant response of the aortic rings to ACh in Mulvany organ 
baths,21 is decreased in the 100-week-old V235fs KI mice. The CRCs of the aortic 
rings to SNP do not differ between the V235fs KI mice and WT. Notably, in the 
aortae of the 100 week old mice the relaxation to SNP even tended to be greater 
in the V235s KI mice. Thus, we can conclude that the vascular smooth muscle cell 
(VSMC) function is intact and the decrease in vasodilator response to ACh in the 
100 week old mice is probably due to the effect of endothelial dysfunction. With the 
diminished PORH AUC in the V235fs KI mice we demonstrate the involvement of 
an affected EDHF response. As EDHF is known to contribute more to vasorelaxation 
in microvessels than in larger vessels,22, 23 extensive endothelial dysfunction in the 
aortae of the V235fs KI mice was not to be expected based on our in vivo findings. 
Therefore the results of our in vitro studies are not in contrast with the microvascular 
PORH results. 
The 5-HT system is involved in migraine pathophysiology and for decades now 
5-HT1 receptor agonists have been applied successfully in migraine therapy.
24 As 
migraine is a prominent feature of RVCL, we also assessed the function of the 5HT 
receptor present on VSMC using the a selective natural ligand, 5-HT.25  CRCs to 
5-HT tended to be lower in the 52- and 100-week-old V235fs KI mice compared 
with WT, however, this was not statistically significant.  
The results of the present study clearly indicate a microvascular dysfunction, 
evidenced by the lower AUC of the PORH, in the V235fs KI mice that is present from 
as early as 13 weeks. This microvascular, endothelial dysfunction is present in the 
V235fs KI mice up to the age of 100 weeks. Macrovascular endothelial dysfunction 
revealed by the diminished relaxant responses to ACh in the V235fs KI mice is only 
present in the 100-week-old animals. The V235fs mutation does not seem to affect 
endothelium-independent relaxant or contractile vascular responses.
In conclusion, our vascular characterization indicates microvascular abnormalities, 
most likely due to endothelial dysfunction, in the V235fs KI mice. This seems in 
accordance with the clinical presentation in the RVCL patients. 
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CHAPTER 9 
Migraine and perimenopause
K. Ibrahimi, E.G.M. Couturier & A. MaassenVanDenBrink
Abstract
Perimenopause and migraine are closely linked. The hormonal instability during the 
perimenopausal period not only causes vasomotor symptoms and mood disturbances, 
but also increases migraine incidence. Women do report new onset migraine during 
this period, but the increased incidence is reported by women with menstrually 
related migraine (MRM). The hormonal fluctuations can be stabilized with hormone 
replacement therapy (HRT), while simultaneously improving the migraine in some 
patients. The increased stroke risk in women with migraine with aura (MA) should 
be taken into consideration when intending to treat perimenopausal women with 
migraine with HRT.
Introduction
The onset of the perimenopausal period, the period of 2 to 8 years prior the 
menopause as well as the year after the end of menses, is usually characterized by 
a sequence of symptoms caused by an estrogen deficit that occurs due to a decline 
in ovarian function.  These symptoms consist foremost of night sweats, hot flushes, 
joint pain and vaginal dryness, however sleep disturbances and irritability are also 
prevalent. There is a link between the menopausal transition and migraine as well. 
Preexisting migraine can remain unchanged, improve, but may also worsen during 
perimenopause.1, 2 Consequently, perimenopause is a turbulent period in women’s 
life, not only with regard to migraine. Unfortunately, prospective studies documenting 
the course of migraine during and after the menopausal transition remain rare. 
Migraine pathophysiology
Migraine is a paroxysmal disorder of a neurovascular origin, with great adverse 
effects on the quality of life. According to the Global Burden of Disease Survey 
2010 conducted by the World Health Organization, migraine is ranked as seventh 
highest cause of disability in the world.3 The distinctive pulsating headaches 
manifest as attacks that can last from 4 up to 72 h and are located unilaterally. The 
headaches worsen with physical activity and/or are associated with photophobia 
and phonophobia. When the headache is preceded and in some cases accompanied 
by gradually developing visual, sensory or other central nervous system symptoms 
(aura), then it is diagnosed as migraine with aura (MA) otherwise it is considered 
migraine without aura (MO).4 Migraine is thought to originate from neural events 
that results in dilation of cranial blood vessels, inducing headache and further nerve 
activation.5 Calcitonin gene related peptide (CGRP) is a key neuropeptide in migraine 
pathophysiology. Indicative of its importance, CGRP levels are elevated in jugular 
blood and saliva during migraine attacks and normalize after the use of antimigraine 
drugs.6, 7 CGRP receptor antagonists and antibodies against CGRP or its receptor are 
currently being developed as acute migraine therapy.8, 9 
Estrogen fluctuations and migraine
The prevalence of migraine is according to the recently published American 
Migraine Prevalence and Prevention study 17% in women and 6% in men.11 
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Especially hormonal milestones accompanied by fluctuations in estrogen levels 
such as menarche, pregnancy and menopause seem to have vast effects on migraine 
prevalence and frequency (Figure 1). The onset of migraine in women usually 
coincides with menarche and a close relation between migraine occurrence and the 
menstrual cycle remains during the reproductive years.12 Approximately 50% of 
women with migraine are affected by MRM;13 migraine without aura that occurs on 
day 1±2 of the menstrual cycle in at least 2 of 3 consecutive menstrual cycles with 
additional attacks with or without aura that can occur at other times of the month.4 
During perimenopause changes in migraine prevalence have been reported.14 Major 
fluctuations in estrogen levels take place during perimenopause, ultimately leading 
to dropping levels.15  The prevalence of migraine headaches during this period seems 
to be higher in patients who previously had a history of MRM and premenstrual 
syndrome.16, 17 
Figure 1. Migraine incidence and female hormones during the menstrual cycle, pregnancy and a women’s life. 
Adapted from Saco et al.10
Perimenopausal migraine
During the perimenopausal period serum estradiol levels are low (10-20 pg/ml). 
Nevertheless, 8-13% of women with migraine report the onset of their migraine 
during this period.18, 19 Interestingly, the type of menopause (surgical or spontaneous) 
influences the effect of the menopausal transition on pre-existing migraine. 
Improvement of migraine occurs in two-thirds of women after spontaneous 
menopause, but migraine worsens in two-thirds after surgical menopause.20 With 
the increase of time after the start of the menopausal transition, there is a decrease 
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of migraine prevalence,17, 21 which is most pronounced in MO.16 It is not surprising 
that, given the improvement of migraine in women after spontaneous menopause, 
oophorectomy has been considered as preventive migraine therapy in perimenopausal 
women. Pharmacological oophorectomy induced by a gonadotropin-releasing 
hormone agonist with estrogen add-back therapy seems to improve headache pain 
severity, but not the headache frequency.22 Anecdotal evidence suggests that total 
hysterectomy with bilateral oophorectomy and add-back estrogen therapy being 
successful in treatment of migraine.23 This kind of drastic surgical intervention is 
considered by some doctors in cases of women suffering from severe and debilitating 
migraine that has improved after pharmacologically induced menopause. These 
claims have an insufficient scientific base, so gynecological operations like this 
should be discouraged.
Treatment/management
During perimenopause, HRT may be prescribed to women to fight the symptoms 
of dropping estrogen levels.24 HRT can have an improving or worsening effect 
on migraine in perimenopausal women.25 Transdermal estrogen patches or gel are 
preferred in treating women with migraine during this period, since oral treatment 
can lead to estrogen fluctuations and consequently worsening of the migraine.26 
Estrogen replacement in perimenopausal patients with MA has been associated with 
an increase in headache severity and visual auras.27  Prescribing the lowest effective 
dose of estrogen seems to prevent this undesired effect.28  This is also prudent 
considering MA is a risk factor for ischemic stroke, see below.29-31  When systemic 
estrogen is used, endometrial protection is needed in perimenopausal women with an 
intact uterus. Progesterone, preferably micronized as this may be safer with regard to 
breast cancer risk,32 should be prescribed next to estrogen. Independent of the HRT to 
regulate estrogen levels, (pre)menopausal migraine can be treated with prophylactics 
or acute antimigraine therapy according to standard treatment strategy. While 
guidelines differ between internationally and even nationally,33 generally migraine 
attacks are initially treated with acutely acting medication. According to a treatment 
ladder, therapy is usually started with an oral analgesic (acetaminophen or NSAID’s) 
combined with an anti-emetic. When migraine relief is not achieved triptans are 
prescribed. Migraine prophylaxis consisting of beta-blockers, topiromate, depakine 
or other prophylactics are prescribed in patinets with frequent attacks or in case of 
insufficient efficacy or overuse of acutely acting drugs.34 
Future therapeutic options
CGRP seems to be involved in the development of vasomotor changes such as 
hot flushes, which occur during menopause.35 A combined therapy of migraine 
and vasomotor changes during perimenopause is very likely to be a therapeutic 
development in the future. The CGRP receptor antagonist telcagepant was the most 
promising amongst the ‘gepants’, until raised liver enzymes detected during a Phase 
II clinical trial led to suspension of its development.36 CGRP antibodies are likely the 
next chapter in blocking CGRP and are now undergoing clinical trials.29 Considering 
the unpredictability of hot flushes, prophylactic treatment with CGRP receptor 
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antagonists or antibodies is probably required. CGRP receptor antagonists are likely 
the safest choice as in case of adverse events they can be stopped without the long 
term effect that would be present with CGRP antibodies. 
Long term effects and conditions associated with migraine
Over the last years, migraine has been linked with stroke. More specifically, meta-
analysis of observational studies indicates that patients with migraine have a two-
fold increased risk of ischemic stroke.30, 31, 37 This risk is apparently linked to migraine 
with aura (MA)30, 31 and seems to increase with attack frequency.38 However, the 
recently presented cardiovascular disease (CVD) incidence rate (IR) data from 
the Women’s Health Study during the American Academy of neurology meeting39 
indicates an even higher CVD IR for MA (IR = 7.9; 6.2-10.0) than for example a 
more well-known CVD risk factors as current smoking (IR = 5.4; 95% CI; 4.6-6.4) 
and BMI higher than 35 kg/m2 (IR = 5.3; 95% CI; 4.0-7.2). Since there is evidence 
of continuation of MA after the menopause, postmenopausal women with migraine 
requiring HRT should be treated with caution while bearing in mind their increased 
stroke risk and possible additional risk factors. Moreover, some studies indicate that 
younger menopausal age increases the risk of ischemic stroke further.31 
Migraine has also been associated with increased prevalence and progression of 
clinically silent brain lesions,40 with the increased progression evident in women, 
but not in men.41 Combined with the increased stroke risk, a link between cognitive 
impairment and migraine would be expected. Nevertheless, results from longitudinal 
studies show no association between cognitive decline over time and migraine.41, 42 
On the other hand, there seems to be some positive long term effect of migraine on 
the risk of developing specific types of postmenopausal breast cancer. A study by 
Li et al. suggests that women with a history of migraine had a lower risk of breast 
cancer (hazard ratio [HR], 0.89; 95% CI, 0.80-0.98) than women without a migraine 
history.43  This risk reduction was not influenced by use of medication prescribed for 
migraine.43
Summary
Strong hormonal fluctuations, as occurring during menopause, are associated with 
migraine. However, the pathogenic mechanism behind this association remains to 
be clarified. With the recent advancement in the research of migraine, there is hope 
for better understanding of these mechanisms and eventually leading to a better 
treatment of patients suffering from this debilitating disorder.
97
Migraine and perimenopause
C
hapter 9
References
1. Mueller L. Predictability of exogenous hormone effect on subgroups of migraineurs. Headache 
2000;40:189-193.
2. Hodson J, Thompson J, al-Azzawi F. Headache at menopause and in hormone replacement therapy users. 
Climacteric 2000;3:119-124.
3. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 
diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2012;380:2163-2196.
4. Headache Classification Committee of the International Headache S. The International Classification of 
Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808.
5. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for 
primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow 
Metab 1999;19:115-127.
6. Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide 
levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009;49:1258-1266.
7. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of 
humans during migraine headache. Ann Neurol 1990;28:183-187.
8. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment 
of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2013.
9. De Hoon J, Montieth D, Vermeersch S, et al. Safety, pharmacokinetics, and pharmacodynamics of 
LY2951742: a monoclonal antibody targeting CGRP. Cephalalgia 2013;33:247.
10. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on 
vascular diseases. J Headache Pain 2012;13:177-189.
11. Buse DC, Loder EW, Gorman JA, et al. Sex differences in the prevalence, symptoms, and associated 
features of migraine, probable migraine and other severe headache: results of the American Migraine 
Prevalence and Prevention (AMPP) Study. Headache 2013;53:1278-1299.
12. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the 
United States: data from the American Migraine Study II. Headache 2001;41:646-657.
13. Martin VT. Menstrual migraine: a review of prophylactic therapies. Curr Pain Headache Rep 2004;8:229-
237.
14. Lakso M, Pichel JG, Gorman JR, et al. Efficient in vivo manipulation of mouse genomic sequences at the 
zygote stage. Proc Natl Acad Sci U S A 1996;93:5860-5865.
15. Yamada M, Soda M, Fujiwara S. Follicle-stimulating hormone and oestradiol levels during perimenopause 
in a cohort of Japanese women. Int J Clin Pract 2008;62:1623-1627.
16. Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. 
Headache 2003;43:27-35.
17. Wang SJ, Fuh JL, Lu SR, Juang KD, Wang PH. Migraine prevalence during menopausal transition. 
Headache 2003;43:470-478.
18. Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M. Sex-hormone-related events in 
migrainous females. A clinical comparative study between migraine with aura and migraine without aura. 
Cephalalgia 1995;15:140-144.
19. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and 
reproductive life events: a clinical epidemiological study in 1300 women. Headache 1993;33:385-389.
20. Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F, Genazzani AR. Characteristics of headache at 
menopause: a clinico-epidemiologic study. Maturitas 1993;17:31-37.
21. Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S. Symptoms in the menopausal transition: 
hormone and behavioral correlates. Obstet Gynecol 2008;111:127-136.
22. Martin V, Wernke S, Mandell K, et al. Medical oophorectomy with and without estrogen add-back 
therapy in the prevention of migraine headache. Headache 2003;43:309-321.
23. Jonsdottir GM, Herzog A, Istre O. Laparoscopic bilateral oophorectomy - feasible migraine management? 
Acta obstetricia et gynecologica Scandinavica 2012;91:271-272.
24. Panay N, Hamoda H, Arya R, Savvas M, British Menopause S, Women’s Health C. The 2013 British 
Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. 
Menopause Int 2013;19:59-68.
25. Facchinetti F, Nappi RE, Tirelli A, Polatti F, Nappi G, Sances G. Hormone supplementation differently 
affects migraine in postmenopausal women. Headache 2002;42:924-929.
26. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a 
double-blind placebo-controlled crossover study. Neurology 2006;67:2159-2163.
27. Kaiser HJ, Meienberg O. Deterioration or onset of migraine under oestrogen replacement therapy in the 
menopause. Journal of neurology 1993;240:195-196.
28. MacGregor A. Estrogen replacement and migraine aura. Headache 1999;39:674-678.
98
Chapter 9
29. Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for 
acute migraine? Expert opinion on investigational drugs 2012;21:807-818.
30. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic 
stroke risk: an updated meta-analysis. Am J Med 2010;123:612-624.
31. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: 
systematic review and meta-analysis. BMJ 2009;339:b3914.
32. Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani AR. Progestagen component in combined 
hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. 
Gynecol Endocrinol 2009;25:807-815.
33. Schuurmans A, van Weel C. Pharmacologic treatment of migraine. Comparison of guidelines. Can Fam 
Physician 2005;51:838-843.
34. Steiner TJ, MacGregor EA, Davies PTG. Guidelines for All Healthcare Professionals in the Diagnosis 
and Management of Migraine, Tension-Type, Cluster and Medication-Overuse Headache (3rd edn). 
2007;http://www.bash.org.uk/wp-content/uploads/2012/07/10102-BASH-Guidelines-update-2_v5-1-
indd.pdf.
35. Gennari C, Nami R, Pecchi S, De Franco V, Panza F, Pavese G. Plethysmographic evaluation of the 
vascular effects of human calcitonin gene-related peptide in man. Angiology 1991;42:462-467.
36. Han TH, Blanchard RL, Palcza J, et al. Single- and multiple-dose pharmacokinetics and tolerability of 
telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. Journal of clinical 
pharmacology 2010;50:1367-1376.
37. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: 
systematic review and meta-analysis of observational studies. BMJ 2005;330:63.
38. Kurth T, Schurks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in 
women. Neurology 2009;73:581-588.
39. Kurth T, Bubes V, Buring JE. Relative Contribution of Migraine with Aura to Cardiovascular Disease 
Occurrence in Women. . Neurology 2013;80:S40.001.
40. Kurth T, Mohamed S, Maillard P, et al. Headache, migraine, and structural brain lesions and function: 
population based Epidemiology of Vascular Ageing-MRI study. BMJ 2011;342:c7357.
41. Palm-Meinders IH, Koppen H, Terwindt GM, et al. Structural brain changes in migraine. JAMA 
2012;308:1889-1897.
42. Kalaydjian A, Zandi PP, Swartz KL, Eaton WW, Lyketsos C. How migraines impact cognitive function: 
findings from the Baltimore ECA. Neurology 2007;68:1417-1424.
43. Li CI, Mathes RW, Bluhm EC, et al. Migraine history and breast cancer risk among postmenopausal 
women. J Clin Oncol 2010;28:1005-1010.
99
Migraine and perimenopause
C
hapter 9

Based on: Neurology, 2015, 84:2, 125-131
CHAPTER 10 
Reduced trigeminovascular cyclicity in patients with 
menstrually related migraine
K. Ibrahimi, W.P.J. van Oosterhout, W. van Dorp, A.H.J. Danser, 
I.M. Garrelds, S.A. Kushner, E.M.E.H. Lesaffre, G.M. Terwindt, 
M.D. Ferrari, A.H. van den Meiracker & A. MaassenVanDenBrink
Abstract
Objective: A case-control study to investigate the effect of the menstrual cycle on 
trigeminal nerve-induced vasodilation in healthy women and patients with menstru-
ally-related migraine (MRM). Methods: Using a laser-Doppler imager, we com-
pared the vasodilator effects of capsaicin application and electrical stimulation (ES) 
on the forehead skin, a trigeminal nerve-innervated dermatome, in premenopausal 
MRM patients (n=22), healthy controls (n=20), and postmenopausal women without 
migraine (n=22). Blood samples were collected for female sex hormones measure-
ments. Results: Dermal blood flow (DBF) responses to capsaicin were higher in 
controls during days 1-2 than during days 19-21 of their menstruation cycle (Mean 
Emax ±SEM:  203±28 a.u. vs 156±27 a.u. (p=0.031) for 0.06 mg/ml capsaicin and 
497±25 a.u. vs 456±24 a.u. (p=0.009) for 6.0 mg/ml capsaicin). In contrast, MRM 
patients demonstrated DBF responses without significant cycle-dependent variabil-
ity (day 1-2 vs day 19-21: Emax 148±20 a.u. vs 154±20 a.u. (p=0.788) for 0.06 mg/
ml capsaicin and 470±17 a.u. vs  465±20 a.u. (p=0.679) for 6.0 mg/ml capsaicin). 
DBF response to ES were not different between either MRM patients or controls, 
at either occasion. Estradiol levels on day 19-21 of the menstrual cycle were higher 
in healthy controls (Mean±SEM: 75±8 pg/ml) than in MRM patients (52±4 pg/ml, 
p=0.014). In postmenopausal women, DBF responses to capsaicin and ES, as well as 
estradiol levels at both visits, were all significantly reduced compared to MRM pa-
tients and controls (in all cases, p<0.05). Conclusions: Our study provides evidence 
for a reduced menstrual cyclicity of both estradiol levels and the trigeminovascular 
vasodilator system in MRM patients. 
Introduction
Migraine is twice as prevalent in women than in men1. Migraine incidence in women 
changes  because of estrogen variations around menarche and menopause, but also 
during the menstrual cycle.2, 3 Estrogen withdrawal increases migraine attack inci-
dence migraine attacks,4  a process that may be postponed by estradiol injections.5-7 
Migraine attacks associated with menstruation are generally perceived as more se-
vere than attacks outside this period.8, 9
The potent vasodilator calcitonin gene-related peptide (CGRP), a key mediator in 
migraine,10  is released from primary afferents of the trigeminal ganglion, exerting 
its effects via the trigeminovascular system.11, 12 Given the relationship between mi-
graine attack incidence and hormonal fluctuations, an interaction between female 
sex hormones and CGRP seems likely.13, 14
We have developed a human model to study trigeminal nerve-mediated vasodila-
tation, by applying capsaicin and electrical stimulation (ES) to the forehead skin, a 
trigeminal nerve-innervated dermatome.15 Capsaicin activates the transient receptor 
potential vanilloid type 1 (TRPV1) channel, thereby enhancing CGRP release from 
trigeminal nerve terminals.15 In contrast, ES appears to act directly on trigeminal 
nerve terminals, without the need for TRPV1 activation  to evoke release of CGRP.15 
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We investigated whether (1) varying levels of sex hormones during the menstrual 
cycle affect trigeminal nerve-mediated vasodilatation, and (2) this pattern differs 
between patients with menstrually-related migraine (MRM) and healthy controls. 
We hypothesized that (1) trigeminal nerve-mediated vasodilatory responses are in-
creased preceding the menstruation, (2) this increase is more pronounced in patients 
with MRM than in controls, and (3) trigeminal nerve-mediated vasodilatory respons-
es are consistently low in postmenopausal women.  
Methods
Standard protocol approvals, registrations, and patient consents 
The Independent Ethics Committee of Erasmus MC, Rotterdam, The Netherlands, 
reviewed and approved the study protocol. All participants gave written informed 
consent after explanation of the study, which was conducted in accordance with local 
laws, the ethical principles of the Declaration of Helsinki, as well as the principles 
of Good Clinical Practice. 
Design and procedures
For our case-control study design we compared patients with MRM to age-matched 
healthy controls. We included postmenopausal women as a reference group (without 
menstrual cycle) for both the patients with MRM and their age-matched healthy con-
trols. Patients with MRM were recruited via a Dutch Web site inviting migraineurs 
to participate in research as part of the LUMINA project.16 On the website, patients 
completed validated questionnaires based on the International Classification of 
Headache Disorders, third edition (beta version)  (ICHD-3-b) criteria to diagnose 
migraine and MRM.17  MRM is classified as migraine without aura occurring on 
day 1±2 of the menstrual cycle with additional attacks of migraine at other times of 
the menstrual cycle.17 Our MRM diagnosis was adapted from the ICHD-3-b with a 
record of 3 menstrual cycles, of which 2 were prospective, and an interview.  We 
recruited women without migraine   via advertisement in local (Rotterdam, Nether-
lands) newspapers and flyers distributed in the Erasmus MC. 
Data on medical history, medication, and information about the menstrual cycle or 
menopausal status were collected via an additional questionnaire. Information  about 
headache frequency and severity of the patients with MRM was acquired from the 
LUMINA database.16  Only patients with MRM who were not using migraine pro-
phylactic treatment and who consented to refrain from the use of acute migraine 
therapy 48 hours before visits participated to prevent bias. Patients with MRM and 
healthy age-matched controls with a regular menstrual cycle, not using hormonal 
contraceptives, were eligible for inclusion. 
Recruitment started March 2011 and continued until August 2012. Research was 
executed in the Internal Medicine Department of Erasmus MC. Patients with MRM 
did not have any medical condition besides migraine. Healthy age-matched controls 
and postmenopausal women were screened with a thorough interview checking for 
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any (cardiovascular) disease or medication use. Nonsmoking healthy women were 
included. For premenopausal women, one study visit was 19-21 days after the first 
day of menstruation and the second visit on day 1-2 of the subsequent menstruation 
(Figure 1). For postmenopausal women, 2 visits were scheduled 7-10 days apart. 
Weight, height and (supine) blood pressure were measured.
The first research visit was in July 2011 and the last one in September 2012. Mi-
graine attack incidence was recorded from 1 month before the first research visit 
until 2 months later. Follow-up ended December 2012.                                                                                                                   
Figure 1. Estrogen and progesterone levels during menstrual cycle and time points of investigations. Yellow 
highlighted sections: time point of investigations for MRM patients and controls.
Forehead dermal blood flowstudies
Experiments were performed in a quiet, temperature-controlled room. Participants 
fasted for 3 hours before the measurements and both visits were during the same 
period of the day.
After 15 min acclimatization, 3 electrodes containing a 0.5-ml reservoir were placed 
on the forehead (for details, see our model validation article15). The electrodes were 
subsequently filled with three different types of solutions: normal saline, 0.06 mg/
ml capsaicin, and 6.0 mg/ml capsaicin. A fourth electrode was placed in the neck 
region. An iontophoresis device (PeriIont 382b, Perimed, Sweden) was connected 
with the negative lead to the electrode containing saline and the positive lead to the 
electrode in the neck. Dermal blood flow (DBF) was measured with the PeriScan 
PIM-3 system (Perimed). 
DBF at the site of the electrodes on the forehead was continuously measured for 40 
min. After 2 min baseline measurement, a current (0.2 mA) was applied for 1 min to 
the electrode containing saline. DBF was subsequently measured during 6 min. This 
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process was repeated with increasing current intensities (0.4 mA, 0.6 mA, 0.8 mA), 
up to 1.0 mA. 
Peripheral dermal blood flow response to ischemic stimulus
Post-occlusive reactive hyperemia (PORH) was measured at the volar site of the 
nondominant forearm (area 1x1 cm). A blood pressure cuff was placed around the 
upper arm. After a 2-min baseline DBF measurement, the pressure in the cuff was 
quickly increased to 200 mmHg, maintained for 5 min and subsequently released. 
PORH was continuously measured for 10 min.
CGRP measurements in saliva
Test subjects were given a cotton Salivette swab (Sarstedt AG & Co., Nümbrecht, 
Germany) to chew for 5 min. The swab was collected in the Salivette and stored at 
-80ºC. CGRP was determined by radioimmunoassay (Phoenix Pharmaceuticals, Inc, 
Burlingame, CA, USA), according to the manufacturer’s instructions. Total protein 
content was determined using the Pierce BCA Protein Assay Kit (Thermo Scientific, 
Rockford, Il, USA). Samples were measured in 2 blinded batches. 
Estrogen and progesterone levels 
Blood was collected via the cubital vein.  Serum estradiol and progesterone levels 
were determined with the Coat-A-Count Estradiol and the Coat-A-Count Progester-
one radioimmunoassay kits (Siemens Medical Solutions, Erlangen, Germany). Sam-
ples were measured in 2 blinded batches.
Statistical analysis
The number of cases and controls was based on the previously published validation 
study of our model.15 Based on this study, a sample size of 20 is sufficient to be able 
to detect a 25% shift in the DBF response during the cycle and between the groups 
to 6 mg/ml capsaicin with an 80% power and 5% significance. 
For each subject the maximal DBF (Emax) responses to capsaicin, and the ischemic 
stimulus were calculated. Similarly, for each subject the maximal DBF responses 
to each ES current intensity (0.2 mA-1.0 mA) was calculated. Individual data were 
analyzed in a blinded manner. Group values are provided as mean values and SEM, 
except for the demographic data in the Table, where SDs and  ranges are presented 
as indicated. Differences between groups were analyzed using analysis of variance 
(ANOVA) and unpaired Student t test. Differences within groups were examined 
by Student paired t test. Repeated-measures ANOVA with multiple comparison 
tests were computed. Linear regression analysis was performed and β values with 
95% confidence intervals are presented. The difference in DBF responses to capsa-
icin (Δ DBF) between groups and across the menstrual cycle were tested with the 
Mann-Whitney U test.  A p value <0.05 was considered to indicate statistical signif-
icance. No correction for multiple testing was applied. 
105
Reduced trigeminovascular cyclicity in patients with MRM
C
hapter 10
Patients with 
migraine
Controls Postmenopausal 
women
Population, n 22 20 22
Age, years 37±7 (21-45) 33±9 (19-45) 60±5 (50-68)
BMI, kg/m2  22.9±3.9 24.0±1.6 23.8±2.3
BP, mmHg
     Systolic 
     Diastolic 
105±17
66±7
109±9
64±6
118±9
71±6
HR , bpm 61±8 63±9 62±8
Age at migraine onset, years 18±7 (4-36)
Disease duration, years 19±9 (6-41)
Attack frequency, attacks per year
          1–2
          3–6
          7–12
          13–54
1
2
5
14
Migraine incidence on day 1±2 of 
the menstrual cycle, No. of attacks
          Day 27
          Day 28
          Day 1
          Day 2
          Day 3
1
1
7
1
2
Table 1. Demographics of the study population. BMI, body mass index. BP, blood pressure. HR, heart rate. 
Mean ± SD (Range).
Results
Subjects
Flow diagrams providing details on the recruitment are provided in Supplemental 
Figure 1. BMI, blood pressure, and heart rate were similar between groups (Table). 
Migraine attack incidence of the patients with MRM was highest on day 1 of the 
menstrual cycle (Table).
Forehead DBF responses
In healthy controls, DBF responses to 0.06 mg/ml and 6.0 mg/ml capsaicin were 
significantly higher during day 1-2 of their menstrual cycle compared to day 19-21 
(Figures 2A and 2B). In contrast, in patients with MRM, DBF responses to 0.06 mg/
ml and 6.0 mg/ml capsaicin were similar throughout their menstrual cycle. The in-
crease in DBF responses of healthy controls to 0.06 mg/ml capsaicin between visits 
(Δ: 47±20 a.u.) was significantly different from the slight decrease in DBF responses 
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of the MRM patients (Δ: 6±24 a.u., p=0.040), whereas the slightly smaller increase 
in response to 6.0 mg/ml capsaicin (Δ: 41±14 a.u.) in healthy controls was not sig-
nificantly different from that in patients with MRM (Δ: 6 ±14 a.u., p=0.078).  There 
was no association between DBF responses of patients with MRM and the time to/
since their migraine attacks. DBF responses in postmenopausal women were sig-
nificantly lower than those in women with a menstrual cycle (controls and patients 
with MRM) and were similar between visits.  DBF responses to ES between visits 
did not differ for either of the groups (Figure 2C). Repeated-measures ANOVA with 
a Greenhouse-Geisser correction revealed that mean DBF responses to ES differed 
significantly between stimulation intensities (0.2 mA-1 mA (F(2.017, 121.032): 
414.878, p<0.0001). Repeated-measures ANOVA revealed a group effect, with the 
lowest responses to ES in the postmenopausal women.
Figure 2. Maximal forehead dermal blood flow responses (DBF). DBF responses to 0.06 mg/ml capsaicin (2A), 6.0 
mg/ml capsaicin (2B) and electrical stimulation (2C). For Controls ( green ■)  and patients with MRM (red ▲): Visit 1 
= days 19-21 of the menstrual cycle and Visit 2 = days 1-2 of menstruation. For Postmenopausal women (blue ♦): Visit 
1 and Visit 2 planned randomly with 7-10 days in-between. Figure 2C: visit 2 Controls (light green ■), visit 2 MRM 
patients (light red ▲) and visit 2 post-menopausal women (light blue ♦) *: Significant difference in Emax between 
Visit 1 and Visit 2. #: Significant difference in Emax during both visits compared to MRM patients and Controls.
Hormone levels
Serum estradiol levels on day 19-21 of patients with MRM were significantly lower 
than those of the healthy controls (52±4 pg/ml vs. 75±8 pg/ml respectively), while 
no differences in estradiol levels between MRM patients and healthy controls (25±5 
pg/ml vs. 21±4 pg/ml respectively) were present on day 1-2 of the cycle (Figure 3A). 
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Serum progesterone levels in patients with MRM and healthy controls at the 2 occa-
sions were similar (Figure 3B). Estradiol and progesterone levels during day 19-21 
of the menstrual cycle were significantly higher than during day 1-2. Estradiol and 
progesterone levels of the postmenopausal women were low, consistent with their 
nonreproductive life stage. 
Figure 3. Serum estradiol levels (A) and progesterone levels (B). For Controls (green ■)  and MRM 
patients (red ▲): Visit 1 = days 19-21 of the menstrual cycle and Visit 2 = days 1-2 of menstruation. 
For Postmenopausal women (blue ♦): Visit 1 and Visit 2 planned randomly with 7-10 days in-between. 
*: Significant difference in estradiol levels between MRM patients and controls. #: Significantly lower 
levels in Postmenopausal women during both visits compared to patients with MRM and controls.
Peripheral dermal blood flow response to ischemic stimulus
There were no significant differences in PORH responses between visits or between 
groups (Figure 4).  Both age and the maximum PORH response were significant 
predictors for the Emax DBF response to 1 mA electrical stimulation (respectively: 
β:-2.455, 95% CI[-4.206; -0.705] and β: 0.813, 95% CI[0.165; 1.461]).
Figure 4. Maximal post occlusive reactive hyperemia (PORH) responses. For Controls (green ■) and 
patients with MRM (red ▲): Visit 1 = days 19-21 of the menstrual cycle and Visit 2 = days 1-2 of menstruation. 
For Postmenopausal women (blue♦): Visit 1 and Visit 2 planned randomly with 7-10 days in between.
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CGRP in saliva
No differences in salivary CGRP levels between visits or between groups were ob-
served (Supplemental 2).  There was no correlation between saliva CGRP levels and 
the time to/since the last migraine attack of the MRM patients. The saliva volume 
collected from postmenopausal women was significantly lower than from healthy 
controls and patients with MRM on cycle days 19-21.
Discussion
We investigated the association between the menstrual cycling of female sex hor-
mones on trigeminal nerve-mediated vasodilatation in healthy controls and MRM 
patients. 
We clearly demonstrated a DBF response difference to capsaicin over the course of 
the menstrual cycle in healthy women, indicating that our model is suitable to de-
tect cycle-dependent changes in trigeminovascular reactivity. In contrast, this cyclic 
DBF response difference was absent in patients with MRM. Notably, DBF responses 
to ES were similar throughout the menstrual cycle in both patients with MRM and 
healthy controls. As expected because of their stable low female sex hormone levels, 
postmenopausal women showed no cyclicity in their DBF responses to either capsa-
icin or ES between visits. Rather, when compared to the healthy controls and patients 
with MRM, they responded significantly lower to both stimuli. Another surprising 
finding of our study is the relatively low mean estradiol level detected during days 
19-21 of the menstrual cycle of the patinets with MRM, which seems in agreement 
with their reduced cyclicity in DBF responses.
In accordance with our hypothesis, DBF responses to capsaicin during days 1-2 of 
the menstrual cycle were increased in healthy controls. The enhanced DBF response 
to capsaicin of healthy women around the time of their menstruation is consistent 
with previously published data, whereby, in healthy women,  sensory and vasomotor 
responses to intradermal capsaicin injections of the forehead were increased during 
the menstruation compared to responses during the luteal phase.18 The higher re-
sponses were attributed to either the direct effect of estrogen withdrawal on trigem-
inal nerve-innervated vasculature or to its effect on modulation of serum levels of 
ionized magnesium. Indeed, estrogen has been suggested to enhance neurogenic 
vasodilatation, primarily by CGRP, in rats.19, 20 Because we did not detect cyclic 
responses to ES, the higher responses during menstruation in healthy controls may 
be attributed to differential activity of the TRPV1 channel. Alternatively, release of 
other neuropeptides in response to ES might mask the CGRP-specific component of 
the DBF response. Finally, the lack of cyclic responses to ES could be attributed to 
the stimulation time and intensity. With ES, we applied a brief (1-min) stimulus with 
a 6-min recovery time. Therefore, this recovery time might have been sufficient for 
the replenishment of the readily releasable pool of neuropeptide vesicles at the nerve 
terminals.21 In contrast, with capsaicin application there is no recovery phase, but 
rather a constant stimulation during 40 min. This might lead to not only the exhaus-
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tion of the readily releasable pool of vesicles, but also of the more slowly replenished 
neuropeptide vesicle reserve pool.                        
Contrary to our expectations, the DBF responses to capsaicin in patinets with MRM 
were unchanged throughout their menstrual cycle. Elevated CGRP levels in jugular 
blood during migraine attacks have been previously reported.22 Consequently, we 
expected patients with MRM to have higher DBF responses to capsaicin during days 
1-2 of their menstrual cycle. Our results may be explained by activity-dependent 
transport of neuropeptide in the trigeminal nerve. In particular, the higher release 
of CGRP from the dural fibres of the trigeminal nerve during the perimenstrual pe-
riod might be attributable to enhanced anterograde transport from the cell soma, 
where CGRP is synthesized and packaged, to the nerve terminals from where it 
is synaptically released. Supporting such a potential mechanism is recent evidence 
from Drosophila that also suggests an activity-dependent mechanism of neuropep-
tide release.23 Another possible explanation for the lack of cyclic responses in MRM 
patients could be an inhibition of TRPV1 channel function induced by the lower 
decline in estradiol levels in migraine patients as compared with healthy controls. 
Admittedly, the role of the TRPV1 channel in migraine is still ambiguous.24, 25          
We included salivary measurements of CGRP levels as these reflect the activation 
state of the trigeminovascular system. Although previous studies have detected ele-
vated CGRP levels in saliva in migraine patients during the premonitory and head-
ache phase of a migraine attack,26, 27 this finding was not replicated in a study with 
chronic migraine patients.28 Notably, we observed similar levels of salivary CGRP 
in patinets with MRM and healthy controls. These data confirm our DBF measure-
ments, because both the fibres of ophthalmic branch on the forehead (DBF response), 
as well as the fibres of the mandibular branch of the trigeminal nerve (saliva produc-
tion) show similar responses in migraine patients independent from the timing in the 
menstrual cycle or the temporal relationship to a migraine attack. It is important to 
note that, contrary to the studies mentioned above, we did not collect saliva samples 
during the premonitory or headache phase of our patients with migraine, because 
we primarily intended to investigate the relation between CGRP and the menstrual 
phase of healthy controls and patients with migraine. Because this limits the conclu-
sions that can be drawn from our salivary measurements, it would be interesting to 
study ictal salivary CGRP levels in patients with MRM in future.          
As hypothesized, the DBF responses to capsaicin application and electrical stim-
ulation in postmenopausal women were consistently lower than in menstruating 
women. To verify whether these findings were caused by general, age-dependent 
decreases of microcirculatory function, we performed the PORH test. Notably, the 
PORH response between groups was not significantly different. The relatively low 
age and good health of the included postmenopausal women  may explain the normal 
PORH responses. Although not significant, the PORH responses of the postmeno-
pausal women tended to be lower than the PORH responses of the premenopausal 
groups (Figure 4). However, this slight difference in PORH responses is not of such 
110
Chapter 10
magnitude to plausibly explain the significantly lower DBF responses of the post-
menopausal women to capsaicin application and ES, which was confirmed by the 
regression analysis.  Lower DBF responses to capsaicin application and ES thus 
seem to be related to the low estradiol levels after the menopause, which specifically 
affect the trigeminovascular system and do not induce generalized microcirculatory 
dysfunction.            
Our surprising finding of lower estradiol levels measured in patients with migraine 
during days 19-21 of the menstrual cycle is not attributable to the mean age of our 
study groups. In fact, previous studies have reported higher estradiol levels in per-
imenopausal women.29 In our study, the patients with MRM had a slightly, but not 
significantly, higher mean age than the healthy controls (Table), despite having low-
er estradiol levels during the luteal phase (days 19-21 of the cycle). A relationship 
between low luteal estradiol levels and MRM has never previously been reported. 
High estradiol levels preceding ovulation have been linked to migraine with, but not 
to migraine without, aura.30 Our observation is in accordance with previously pub-
lished data,4 in which the ratio between a urinary metabolite of estradiol measured 
during the luteal phase and during menses in menstrual migraine patients is the same 
as in our study (estradiol levels in patients with MRM: days 19-21:days 1-2 = 2:1). 
To replicate the data observed in our healthy controls, we used data from a previous 
study at our institution on healthy women with a regular menstrual cycle (n=9).31 
Indeed, the ratio between serum estradiol during the luteal phase and menses was the 
same as in our current study (estradiol levels healthy controls: days 19-21:days 1-2 = 
4:1). We conceive that the number of subjects in the current study and the replication 
group is relatively small to make definite statements about the hormone levels in 
patients with MRM. Future studies should investigate these levels in a larger set of 
patients with MRM.
Taken together, our data confirms the pre-existing theory that the premenstru-
al withdrawal of estradiol influences the trigeminovascular system. Moreover, our 
study provides evidence for a disturbed systemic as well as trigeminovascular cy-
clicity in patients with MRM, which may augment their susceptibility to migraine 
around the time of menstruation. 
111
Reduced trigeminovascular cyclicity in patients with MRM
C
hapter 10
References
1. Buse DC, Loder EW, Gorman JA, et al. Sex Differences in the Prevalence, Symptoms, and Associated 
Features of Migraine, Probable Migraine and Other Severe Headache: Results of the American Migraine 
Prevalence and Prevention (AMPP) Study. Headache 2013.
2. Bille B. A 40-year follow-up of school children with migraine. Cephalalgia 1997;17:488-491; discussion 
487.
3. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the 
United States: data from the American Migraine Study II. Headache 2001;41:646-657.
4. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual 
cycle phases of rising and falling estrogen. Neurology 2006;67:2154-2158.
5. Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 
1972;22:355-365.
6. Somerville BW. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted pr-
ophylaxis by premenstrual estrogen administration. Neurology 1975;25:239-244.
7. Somerville BW. Estrogen-withdrawal migraine. II. Attempted prophylaxis by continuous estradiol admi-
nistration. Neurology 1975;25:245-250.
8. Couturier EG, Bomhof MA, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch 
population sample: prevalence, disability and treatment. Cephalalgia 2003;23:302-308.
9. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neu-
rology 2004;63:351-353.
10. Edvinsson L, Villalón CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treat-
ment. Pharmacology & therapeutics 2012;136:319-333.
11. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calci-
tonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 
2010;169:683-696.
12. Edvinsson L, Elsas T, Suzuki N, Shimizu T, Lee TJ. Origin and Co-localization of nitric oxide syntha-
se, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microscopy research and technique 
2001;53:221-228.
13. Sarajari S, Oblinger MM. Estrogen effects on pain sensitivity and neuropeptide expression in rat sensory 
neurons. Exp Neurol 2010;224:163-169.
14. Multon S, Pardutz A, Mosen J, et al. Lack of estrogen increases pain in the trigeminal formalin model: a 
behavioural and immunocytochemical study of transgenic ArKO mice. Pain 2005;114:257-265.
15. Ibrahimi K, Vermeersch S, Danser AH,, et al. Development of an experimental model to study trigeminal 
nerve-mediated vasodilation on the human forehead. Cephalalgia 2014;34: 514-522.
16. van Oosterhout WPJ, Weller CM, Stam AH, et al. Validation of the web-based LUMINA questionnaire 
for recruiting large cohorts of migraineurs. Cephalalgia 2011;31:1359-1367.
17. Headache Classification Committee of the International Headache S. The International Classification of 
Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808.
18. Gazerani P, Andersen OK, Arendt-Nielsen L. A human experimental capsaicin model for trigeminal sen-
sitization. Gender-specific differences. Pain 2005;118:155-163.
19. Gupta S, Mehrotra S, Villalón CM, Perusquia M, Saxena PR, MaassenVanDenBrink A. Potential role of 
female sex hormones in the pathophysiology of migraine. Pharmacology & Therapeutics 2007;113:321-
340.
20. Gupta S, Villalon CM, Mehrotra S, et al. Female sex hormones and rat dural vasodilatation to CGRP, 
periarterial electrical stimulation and capsaicin. Headache 2007;47:225-235.
21. Rizzoli SO, Betz WJ. Synaptic vesicle pools. Nature reviews Neuroscience 2005;6:57-69.
22. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cere-
brovascular and neuropeptide changes seen in humans and cats. Annals of neurology 1993;33:48-56.
23. Shakiryanova D, Tully A, Levitan ES. Activity-dependent synaptic capture of transiting peptidergic ve-
sicles. Nat Neurosci 2006;9:896-900.
24. Meents JE, Neeb L, Reuter U. TRPV1 in migraine pathophysiology. Trends Mol Med 2010;16:153-159.
25. Shimizu T, Shibata M, Toriumi H, et al. Reduction of TRPV1 expression in the trigeminal system by 
botulinum neurotoxin type-A. Neurobiol Dis 2012;48:367-378.
26. Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide 
levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009;49:1258-1266.
27. Bellamy JL, Cady RK, Durham PL. Salivary levels of CGRP and VIP in rhinosinusitis and migraine 
patients. Headache 2006;46:24-33.
28. Cady R, Turner I, Dexter K, Beach ME, Cady R, Durham P. An Exploratory Study of Salivary Calcitonin 
Gene-Related Peptide Levels Relative to Acute Interventions and Preventative Treatment With Onabotu-
linumtoxinA in Chronic Migraine. Headache 2014;54:269-277.
112
Chapter 10
29. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the 
perimenopause. J Clin Endocrinol Metab 1996;81:1495-1501.
30. Nagel-Leiby S, Welch KM, Grunfeld S, D’Andrea G. Ovarian steroid levels in migraine with and without 
aura. Cephalalgia 1990;10:147-152.
31. van Santbrink EJ, Hop WC, van Dessel TJ, de Jong FH, Fauser BC. Decremental follicle-stimulating 
hormone and dominant follicle development during the normal menstrual cycle. Fertility and sterility 
1995;64:37-43.
113
Reduced trigeminovascular cyclicity in patients with MRM
C
hapter 10
(B)(A)
(C)
Supplemental Figure 1. Recruitment fl ow diagram. MRM patients (A), premenopausal healthy controls (B) and 
postmenopausal healthy controls (C).
Supplemental Figure 2. Collected saliva and measured CGRP levels. Collected saliva volume (5A) and 
CGRP levels (5B). For Controls (green ■) and patients with MRM (red ▲): Visit 1 = days 19-21 of the 
menstrual cycle and Visit 2 = days 1-2 of menstruation. For Postmenopausal women (blue ♦): Visit 1 and Visit 
2 planned randomly with 7-10 days in-between. #: Signifi cant difference in saliva levels during both visits.
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Cephalalgia, under revision
CHAPTER 11 
The infl uence of migraine and the menstrual cycle on 
capsaicin-induced dermal blood fl ow
K. Ibrahimi, S. Vermeersch, P. Frederiks, V. Geldof, C. Draulans, 
L. Buntinx, E.M.E.H. Lesaffre, A. MaassenVanDenBrink & J. de Hoon
Abstract
Background: Migraine is much more common in females than in males and 
occurrence is associated with changes in female sex hormones. Calcitonin gene-
related peptide (CGRP) plays a key role in migraine and variations in female sex 
hormones may affect CGRP sensitivity and or production. Objectives: Investigate 
repeatability, gender differences, influence of the menstrual cycle and of migraine on 
CGRP-dependent changes in dermal blood flow (DBF). Methods: CGRP-dependent 
increases in DBF were assessed using laser Doppler perfusion imaging after topical 
application of 300 or 1000 µg capsaicin on the forearm of healthy subjects and 
migraine patients. Results: In healthy males, DBF response did not vary over time 
and was comparable with DBF in male migraineurs. In healthy females, capsaicin-
induced DBF responses to both doses of capsaicin were higher during menstruation 
compared to the late-secretory phase (p= 0.004-0.049). Compared to healthy 
subjects, female migraineurs displayed a higher DBF during menstruation and the 
late-secretory phase, which was not significantly different during the 2 phases of the 
cycle. Conclusions: An increased capsaicin-induced, CGRP-mediated DBF response 
was observed during menstruation in healthy women, but in female migraine patients 
this increased response was not affected by the menstrual cycle.
Introduction
Migraine headache is a neurovascular disorder in which the trigeminovascular 
system is primarily involved. Migraine is much more prevalent in women than in 
men1, 2 and women with migraine also have higher rates of most migraine symptoms, 
more severe associated impairment, and higher healthcare resource utilization than 
males.2 
Migraine attacks seem to be associated with changes of female sex hormone levels3 
as peaks of migraine frequency occur when estrogen levels drop;4 i.e. around the 
menstruation period,5, 6 at the end of pregnancy (postpartum) and during the transition 
to menopause. In pre-adolescent boys and girls, migraine prevalence is similar. 
However after menarche, migraine prevalence becomes approximately 3 times 
higher in females than males during the reproductive years of life.7 Furthermore, in 
female migraine patients, a higher occurrence of attacks without aura is observed 2 
days before onset of menses and on the first days of menses.8 The exact diagnostic 
criteria for pure menstrual migraine without aura and menstrually related migraine 
without aura are defined by The International Classification of Headache Disorders.9 
As mentioned above, a relationship between migraine and estrogen withdrawal 
has been suggested, while rising levels of estrogen appear to be protective against 
migraine.4 This theory is confirmed by studies reporting improvement of migraine 
during pregnancy,10, 11 particularly during the second and third trimester, when serum 
levels of estradiol and progesterone are much higher than peak levels during native 
menstrual cycles. Postpartum, migraine reoccurs, but less in lactating women. 
It has even been suggested that the improvement observed during pregnancy is 
maintained by breast-feeding, a period of anovulation.12 During the transition 
period to menopause, when estrogen levels vary, a higher migraine prevalence is 
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observed.13 After the menopause, when female hormone levels are low, migraine in 
many patients disappears.14
Sex steroids can exert effects on neurotransmitter systems and pain processing 
networks relevant to migraine headache15 and at the level of downstream signaling.16 
Estrogen affects growth factors and influences the function of neurons, glia cells 
and the vasculature. Therefore, estrogens may contribute to neurological disorders 
including migraine.17 Mechanisms by which estrogens exert vascular functional 
effects, are nicely reviewed by Miller and Duckles.18 
Findings over the last two decades also clearly indicate a pivotal role for calcitonin-
gene related peptide (CGRP) in the pathophysiology of migraine. CGRP is a 
very potent vasodilator and a neuropeptide involved in pain transmission in the 
trigeminovascular system. Blocking CGRP is efficacious in migraine treatment.19-21 
To test receptor engagement of CGRP receptor antagonists in early clinical trials, 
a human exploratory biomarker model was developed.22 This capsaicin-induced 
dermal blood flow (DBF) model was validated23 as a reproducible human neurogenic 
inflammation model to elicit endogenous CGRP release via transient receptor 
potential vanilloid 1 (TRPV1) activation at peripheral nerve endings.24 The resulting 
vasodilatation, as measured with laser Doppler perfusion imaging, was clearly 
shown to depend on CGRP.25 
After validating the long term repeatability of the DBF model in healthy male 
volunteers, this study investigated the influence of the female menstrual cycle and 
of migraine on changes in skin perfusion resulting from the endogenous release of 
CGRP induced by the local application of capsaicin. We hypothesized that the CGRP 
response is fortified by migraine and/or dependent on the female hormonal cycle.
Methods
Subjects
This study was approved by the ethics committee of the University Hospitals of 
Leuven (Leuven, Belgium). Subjects were recruited via public advertisements at the 
university campus and in student magazines. Additionally, a volunteer database was 
used for subject recruitment. During a telephone call and e-mail communication, 
a first eligibility check was performed. During a subsequent screening visit, all 
in- and exclusion criteria were further checked. Written informed consent was 
obtained from all subjects during the screening visit. All subjects were adult, white, 
nonsmoking, healthy subjects (apart for migraine) based on medical history. No 
hormonal contraceptive method was allowed. As part of the health and demographic 
information questionnaire, women reported the first day and length of their most 
recent menstruation and confirmed having a regular menstrual cycle. Migraine 
patients suffering from moderate to severe migraine headache with or without aura 
were included as diagnosed according to IHS criteria (International Committee on 
the Classification of Headache Disorders, 2004). Subjects using cardiovascular 
medication or medication affecting the nervous system were excluded. In case of 
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acute anti-migraine medication use, a time window of 5 half-lives between medication 
intake and the experiment was taken into account. Subjects taking prophylactic 
migraine medication within 1 month of the screening visit or taking medication for 
acute headache on more than 10 days per month were excluded.
Study design
During a screening visit, medical history, inclusion and exclusion criteria were 
checked and basic demographic data collected. During each study visit, supine 
systolic blood pressure, diastolic blood pressure, and heart rate were measured at the 
dominant arm with a semi-automated oscillometric device (Omron HEM-705CP; 
Omron Healthcare, Hamburg, Germany) after an acclimatization period of at least 
20 min. Subsequently, baseline DBF was determined as described previously,22 
using a laser Doppler perfusion imager (HR-LDPI system, Periscan PIMII). Only 
responders, defined as subjects with a capsaicin-induced increase in DBF of ≥100% 
in both proximal sites of both forearms were included after the screening visit. All 
measurements were performed while the subjects rested in a supine position on a 
comfortable bed in a quiet, temperature-controlled room (ambient temperature 23 
± 1°C). Subjects were instructed to abstain from chocolate-, alcohol-, and caffeine-
containing beverages and food during the 12 h period preceding each study visit. 
General fasting for 3 hours before the experiment was demanded. Blood samples 
were taken from participating women to assess female hormone levels (i.e. estrogen 
and progesterone).
Repeatability of capsaicin-induced DBF over time
Male healthy subjects were included in a 4-period, single-blind study. Study periods 
with capsaicin-induced DBF assessments were separated by a wash-out period of 
7(±1) days.
Menstrual cycle effects in healthy females
For the study part assessing menstrual cycle effects in healthy females, capsaicin-
induced DBF was evaluated weekly up to 2 menstrual cycles. Women were included 
at random periods of their menstrual cycle to avoid confounding effects over time. 
Measurements from women with an irregular menstrual cycle were excluded from 
the analysis.
Migraine patients
In the study part with migraine patients, male subjects were assessed at 2 study visits 
apart from the screening visit. Average capsaicin-induced DBF was calculated from 
these 2 visits. After screening, female migraineurs underwent the DBF experiment 
one week before expected menstruation, and once during their menstruation period. 
All experiments in migraine patients were performed during the interictal period.
Capsaicin-induced DBF response
In each subject, 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings 
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(8 mm inner diameter) were placed on the volar surface of each forearm. In the 
2 most proximal rings, subjects received a topical dose of 300 or 1000 µg/20 µL 
capsaicin (single-blind, randomized). In the distal ring of both arms, placebo (i.e. 
vehicle) was applied. The application of capsaicin/placebo started on the dominant 
arm (t=0) with a 1-min interval between each ring. The applications at the non-
dominant arm started 5 min after the first application at the dominant arm. DBF was 
assessed using laser Doppler perfusion imaging just before and at 10, 20, 30 and 40 
min after capsaicin/vehicle application.
Estradiol and progesterone plasma levels 
Serum estradiol and progesterone levels were determined with the Coat-A-Count 
Estradiol and the Coat-A-Count Progesterone kits (Siemens Medical Solutions, 
Netherlands). These are no-extraction, solid-phase 125I radioimmunoassay kits 
designed for measurement of estradiol and progesterone in serum.
Data analysis and statistics 
Based on the within-subject standard deviation observed in the reproducibility 
study and given a type I error probability (α) of 0.05, a sample size of 11 subjects 
provides 80% power for detecting a difference in DBF increase of 20%.22 To assess 
repeatability of DBF after capsaicin/vehicle application, percentage change in 
DBF from baseline to 40 min after capsaicin/vehicle application was calculated by 
ANOVA including dose, time point and week in the model. For comparison between 
healthy and migraine subjects, percentage change in DBF (corrected for  the vehicle 
response) was calculated at each time point (pre-capsaicin, 10, 20, 30 and 40 min 
post-capsaicin). The area under the curve of DBF response from 0 up to 40 min after 
capsaicin application (AUC0-40, % · min) was calculated as a summary measure using 
DBF ratios. Unless stated otherwise, mean and standard error of the mean (SEM) are 
presented. 
SPSS version 21 (SPSS inc, IBM,Chicago, IL, USA) was used for statistical 
analysis. Repeated-measures analysis of variance (ANOVA) with a Bonferroni 
post-hoc test was used to assess reproducibility in healthy males, menstrual cycle 
effects in healthy females, and comparison of differences between healthy subjects 
and migraine patients.  To compare the effects of female hormones on capsaicin-
induced DBF with those recently reported in literature,26 we performed paired t-tests 
comparing the response during menses and the late-secretory phase of the menstrual 
cycle. Kruskal-Wallis ANOVA was used to assess hormonal changes during the 
4-week menstrual cycle of healthy subjects and migraine patients. With a Dunn’s 
post hoc test we compared the hormone levels within and between groups. A two-
tailed p-value <0.05 was considered statistically significant. 
Results
Subjects
Five healthy subjects and two migraineurs were excluded at screening being non-
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responder to capsaicin. Data of 5 subjects were excluded from analysis because of 
medication use; 4 others were excluded because of irregular menstrual cycles. Due to 
technical breakdown of the LDI scanner, data from 7 out of 26 healthy females were 
exclusively used for analysis of menstrual cycle effects within the group of healthy 
females and excluded from comparison with migraine women as they were scanned 
with a differently calibrated scanner. Likewise, data from 2 out of 16 healthy men 
were only used for weekly repeatability analysis within healthy males, and not for 
inter-group comparison.
Repeatability in males
Figure 1 describes DBF response 10, 20, 30 and 40 min after application of vehicle, 
300 or 1000 µg capsaicin solution, assessed at 4 consecutive weeks in 16 healthy 
men (average age 23.6 years, range: 20-28). Significant differences were found 
between doses (placebo, 300 µg and 1000 µg capsaicin; p<0.001) and between time 
points (10, 20, 30 and 40 min post-capsaicin; p<0.001). Over a period of 4 weeks the 
capsaicin-induced increase in DBF did not change (p=0.06).
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Figure 1: Repeatability of dermal blood flow over 4 consecutive weeks in healthy men (n=16). 
DBF is presented as percentage change from baseline. Mean and 95% CI. DBF: dermal blood flow.
Menstrual cycle effects in healthy females
Twenty-six healthy females, not taking hormonal contraceptives were enrolled 
(average age 21.6 years, range 18-26). DBF was expressed as (i) percentage increase 
in DBF 40 min post-capsaicin application compared to placebo, as well as (ii) area-
under-the-curve of percentage change in DBF response, expressed as percentage 
increase compared to placebo, from 0 up to 40 min (AUC0-40). Repeated measures 
ANOVA did not reveal a significant effect of the menstrual cycle on the 40 min 
DBF response to 300 µg capsaicin (figure 2A), neither on the 40 min DBF response 
(figure 2B) and nor on the AUC of the DBF response to 1000 µg (figure 2D). We did 
however find a trend for significance of the menstrual cycle effect on the AUC of the 
DBF response to 300 µg capsaicin (figure 2C, P=0.053). The 40 min DBF response 
to 300 µg capsaicin. When specifically comparing the menses with the late secretory 
phase, we in most comparisons observed increased DBF responses to both doses of 
capsaicin during the menstruation (figure 2A: p=0.049, figure 2B: p=0.004, figure 
2C: p=0.023, figure 2D: p=0.065). 
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Migraine patients
Demographics for inter-group comparison of healthy subjects and migraine patients 
are displayed in table 1. Overall, migraine patients were well matched with healthy 
control groups for age, body mass index and blood pressure parameters. However, 
the female migraine patient group was slightly older than the female control group 
(25.1 versus 21.5 years; p<0.001). On average, migraine patients suffered from 
migraine for 11 years (± 5.8 years), with a frequency of 5.6 attacks (± 6.9 attacks) 
over the last 3 months preceding participation to this study. Sixteen (=53%) of 
participating migraine patients had aura attacks preceding their headache: 7 out of 14 
(50%) females and 9 out of 16 males (56%). Fifteen patients (50%) reported dietary 
causes of migraine attacks, 15 patients (50%) reported a sleep pattern relationship 
and 17 patients (57%) indicated stress-related migraine attacks. From the 14 female 
migraineurs, 4 (29%) reported migraine attacks were associated with menstruation. 
For acute treatment of their migraine attacks, participants used paracetamol (21 
patients, i.e. 70%), non-steroidal anti-infl ammatory drugs (14 patients, i.e. 47%), 
opioids (1 subject, i.e. 3%), anti-emetics (12 subjects, i.e. 40%), and triptans (2 
subjects, i.e. 7%).
Figure 2: DBF during each week of the menstrual cycle in healthy females (n=26). DBF was expressed as 
percentage change in perfusion after 300 µg (panel A) and 1000 µg capsaicin (panel B) compared to vehicle. 
DBF40min: capsaicin-induced dermal blood fl ow 40 min after capsaicin application; AUC0-40: area under 
the curve of the DBF response from 0 till 40 min after 300 µg (panel C) and 1000 µg (panel D) capsaicin 
application; * Student’s paired t-test comparing menses with late secretory phase, p<0.05. Mean and 95% CI.
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Repeated measures ANOVA did not reveal a significant effect of the menstrual cycle 
phase within the migraine patients on the 40 min response or on the AUC of the 
capsaicin induced DBF neither for 300 nor for 1000 µg capsaicin (figure 3A-figure 
3D). When comparing the DBF response at 40 min between migraine patients and 
healthy women together in one analysis, effect of disease state (healthy vs. migraine, 
p=0.052) appeared to influence the response to the low dose of capsaicin (300 µg), 
but not (p=0.07) when studying the high dose (1000 µg) of capsaicin. In contrast, the 
AUC was significantly affected by disease state for both doses of capsaicin.  These 
differences in AUC values are in line with the observation that migraine patients 
tended to reach their maximal response to capsaicin at an earlier time point than the 
healthy women (supplementary figure 1). No difference in DBF was found between 
healthy men and men suffering from migraine after both 300 and 1000 µg capsaicin 
(figure 3). 
Hormone levels
During the menstrual cycle within the healthy women (73 ± 12 pg/ml to 25 ± 3 pg/
ml, p<0.05) and within migraine patients (75 ± 12 pg/ml to 28 ± 3 pg/ml, p<0.001), 
a significant drop in estrogen before menstruation was observed. No differences 
in estrogen levels were found between both groups during menstruation and late-
secretory week.
Similarly, within both the healthy women (10 ± 2 ng/ml to 0.6 ± 0.1 ng/ml, 
p<0.001) as well as migraine patients (5 ± 1 ng/ml to 0.7 ± 0.2 ng/ml, p<0.05), a 
significant drop in progesterone before menstruation was observed. No differences 
in progesterone levels were found between groups during either the late-secretory 
week or menstruation.
Discussion
The present study confirms the repeatability of DBF changes induced by weekly 
applications of capsaicin in healthy males without evidence for major desensitization. 
Unlike men, females displayed fluctuations in the CGRP-dependent dermal blood 
♀ ♂
Healthy
(N=19)
Migraine
(N=14)
p-value Healthy
(N=14)
Migraine
(N=16)
p-value
Age (years) 21.5 ± 1.8 25.1 ± 3.5 0.0006 22.8 ± 2.0 21.6 ± 3.4 0.21
BMI (kg/m2) 22.5 ± 2.0 22.5 ± 3.9 0.97 23.2 ± 2.8 22.2 ± 3.1 0.42
BP, (mm Hg)
Systolic
Diastolic
114.6 ± 9.6
66.6 ± 6.3
114.7 ± 9.8
69.8 ± 7.4
0.97
0.20
125.2 ± 10.7
65.9 ± 6.6
122.4 ± 7.7
65.1 ± 5.5
0.40
0.70
Heart rate, bpm 65.6 ± 10.8 67.4 ± 9.6 0.63 60.6 ± 6.3 60.3 ± 8.2 0.92
Table 1: Inter-group comparison of demographics of healthy subjects and migraine patients. Data presented 
as mean ± SD. 
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flow response, which was increased during the menstruation period. DBF responses 
were elevated in female migraine patients compared to healthy subjects.
Since the capsaicin-induced DBF response is repeatable over time in healthy male 
volunteers , the “capsaicin-model” can also be used as target-engagement biomarker 
for the prospective follow-up of long-acting biologicals including monoclonal 
antibodies targeting CGRP,27 next to short acting small molecule CGRP-receptor 
antagonists in early clinical drug development.25
As there was no significant desensitization to capsaicin observed in healthy males and, 
moreover, because women were included at random weeks during their menstrual 
cycle, the changing DBF response in healthy women during the menstrual cycle 
can most likely be attributed to hormonal changes related to the menstrual cycle. 
This was previously suggested by findings of Gazerani et al.26, 28 After intradermal 
capsaicin injection to the forehead, they found an increased flare area in women 
during the menstrual phase compared to the luteal phase. Accordingly, after topical 
application of capsaicin on the forearm, we found an increased DBF in healthy 
females during their menstrual phase compared to the luteal phase. In contrast, 
we did not find an effect of the menstrual cycle on the capsaicin-induced DBF in 
Figure 3: Increased DBF in migraine women (n=14) compared to healthy women (n=19). No difference be-
tween healthy men (n=14) and migraine men (n=16) after 300 and 1000 µg capsaicin. DBF was expressed as per-
centage change in perfusion after 300 µg or 1000 µg capsaicin compared to vehicle. DBF40min.: capsaicin-induced 
dermal blood flow 40 min after capsaicin 300 µg (panel A) and 1000 µg (panel B) capsaicin application; AUC0-40: 
area under the curve of the DBF response from 0 till 40 min after capsaicin after 300 µg (panel C) and 1000 µg 
(panel D) capsaicin application. Mean and 95% CI.
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migraine patients. Interestingly, upon comparison of corresponding phases of the 
menstrual cycle, female migraine patients responded with higher increases in DBF to 
capsaicin application than healthy women did. This effect may have been augmented 
by an earlier response to capsaicin in patients (Supplemental Figure 1)  and suggests 
an increased availability of CGRP or an increased sensitivity to capsaicin and/or 
CGRP. The lack of menstrual cycle-dependent variation in migraine has previously 
been reported in our study where we assessed the influence of the menstrual cycle 
on capsaicin-induced forehead DBF, thus comparing trigeminovascular activation in 
healthy women to that in women with menstrually related migraine.26 
The importance of CGRP in the pathophysiology of migraine and a correlation 
between migraine incidence, menstrual cycle and decreasing estrogens, as described 
in literature, are in line with our findings. A substantial period with high estrogen 
exposure seems to be necessary for migraine attacks to result from estrogen 
withdrawal.29-31 Many studies have described an association between the occurrence 
of migraine attacks and menstrual cycle,4 pregnancy,32, 33 partus34 and menopausal 
transition.13 However, effective hormonal treatment of migraine associated with 
menstruation and the menopause is lacking.3, 35-37 Also, association studies focusing 
on the role of sex hormone receptor gene polymorphisms in migraine remain 
inconclusive.38 Nevertheless, changes in levels of female sex hormones like estrogen 
and progesterone, clearly modulate neurotransmitter systems,17 influence brain 
function15 and vascular function18 in diverse ways.
In contrast to females, comparison of healthy men with male migraine patients 
showed no difference in DBF response. Gender differences (due to hormonal 
fluctuations) are suggested to have implications on both migraine susceptibility 
and migraine mechanism between males and females.39 Gender differences further 
illustrate the complexity of migraine and may support the hypothesis that clinically 
observed migraine features are modulated by different mechanistic pathways that 
trigger migraine.
Migraine subjects included in this study met the criteria for episodic migraine as 
classified in the International Classification for Headache (ICHD-II). No distinction 
was made between menstrual, menstrually-related or non-menstrual migraine subjects 
due to small subgroup under powering. As there are subtle differences between these 
groups, the hormonal effects observed in our study should represent a more general 
migraine population, but might be more pronounced in purely menstrual migraine 
without aura patients. Hormone levels between healthy female subjects and migraine 
patients in our study did not differ, suggesting that in this group of migraine patients 
higher sensitivity to female hormones is more important than absolute plasma levels. 
The exclusion of non-responders to capsaicin could be a limitation of this study 
as this may bias our results. However, we excluded 5 healthy subjects and only 2 
migraineurs because of this criterion, implicating that inclusion of non-responders 
would even fortify our findings. The reason why some subjects do not respond to 
topical applied capsaicin is unknown, but has been observed in other studies as 
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well.23, 40 Genetic analysis of non-responders to detect TRPV1 polymorphisms or 
other mutations could provide an explanation. However, it has been suggested that 
the absence of a DBF response may be purely related to insufficient skin penetration 
rather than to the absence of (functional) TRPV1 channels. This was supported by 
the observation that subjects with an apparently absent response to capsaicin applied 
on the forearm do respond after application on the forehead skin.41 
Molecular and physiological mechanisms for increased DBF response after capsaicin 
application could be the result of several mechanisms including increased neuronal 
sensitivity to capsaicin, perhaps due to increased TRPV1 expression, increased 
release of CGRP, or increased sensitivity to CGRP. Female hormones influence 
neurotransmitter systems,17 vasculature18 and thus migraine,15 but further research is 
needed to clarify which mechanisms are involved.42 
In summary, we first validated long-term repeatability of the CGRP-dependent 
DBF response in men. Secondly, we showed increased DBF response during the 
menstruation period in healthy women. Finally, a higher and seemingly faster 
CGRP-dependent DBF response that was not influenced by the menstrual cycle, was 
confirmed in women suffering from migraine. Our data demonstrate the influence of 
female menstrual cycle and migraine on CGRP-mediated vascular responsiveness, 
which further supports hormonal effects and increased female susceptibility to 
migraine. 
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Supplemental Figure 1. DBF in migraine women (n=14) compared to healthy women (n=19) 
and healthy men (n=14) and migraine men (n=16) after 300 µg and 1000 µg capsaicin. DBF was 
expressed as percentage change in perfusion after 300 µg or 1000 µg capsaicin compared to vehicle.
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CHAPTER 12 
Summarizing discussion and future perspectives
Part I: Experimental models of migraine
Since the advent of triptans, no other family of drugs has been as successful in 
the treatment of migraine. Despite being widely used, triptans are not effective in 
all patients. Due to their vascular effects they are contraindicated in patients with 
cardiovascular disease, and 14-30 % of patients are non-responders.1, 2 Thus, the 
search for new anti-migraine therapy, preferably prophylactic therapy that could 
prevent attacks altogether, is still ongoing. The potent vasodilator calcitonin gene-
related peptide (CGRP) is the key peptide in the pathophysiology of migraine and 
together with its receptor(s) the most promising target for new drug development.3 
In Chapter 3 we reviewed several in vitro and in vivo experimental models that can 
be applied for the discovery and characterization of new CGRP receptor antagonists. 
These models are also well suitable in researching the recently developed antibodies 
directed against CGRP and its receptor, that are now undergoing Phase II and Phase 
III clinical trials. Migraine models not only are essential in investigating new anti-
migraine therapy, they also provide an opportunity to study migraine pathophysiology. 
We do have to keep in mind that experimental models not always accurately predict 
or mimic disease. For example, in Chapter 4 we have commented on a study 
investigating vasodilatation of intra- and extra-cranial arteries in relation to attacks 
of migraine without aura (MO) and treatment with sumatriptan.  In comparison with 
earlier publications where migraine attacks in migraine patients were provoked 
by infusion of CGRP, the results of this study with spontaneous migraine were 
contradictory.4 The results of the migraine provocation study indicated that MO 
was associated with dilation of cranial arteries and that the headache location was 
associated with the location of vasodilatation.5 In contrast, the results of the study with 
spontaneous migraine showed no significant dilatation of the extracranial arteries on 
the migraine headache pain side and only minor dilatation of the cerebral arteries.4 
This contrast could be due to differences between mechanisms leading to a provoked 
or a spontaneous migraine attack, but might also be due to technical limitations of the 
detection method that was used. In both the above-mentioned studies, vasodilatation 
was assessed with magnetic resonance imaging (MRI). A limitation of MRI is that 
the intracranial part of the middle meningeal artery cannot be measured, while this 
intracranial portion of the middle meningeal artery is most likely crucial in the 
pathophysiology of migraine. As with most experimental migraine models, MRI 
does not integrate the neuronal and vascular components of migraine. 
Considering this lack, we set up a non-invasive human model where we could 
investigate the trigeminovascular activation of the forehead skin in humans. In 
Chapter 5, we have described the development and validation of this model. It is 
known that during migraine, CGRP is released from the trigeminal sensory nerves.6 
Within our model we induce the release of endogenous CGRP by applying capsaicin, 
the pungent component of chili peppers, to the forehead skin. Capsaicin activates 
the transient receptor potential vanilloid type 1 (TRPV1) cation channel and 
subsequently causes the release of CGRP.7, 8 Similar to the meninges, the dermatome 
of the forehead is innervated by the trigeminal nerve, making this anatomical location 
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suitable to investigate trigeminovascular mechanisms of migraine. The capsaicin-
induced CGRP release causes increases in dermal blood flow (DBF) that we can 
detect and quantify with laser Doppler perfusion imaging. Beside capsaicin we 
induce increases in DBF with electrical stimulation. The involvement of CGRP in the 
capsaicin-induced increases in DBF has previously been demonstrated with a CGRP 
receptor antagonist.8 Unfortunately, CGRP receptor antagonists were not available at 
the time of our study to assess to what extent CGRP was involved in the increases in 
DBF caused by electrical stimulation. With a within subject coefficient of variation 
(WCV) of 6% for capsaicin (6 mg/ml) and of 11% for electrical stimulation (1.0 mA), 
this trigeminal nerve-mediated vasodilatation model was well reproducible in healthy 
volunteers. In Chapter 6, we validated the trigeminal nerve-mediated vasodilatation 
model as a biomarker for the trigeminovascular effects of anti-migraine drugs in a 
double blind placebo-controlled crossover study with sumatriptan. For the validation 
in this study we investigated the effect of sumatriptan, the most established and 
the first marketed out of 7 triptans now available,9 on the CGRP-mediated rise of 
capsaicin-induced DBF in healthy volunteers. With this study we demonstrated that 
sumatriptan inhibited the capsaicin-induced vasodilatory DBF response, but not the 
vasodilatory DBF response to electrical stimulation. These results confirmed that 
sumatriptan is indeed able to inhibit the release of CGRP within our trigeminal nerve-
mediated vasodilatation model. Thus, we established that with our experimental 
human model the trigeminovascular effects of future anti-migraine drugs could be 
investigated. 
Migraine is comorbid with Raynaud’s phenomenon and other small vessel 
diseases, such as RVCL (autosomal dominant Retinal Vasculopathy with Cerebral 
Leukodystrophy) and CADASIL (Cerebral Autosomal-Dominant Arteriopathy with 
Subcortical Infarcts and Leukoencephalopathy).10, 11 Considering that migraine is a 
major risk factor for cardiovascular disease in women,12 there seems to be ample 
evidence for an association between migraine and generalized vascular dysfunction. 
However, as mentioned in the introduction of this thesis, results of cross-sectional 
studies investigating vascular dysfunction in migraine patients are conflicting. One 
of the reasons for these conflicting results might be the use of unreliable methods in 
these studies to investigate vascular function, or methods that are reliable but measure 
different aspects of vascular function. Therefore, in Chapter 7 we investigated the 
reproducibility of and correlation between different measures of vascular function. 
To exclude variations in our results due to variant hormone levels, we performed this 
study in healthy non-smoking and as well as in smoking men; this latter group was 
included to also involve men with presumed endothelial dysfunction. We assessed 
three different measures of vascular function: flow-mediated dilatation (FMD), local 
thermal hypaeremia (LTH) and post-occlusive reactive hyperaemia (PORH). We 
also investigated the nitric oxide (NO)-dependency of LTH. 
Our results show that the coefficient of variation of the LTH peak and plateau 
response was 16% and 21%, of the PORH peak and AUC 11% and 10%, and of the 
FMD response 12%. The LTH peak response tended to be lower, while the LTH-
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plateau response was significantly lower in smokers than in non-smokers, whereas 
the FMD and PORH responses in smokers and non-smokers were identical. Both in 
non-smokers and smokers, the LTH peak and LTH plateau responses were inhibited 
by the NO synthase inhibitor NG-monomethyl-l-arginine (L-NMMA), indicating 
that both the LTH peak and plateau response are in part mediated by increased NO 
release. The lower LTH plateau phase in smokers indicates less NO release, and 
consequently points to an endothelial dysfunction in the smokers.  Additionally, 
we showed that the LTH plateau phase correlated with the PORH peak response 
(r = 0.56, P = 0.008), whereas FMD and PORH AUC were closely correlated (r = 
0.64, P = 0.002). In both the LTH and the PORH response, endothelium-derived 
hyperpolarizing factor (EDHF) pathway activation is involved,13, 14 likely explaining 
the correlation between PORH peak response and LTH plateau phase. As both 
PORH and FMD are caused by post-ischemic reactive hyperaemia, both measures 
are possibly dependent upon the release of similar vasodilatory mediators, resulting 
in a correlation between FMD and PORH.  Neither the LTH peak nor the LTH 
plateau response correlated with the FMD response. Given that both responses 
are largely NO-dependent, this absent association, although previously reported in 
studies with similar group size,15 is surprising. However, it should be kept in mind 
that the dynamic range of LTH and FMD is vastly different; while with LTH the 
DBF response can increase by 900% from baseline DBF, with FMD only diameter 
changes of up to 12% can be achieved. This difference in magnitude may underlie 
the lack of correlation between LTH and FMD. FMD is known to be a predictor of 
cardiovascular risk16 and our results show that the LTH plateau response is highly 
endothelium-dependent. With LTH, but not FMD or PORH, we were able to show 
differences in endothelial function between non-smoking and smoking subjects. 
Therefore, in future studies assessing vascular function LTH, FMD and PORH 
should be complementary measures and are not interchangeable. PORH proved a 
reproducible and easily applicable measure of microvascular function. The PORH 
peak response is known to be mostly dependent on the release of neuropeptides and 
the time course of the PORH response is predominantly dependent upon activation 
of the endothelium-derived hyperpolarizing factor (EDHF) pathway causing the 
resulting vasodilation.13 
In Chapter 8 we applied PORH measurements in combination with laser Doppler 
flowmetery to perform in vivo microvascular characterization of the novel TREX1 
knock-in mouse model for RVCL. We specifically opted for PORH measurements, 
because we had not characterized the LTH response yet and PORH enabled us 
to study both the neurovascular and endothelium-dependent components of the 
microvasculature. Besides in vivo microvascular characterization, we performed 
detailed pharmacological in vitro macrovascular (aorta) characterization using 
Mulvany myographs. The PORH AUC responses were significantly attenuated in 
the 13-week to 100-week old homozygote V235fs KI animals. In the in vitro studies, 
acetylcholine induced significantly smaller relaxations in the aortae of the 100-week 
old transgenic compared to wild type mice. Our data are in line with preliminary 
patient results showing endothelial dysfunction in in RVCL patients.17 This transgenic 
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mouse model for RVCL can be applied to obtain a further understanding of TREX1 
mutation in RVCL as well as migraine. 
Part II: Migraine and female sex hormones
With a prevalence of 17% in women and 6% in men, migraine affects women 
much more than men.18 Major hormonal changes during a woman’s lifetime affect 
migraine and migraine frequency. One of those periods of hormonal change is the 
perimenopausal period. In Chapter 9 we reviewed the effect of the perimenopausal 
period on migraine. During the perimenopausal period, the period of 2–8 years prior 
to the menopause as well as the year after the end of menses, estradiol levels start to 
fluctuate leading to an eventual drop towards the end of the perimenopausal period. 
During this period women report new onset migraine, as well as improvement 
and worsening of existing migraine. Improvement of migraine seems to occur 
most in women with MO.19 Migraine incidence not only changes during hormonal 
milestones, during the reproductive years migraine incidence is also under the 
influence of the menstrual cycle. Approximately 50% of women with migraine 
have menstrually related migraine (MRM).20 Despite the importance of female sex 
hormones in influencing migraine onset, incidence and frequency in women, there 
are not many studies investigating this link. Therefore, as described in Chapter 10, 
we assessed whether varying levels of sex hormones during the menstrual cycle 
affect trigeminal nerve–mediated vasodilatation. For this purpose we included 
MRM patients, their healthy age-matched controls, and postmenopausal women 
as a reference group with stable low estradiol levels, and investigated them within 
the our trigeminal nerve-mediated vasodilatation model described in Chapter 5. We 
demonstrated a menstrual cycle-dependent response to capsaicin in healthy women. 
In contrast, responses to capsaicin were not dependent on the menstrual cycle in 
MRM patients. Postmenopausal women showed similar responses during the 2 
research time-points. However, their overall DBF responses were significantly lower 
compared to the premenopausal women. During day 19-21 of the menstrual cycle, 
MRM patients had significantly lower estradiol levels compared to their healthy age-
matched controls, confirming a possibly reduced cyclicity, which was also observed 
in the DBF responses to capsaicin. The lower estradiol levels in MRM patients, 
although seemingly in line with previous published data on MRM patients, should 
be confirmed in a study with a larger number of subjects.21 We performed a similar 
study, as described in Chapter 11, investigating the influence of migraine and the 
menstrual cycle on the capsaicin-induced DBF on the forearm. In this study, besides 
including healthy women and women with migraine, we also compared healthy 
male subjects with men with migraine. Measuring the capsaicin-induced DBF on the 
forearm allowed us to compare peripheral responses to that of the trigeminal nerve-
mediated responses measured in Chapter 10. Confirming our results as described 
in Chapter 10, healthy women responded more strongly to capsaicin application 
during their menstruation, while there was no influence of the menstrual cycle on 
the DBF responses to capsaicin in women with migraine. In contrast to our results 
on the forehead, women with migraine responded more strongly to capsaicin 
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application on the forearm during all research time-points. These conflicting findings 
may be attributed to differences in the migraine patients that were included in both 
studies (MRM patients in Chapter 10 and general migraine patients in Chapter 
11). Alternatively, the different finding in Chapter 10 and Chapter 11 could also be 
due to differences between trigeminovascular responses and peripheral responses 
to capsaicin. There may be a higher demand for CGRP in the meningeal region in 
migraine patients, leading to lower levels that can be released upon activation of the 
trigeminal afferents on the forehead. This difference in peripheral and trigeminal 
finding is an interesting contrast to study in the future.
Future Perspectives
Migraine and female sex hormones
Our studies have provided further insight into the effect of female sex hormones on 
the pathophysiology of migraine (Chapters 10 and 11), suggesting that the reactivity 
of the trigeminovascular system in migraine patients in response to varying levels 
of female sex hormones differs from that in healthy women without migraine.  In 
addition, we obtained preliminary evidence (Chapter 10) that not only the response 
to varying levels of female sex hormones, but also the levels of these hormones 
is different in MRM patients compared to healthy women.  Future studies should 
demonstrate whether our findings could indeed be confirmed in a larger study 
sample. Such studies should also focus on female sex hormones beyond estradiol 
and progesterone.  Further, we have up to now assumed that the increased DBF 
responses during the menses in women are mediated by CGRP, since CGRP has 
been shown to almost exclusively mediate the DBF response to capsaicin in forearm 
studies.8 However, since these studies8 were performed in men, we cannot exclude 
that, during specific phases of the menstrual cycle, additional factors may come into 
play, like pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive 
intestinal peptide (VIP), and substance P. Therefore, it is to be recommended 
that, when compounds interfering with CGRP (i.e., CGRP receptor antagonists or 
antibodies directed against CGRP or its receptor) are available for use in humans, 
the cycle-dependent changes in DBF to capsaicin are studied in their presence. This 
would allow more insight into the involvement of other vasodilatory factors, besides 
CGRP, in the DBF responses to capsaicin. In addition, since female sex hormones do 
influence many of the mechanisms involved in migraine, they should be taken into 
account when studying the link between migraine and cardiovascular disease, as well 
as the effects of drugs interfering with the CGRP-ergic system of nerve stimulation 
(see below).
Migraine and cardiovascular disease
As mentioned above, migraine is a major cardiovascular disease risk factor in women. 
Not only is there an association between stroke and migraine 22, but migraine patients 
are now also known to have a higher chance of cardiac events.23 A recent study 
indicates that migraine may be an even larger cardiovascular risk factor than the 
classical risk factors diabetes, obesity and smoking.12 The increased cardiovascular 
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risk due to migraine is not explained by a single vascular risk factor and in fact 
seems to be independent from diabetes mellitus and atherosclerosis.24 Thus, it is 
essential to characterize the vascular system of migraine patients, using a method 
that can discriminate between different components involved in vasorelaxation. 
Such studies could be performed using LTH, as this microvascular measure is 
suitable to pharmacologically assess the role of specific vasodilator components, 
like NO (see Chapter 7), neuropeptides, and EDHF (pilot studies currently ongoing 
in our laboratory). In addition, the LTH response may be related to the DBF increase 
induced by an endothelium-independent vasodilator, such as glyceryl trinitrate. The 
knowledge on the pathophysiological mechanisms involved in the vascular profile 
of migraine patients thus obtained will allow a better prevention in these patients. 
Unfortunately, mechanistic studies that focus on vascular function show inconsistent 
results. A particular limitation of these studies, seems to be the inclusion criteria 
for patients.25 Regrettably, current knowledge obtained from epidemiological studies 
cannot be directly applied for the selection of patients in mechanistic studies. Uniform 
criteria for identification of migraine patients at risk of cardiovascular do not exist. If 
methods for correct sampling would be available to bridge these two scientific fields, 
pathophysiological studies may more consistently elucidate the underlying vascular 
dysfunction in migraine patients. 
Antibodies directed against CGRP and its receptor 
Due to the central role of CGRP in the pathophysiology of migraine, this neuropeptide 
has been a target for drug development for several years. Up to several years ago, 
research focused on the development of CGRP receptor antagonists (gepants). 
CGRP receptor antagonists were promising, as they were as effective as triptans, 
apparently without the vascular side effects. Studies even indicated that triptan non-
responders could benefit from gepants.26 However, the development of olcegepant 
was terminated because of pharmacokinetic limitations of this compound.27 
Subsequently, increased liver transaminases were detected in a phase 3 trial of 
telcagepant, testing its capacity as a prophylactic drug, leading to the immediate 
termination of further development of this compound.  These unfortunate events 
have delayed the development of this class of drugs.28 Monoclonal antibodies against 
CGRP and its receptor bypass the liver metabolism and as such became the new focus 
of anti-migraine drug development.29 Preliminary data show promising results of 
treatment with CGRP antibodies.30, 31 Although blocking CGRP does not have direct 
vascular effects, like the vasoconstrictor effect with triptans, the cardiovascular safety 
of antibodies directed against CGRP or its receptor has to be evaluated extensively, 
because CGRP is involved in ischemia and reperfusion events,32 and blocking the 
function of CGRP for a longer period of time could have detrimental effects. Studies 
with CGRP knockout mice in an angiotensin II-induced hypertension model have 
demonstrated that the CGRP knockout mice display enhanced hypertension and 
aortic hypertrophy compared to wild type mice, reinforcing the importance of the 
protective role of CGRP in the cardiovascular system.33 
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Extracranial peripheral nerve stimulation
In recent years, there has been a focus on device-driven management of migraine. 
Based on the premise that extracranial peripheral nerves can influence migraine, 
several nerve stimulators have been developed. Occipital nerve stimulation (ONS), 
an invasive method of nerve stimulation, has been investigated in clinical trials, 
but yielded variable results. The Occipital Nerve Stimulation for the Treatment of 
Chronic Migraine Headache (ONSTIM) study reported a reduction of at least 50% 
in headache frequency in migraine, while no improvement was found in the sham-
stimulated or medically treated groups.34 In the largest randomized clinical trial in 
patients with chronic migraine however, no difference in primary outcome (50% 
reduction of mean daily headache intensity) between active and sham treatment was 
found.35 However, a sub-analysis indicated a 30% reduction in mean headache days 
(p<0.05) and a decrease in migraine-related disability score (MIDAS) (p<0.01).35 
Non-invasive peripheral nerve-stimulating methods include transcutaneous 
supraorbital nerve stimulation (tSNS) and transcutaneous vagus nerve stimulation 
(tVNS).36, 37 In a randomized, double-blind sham-controlled trial, tSNS significantly 
decreased the number of mean monthly migraine days.36 In an open label study in 
30 patients, tVNS in the neck was effective in aborting migraine attacks in 21% 
of patients (painfree at two hours).37 The studies on peripheral extracranial nerve 
stimulation seem promising, however a major limitation of clinical trials with nerve 
stimulation is the sham treatment. Due to the sensation of nerve stimulation correct 
blinding is very difficult to achieve. Studies that validate sub-threshold stimulation 
are necessary. For example, our trigeminal nerve-mediated vasodilatation model is 
well suitable to assess the effect of tSNS on CGRP release by measuring CGRP-
induced increases in DBF. In addition, similar methods should be developed to 
assess the effects of vagal nerve stimulation.  In this way, these novel modes of nerve 
stimulation might be validated and the role of CGRP and other neuropeptides, such 
as PACAP and VIP in their effects may be studied, leading into more insight into the 
pathophysiology of migraine.  
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Deel I: Experimentele migraine modellen
Geen andere medicijnklasse is meer succesvol geweest in de acute behandeling 
van migraine dan triptanen. Triptanen zijn evenwel niet in alle patiënten effectief; 
schattingen van non-responders variëren van 14-30%. Verder zijn triptanen wegens 
hun vasoconstricties effect gecontraïndiceerd bij patiënten met hart- en vaatziekten. 
Daarom gaat de zoektocht naar nieuwe antimigraine middelen nog steeds door, waa-
rbij voorkeur uitgaat naar middelen die aanvallen kunnen voorkomen. In de pathofy-
siologie van migraine is de krachtige vaatverwijder “calcitonin gene-related pep-
tide” (CGRP) het belangrijkste peptide en vormt samen met de CGRP-receptor het 
meest veelbelovend aanknopingspunt in de ontwikkeling van nieuwe antimigraine 
middelen. 
In hoofdstuk 3 worden de verschillende in vitro en in vivo experimentele modellen 
besproken die kunnen worden aangewend bij de ontwikkeling en karakterisering van 
CGRP-receptorantagonisten. Deze modellen zijn ook geschikt voor het onderzoeken 
van de onlangs ontwikkelde antilichamen, gericht tegen CGRP en de CGRP-recep-
tor.  Deze antilichamen worden momenteel in Fase II en Fase III klinische studies 
getest. Migraine modellen zijn niet alleen essentieel voor het onderzoek naar de 
werkzaamheid van nieuwe antimigraine middelen, maar bieden ook mogelijkheden 
om de pathofysiologie van migraine verder uit te zoeken, waarbij uiteraard rekening 
moet worden gehouden met het feit dat experimentele modellen beperkingen hebben 
en de klinische situatie niet altijd accuraat nabootsen. Bijvoorbeeld, in hoofdstuk 4 
bespreken wij een studie waarin de verwijding van intra- en extracraniële vaten in 
relatie tot spontane migraineaanvallen zonder aura (MO) en het effect van sumatrip-
tan hierop is onderzocht. De resultaten van deze studie zijn tegenstrijdig met de 
resultaten van eerder gepubliceerde studies, waarin migraineaanvallen werden op-
gewekt door de infusie van CGRP. Verschillen in de mechanismen die leiden tot een 
opgewekte en een spontane migraineaanval, maar ook de technische beperkingen 
van de detectiemethode die gebruikt is zouden deze tegenstrijdigheid kunnen verk-
laren. In beide genoemde studies werd de vaatverwijding beoordeeld met behulp van 
magnetische resonantie beeldvorming (MRI). Een belangrijke beperking van MRI is 
dat het intracraniële deel van de arteria meningea media niet gemeten kan worden, 
terwijl dit intracraniële deel verondersteld wordt cruciaal te zijn in de pathofysiolo-
gie van migraine. Zoals dat ook geldt voor de meeste experimentele migrainemod-
ellen, is het met MRI niet mogelijk om de neuronale en vasculaire componenten 
van migraine te integreren. Daarom hebben wij een non-invasief model ontwikkeld 
waarin de trigeminovasculaire activering van de huid van het voorhoofd in mensen 
onderzocht kan worden. Hoofdstuk 5 beschrijft de ontwikkeling en validatie van dit 
model. Tijdens een migraineaanval komt CGRP vrij uit de sensorische zenuwuitein-
den van de nervus trigeminus. In het door ons ontwikkeld model wordt het vrijkomen 
van endogeen CGRP geïnduceerd door het aanbrengen van capsaïcine op de huid 
van het voorhoofd. Capsaïcine is het pittige bestanddeel van chilipepers. Capsaïcine 
activeert het transiënte receptor potentiaal vanillaoid type 1 (TRPV1) ion-kanaal, 
hetgeen leidt tot de afgifte van CGRP. Zoals de hersenvliezen wordt de huid van het 
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voorhoofd geïnnerveerd door de nervus trigeminus, reden waarom dit dermatoom 
uitermate geschikt is voor het onderzoek van de trigeminovasculaire mechanismen 
in migraine. De capsaïcine-geïnduceerde CGRP-afgifte veroorzaakt een toename in 
de doorbloeding van de huid (DBF), die eenvoudig gekwantificeerd kan worden 
met behulp van laser Doppler perfusie imaging. Naast de capsaïcine-geïnduceerde 
toename werd gekeken naar de toename in DBF, geïnduceerd door elektrische stim-
ulatie. De betrokkenheid van CGRP bij de capsaïcine-geïnduceerde toename in DBF 
is eerder aangetoond met een CGRP-receptorantagonist. Helaas konden we tijdens 
onze studies niet beschikken over een CGRP-receptorantagonist om vast te kun-
nen stellen of en in hoeverre CGRP  betrokken is bij de toename van de DBF door 
elektrische stimulatie. Met een intra-individuele variatiecoëfficiënt (WCV) van 6% 
voor capsaïcine (6 mg/ml) en 11% voor elektrische stimulatie (1.0 mA), is dit tri-
geminale zenuw-gemedieerde vasodilatatiemodel in gezonde vrijwilligers goed re-
produceerbaar. In hoofdstuk 6 hebben wij het trigeminale zenuw-gemedieerde vaso-
dilatatiemodel gevalideerd als een biomarker voor de trigeminovasculaire effecten 
van sumatriptan in een dubbelblinde, placebo-gecontroleerde cross-over studie. We 
onderzochten het effect van sumatriptan, omdat van de 7 triptanen die nu beschik-
baar zijn dit middel het meest gebruikt wordt. In deze studie vonden we dat sumatrip-
tan de door capsaïcine geïnduceerde DBF respons remde, maar niet de respons op 
elektrische stimulatie. Met ons trigeminale zenuw-gemedieerde vasodilatatiemodel 
konden we dus aantonen dat sumatriptan in staat is om de afgifte van CGRP te rem-
men. Onze conclusie is dan ook dat het ontwikkelde experimentele humane model 
de mogelijkheid biedt om trigeminovasculaire effecten van nieuwe anti-migraine 
middelen te onderzoeken. 
Migraine is geassocieerd met het Raynaud-fenomeen en andere microvasculaire 
aandoeningen zoals RVCL (autosomaal dominante Retinale Vasculopatie met Cere-
brale Leukodystrofie) en CADASIL (Cerebrale Autosomaal-Dominante Arteriopatie 
met Subcorticale Infarcten en Leukoencefalopathie). Omdat migraine het risico van 
cardiovasculaire ziekten in vrouwen verhoogt, wordt er een verband tussen migraine 
en gegeneraliseerde vasculaire disfunctie verondersteld. Zoals besproken in de in-
leiding van dit proefschrift, zijn de resultaten van de studies die vasculaire disfunctie 
in migraine patiënten hebben onderzocht niet eenduidig. Een mogelijke verklaring 
voor deze tegenstrijdige resultaten is het gebruik van minder valide methoden om de 
vasculaire functie te onderzoeken, of methoden die wel valide zijn maar andere as-
pecten van de vasculaire functies meten dan die zijn aangedaan bij migraine. Daarom 
hebben we in hoofdstuk 7 de reproduceerbaarheid van en correlatie tussen verschil-
lende meetmethoden van vasculaire functie onderzocht. Om variaties door variëren-
de hormoonspiegels uit te sluiten, hebben we deze studie uitgevoerd bij gezonde 
niet-rokende en rokende mannen; deze laatste groep werd geïncludeerd omwille van 
de veronderstelde endotheeldisfunctie. Drie verschillende methoden om vasculaire 
functie te bepalen hebben we gebruikt: flow-gemedieerde dilatatie (FMD), lokale 
thermale hyperemie (LTH) en post-occlusieve reactieve hyperemie (PORH). Tevens 
hebben we de stikstofmonoxide (NO)-afhankelijkheid van LTH onderzocht. Onze 
resultaten tonen aan dat de variatiecoëfficiënt van  de LTH-piek- en LTH-plateaure-
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spons 16% en 21% bedraagt, van de PORH piek- en AUC-respons 11% en 10%, en 
van de FMD-respons 12%. De LTH-plateaurespons was minder bij rokers dan bij 
niet-rokers, terwijl de FMD en PORH-responsen bij rokers en niet-rokers identiek 
waren. Zowel bij rokers als niet-rokers werden de LTH-piek- en LTH-plateaurespons 
geremd door de NO-synthaseremmer NG-monomethyl-l-arginine (L-NMMA), het-
geen erop wijst dat zowel de LTH piek- als plateaurespons, althans ten dele,  geme-
dieerd wordt door een toegenomen NO-afgifte. De lagere LTH-plateaurespons in ro-
kers impliceert een verminderde NO-afgifte, hetgeen in overeenstemming is met de 
veronderstelde endotheeldisfunctie bij rokers. De LTH-plateaurespons correleerde 
met de PORH-piek respons (r = 0.56, P = 0.008), terwijl FMD en PORH AUC sterk 
gecorreleerd waren (r = 0.64, P = 0.002). Bij zowel de LTH- als de PORH-respons 
is activering van de endotheel-afhankelijke hyperpolariserende factor (EDHF) path-
way betrokken, hetgeen de  correlatie tussen de PORH maximale respons en de LTH 
plateaurepons waarschijnlijk verklaart. Omdat de PORH-respons en FMD-respons 
veroorzaakt worden door post-ischemische reactieve hyperemie, zijn beide metin-
gen afhankelijk van de afgifte van vergelijkbare vaatverwijdende stoffen,  hetgeen 
de correlatie tussen FMD en PORH verklaart. Noch de LTH-piek, noch de LTH-pla-
teaurespons correleerden  met de FMD-respons. Aangezien beide responsen gro-
tendeels NO-afhankelijk zijn, is het ontbreken van deze associatie verrassend,  zij het 
eerder gerapporteerd in studies met vergelijkbare groepsgrootte. Hierbij kan worden 
aangetekend dat de dynamische range van LTH en FMD respons sterk verschillen; 
terwijl bij LTH de DBF met 900% kan toenemen, worden bij FMD veranderingen 
in diameter tot maximaal 12% bereikt. Dit verschil in dynamische range kan de 
afwezige correlatie tussen LTH en FMD wellicht verklaren. Het is bekend dat een 
verminderde FMD een voorspeller is van het risico van cardiovasculaire aandoenin-
gen.  Onze resultaten tonen aan dat de LTH-plateaurespons voor een groot deel endo-
theel-afhankelijk is. Met LTH, maar niet met FMD of PORH, waren we in staat om 
verschillen in endotheelfunctie aan te tonen tussen niet rokende en rokende proefper-
sonen. In toekomstige studies naar vasculaire (dis)functie zouden de LTH, FMD en 
PORH als aanvullende, maar niet als  uitwisselbare metingen kunnen worden toege-
past. PORH is een goed reproduceerbare en gemakkelijk uit te voeren meting om de 
microvasculaire functie te evalueren. De PORH-piekrespons is voornamelijk afhan-
kelijk van de afgifte van neuropeptiden en het tijdsverloop van de PORH-respons is 
in grote mate afhankelijk van de activering van de EDHF-pathway. In hoofdstuk 8 
pasten we PORH metingen toe in combinatie met laser Doppler flowmetingen om in 
vivo de microvasculaire functie van het nieuwe TREX1 knock-in muismodel (V235fs 
KI) voor RVCL te karakteriseren. We hebben voor PORH metingen gekozen, om-
dat we de LTH-respons nog niet geëvalueerd hadden en we met de PORH- respons 
zowel de neurovasculaire als de endotheelafhankelijke componenten van de  micro-
circulatie konden bestuderen. Naast de in vivo karakterisering van de microcirculatie 
hebben we ex vivo de vasculaire functie van aorta onderzocht, gebruikmakend van 
de Mulvany myograaf.  De PORH AUC-responsen waren significant verlaagd in de 
13 tot 100 weken oude homozygote V235fs KI dieren. In de ex vivo studies veroor-
zaakte acetylcholine minder relaxatie in de 100 weken oude transgene muizen dan in 
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de controle muizen. Deze experimentele gegevens zijn in overeenstemming met de 
eerste resultaten verkregen in patiënten met RVLC. Het transgene muismodel voor 
RVCL kan worden gebruikt om enerzijds meer inzicht te krijgen in de rol van de 
TREX1-mutatie in RVCL en anderzijds in de pathofysiologie van migraine. 
Deel II: Migraine en vrouwelijke geslachtshormonen
Met prevalenties van 17% in vrouwen en 6% in mannen, komt migraine veel vaker 
voor bij vrouwen dan bij mannen. De grote hormonale veranderingen tijdens een 
vrouwenleven zijn van invloed op de incidentie en de frequentie van migraine. Een 
periode van hormonale veranderingen is de perimenopauze. In hoofdstuk 9 geven 
we een literatuuroverzicht van het effect van de perimenopauze op migraine. Tijdens 
de perimenopauze, de periode van 2–8 jaren voor de menopauze en het eerste jaar 
na de laatste menses, begint de oestradiolspiegel te fluctueren, uiteindelijke leidend 
tot een dalende spiegel rond het einde van de perimenopauze. Rond deze periode 
kunnen vrouwen voor het eerst migraineaanvallen krijgen, maar een verbetering of 
verergering van bestaande migraine kan eveneens optreden. Verbetering van besta-
ande migraine lijkt het meest voor te komen bij vrouwen met MO. De incidentie 
en frequentie van migraine aanvallen veranderen niet alleen tijdens hormonale mi-
jlpalen. Ook tijdens de vruchtbare jaren wordt migraine beïnvloed door hormona-
le veranderingen samenhangend met de menstruele cyclus. Ongeveer 50% van de 
vrouwen met migraine hebben menstruatie-gerelateerde migraine (MRM). Ondanks 
de belangrijke rol van vrouwelijke geslachtshormonen op het ontstaan en de inci-
dentie en frequentie van migraine bij vrouwen, is dit verband weinig onderzocht. 
Daarom hebben wij, zoals beschreven in hoofdstuk 10,  middels een case-control 
studie geëvalueerd of veranderingen die optreden in de vrouwelijke geslachtshor-
monen gedurende de cyclus van invloed zijn op de nervus trigeminus-gemedieerde 
vasodilatatie. Gebruikmakende van ons trigeminale zenuw-gemedieerde vasodila-
tatie model zoals beschreven in hoofdstuk 5 hebben we MRM patiënten, gezonde 
controles van dezelfde leeftijd en postmenopauzale vrouwen (een referentiegroep 
met een stabiele lage oestradiolspiegel) bestudeerd. In onze studie konden we aan-
tonen dat de DBF-respons op capsaïcine in gezonde vrouwen afhankelijk is van de 
cyclus. Daarentegen waren de DBF-responsen in MRM patiënten onafhankelijk van 
de menstruele cyclus. De DBF-responsen van postmenopauzale vrouwen op capsaï-
cine waren identiek gedurende de 2 meetmomenten van het onderzoek, maar signifi-
cant lager dan die in premenopauzale vrouwen. Gedurende dag 19-21 van de cyclus 
hadden MRM-patiënten lagere estradiolspiegels in vergelijking met de controles, 
hetgeen mogelijk de verminderde cycliciteit van de capsaïcine-respons verklaart. 
De lagere estradiolspiegels in MRM-patiënten, alhoewel in overeenstemming met 
eerder gepubliceerde studies, zouden in een grotere studie bevestigd moeten worden. 
In hoofdstuk 11 hebben wij de  invloed van migraine en menstruatiecyclus op de 
capsaïcine-geïnduceerde DBF in de onderarm onderzocht. In deze studie hebben we 
naast gezonde vrouwen en vrouwen met migraine ook gezonde mannen en mannen 
met migraine met elkaar vergeleken. Het meten van de DBF in de onderarm stelde 
ons in staat om de responsen in de onderarm te vergelijken met de trigeminale ze-
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nuw-gemedieerde responsen zoals beschreven in hoofdstuk 10. Gezonde vrouwen 
reageerden sterker op de toediening van capsaïcine tijdens hun menstruatie, terwijl 
de capsaïcine-geïnduceerde DBF-responsen niet werden beïnvloed door de cyclus 
bij vrouwen met migraine, hetgeen in overeenstemming is met de resultaten bes-
chreven in hoofdstuk 10. Echter, in tegenstelling tot de verminderde capsaïcine-re-
spons op het voorhoofd, reageerden vrouwen met migraine sterker op de toediening 
van capsaïcine op de onderarm tijdens alle tijdspunten van het onderzoek. Deze te-
genstrijdige resultaten kunnen wellicht worden toegeschreven aan verschillende mi-
grainepatiënten die in beide studies geïncludeerd zijn: MRM patiënten in hoofdstuk 
10 en algemene migrainepatiënten in hoofdstuk 11. Ook zou het verschil verklaard 
kunnen worden door eventuele verschillen tussen trigeminovasculaire en perifere 
responsen op capsaïcine. Er is mogelijk een grotere vraag naar CGRP in de menin-
geale vasculatuur bij migraine patiënten, hetgeen kan leiden tot lagere hoeveelheden 
CGRP die afgegeven kunnen worden bij de activering van de trigeminale afferenten 
in het voorhoofd. Het contrast in de perifere en trigeminale DBF resultaten is een 
interessante bevinding die verder onderzoek vereist.  
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